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Malignant catarrhal fever (MCF) is a lymphoproliferative, degenerative and often
fatal disease of members of the Artiodactyla family such as cattle and deer. The
causal agents of MCF are a group of gammaherpesviruses of which alcelaphine
herpesvirus-1 (A1HV-1) is a member. A1HV-1 is the most well characterised of the
group and its genome has been sequenced. Continued passage of A1HV-1 in bovine
cells results in attenuation of the virus. Comparison of genomes from wild-type and
attenuated viruses suggested that open reading frames (ORFs) are affected including
ORF50.
The ORF50 gene products of Kaposi's sarcoma-associated herpesvirus (KSHV),
herpesvirus saimiri (HVS), murine gammaherpesvirus-68 (MHV-68) and their
equivalent, the BRLF1 gene product of Epstein-Barr virus (EBV) are called R-
transactivators (Rtas). They have a crucial role in the key mechanism of reactivating
the virus from latency as well as acting as transactivator proteins activating a variety
of virus and cellular promoters.
The aim of this study was to characterise A1HV-1 ORF50. It was demonstrated that
the ORF50 gene product, referred to as A1HV-1/Rta, acted as a transactivator. The
ability to transactivate three A1HV-1 promoters was investigated. It was shown that
A1HV-1/Rta activates A1HV-1 ORF57 and A1HV-1 ORF6 putative promoters but not
the thymidine kinase putative promoter. The ORF57 promoter was examined and the
transcriptional start site and splice acceptor and splice donor sites were located. Also,
activation of the ORF57 promoter by A1HV-1/Rta was investigated further.
XI
Truncated ORF57 promoters were generated and their ability to be activated by
A1HV-1/Rta was investigated. It was found that A1HV-1/Rta required sequences at
least 385 bp upstream of the ORF57 transcriptional start site to exert its effect on
ORF57 transcription. A potential AlHV-l/Rta-responsive region was identified and
this was investigated further using electrophoretic mobility shift assays.
A second approach to characterise A1HV-1 ORF50 was also taken. Various strategies
were designed to generate a recombinant A1HV-1 lacking ORF50. The method
pursued was to generate a bacterial artificial chromosome containing the entire
A1HV-1 genome. These strategies will be discussed.
XII
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"Because of their diversity, each herpesvirus, whether human or
animal, presents a unique challenge..." (Roizman and Baines, 1991).
1.1 Herpesviruses
Most vertebrate organisms investigated so far are hosts for at least one of the 120
known herpesviruses and, in addition, a herpesvirus has been identified in molluscs
(Minson et al., (2000). Different herpesviruses cause a variety of symptoms and
pathology, ranging from asymptomatic to fatal. For example, herpes simplex virus 1
(HSV-1) which causes cold sores can also, under different circumstances, cause
severe encephalitis. Epstein-Barr virus (EBV) ranges from having no clinical
manifestation to causing infectious mononucleosis and is also associated with several
tumours such as nasopharyngeal carcinoma and Burkitt's lymphoma (Roizman and
Baines, 1991).
All herpesviruses have four properties in common: (i) they encode for enzymes
involved in nucleic acid synthesis and DNA metabolism, (ii) viral DNA synthesis
and capsid assembly occurs in the nucleus, (iii) destruction of the cell occurs when
infectious progeny viruses are released and (iv) herpesviruses have the ability to
establish a latent infection in the host cell where the virus genome is maintained as a
circular molecule (Roizman et al., 1992).
The name given to the herpesvirus family is Herpesviridae, and this is further
divided into three subfamilies, the Alphaherpesvirinae, Betaherpesvirinae and
Gammaherpesvirinae (Minson et al., 2000). These subfamilies have distinct
biological properties. The subfamilies are further classified into genera depending on
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DNA and protein sequence homology and genome sequence arrangement.
Herpesviruses are named according to the family or subfamily of the natural host
species in which they are found. Where there is more than one virus found in a host
serial arabic numbers are used. The viruses also have common names that refer to the
common name of the host or occasionally the effect of the virus (Roizman and
Baines, 1991) (See Table 1.1).
Table 1.1: Classification of subfamilies of the Herpesviridae and their defining
biological properties
(HSV - herpes simplex virus, VZV - varicella zoster virus, HCMV - human
cytomegalovirus, MCMV - mouse cytomegalovirus, HHV - human herpesvirus, EBV
- Epstein-Barr virus, HVS - herpesvirus saimiri, HVA - herpesvirus ateles).
Alphaherpesvirinae - Variable host range
Short reproductive cycle
Rapid spread in culture
Efficient destruction of infected cells
Establish latent infection predominantly in sensory
ganglia
Genera - Simplexvirus (e.g. HSV-1+2)
- Varicellovirus (e.g. VZV)
Betaherpesvirinae - Restricted host range
Long reproductive cycle
Slow spread in culture
Frequent formation of cytomegalia
Carrier cultures readily established
Establish latent infection in lymphoreticular cells,
secretory glands, kidneys and other tissues
Genera - Cytomegalovirus (HCMV)
- Muromegalovirus (MCMV)
- Roseolovirus (HHV-6, HHV-7)
Gammaherpesvirinae - Host range frequently limited to family or order to
which the natural host belongs
In vitro replication occurs in lymphoblastoid cells and
also sometimes in epitheloid and fibroblastic
cells.
Usually specific for T- or B-lymphocytes
Latent virus is predominantly found in lymphoid tissue
Genera - Lymphocryptovirus (e.g. EBV)
- Rhadinovirus (e.g. HVS, HVA)
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All herpesviruses have a similar structure consisting of a core of linear double-
stranded DNA, an icosadeltahedral capsid of 100-110 nm in diameter and an
amorphous substance encompassing the capsid named the tegument, which is
surrounded by a membrane, the envelope, from which glycoproteins project (Figure
1.1). The overall size of a herpesvirus particle ranges from 120-300 nm. Herpesvirus
genomes range from 124-235 kb long and their DNA base composition varies from
32-75% G+C (Minson et al., 2000).
Herpesviruses have one of six different genome structures, which differ in the
presence and location of repeat sequences (Figure 1.2). Due to varying sizes of these
repeat regions, there can be variation in genome size between different preparations
of the same virus.
Herpesvirus genomes encode structural proteins and proteins necessary for virus
replication. However, they also contain a third group of non-essential genes that are
not common to all herpesviruses. Although these genes are usually not essential for
replication in tissue culture, they are likely to be important in the pathogenesis of the
virus in vivo. For example, they may encode proteins involved in modulating the host
immune system or regulating host cell growth (Krajcsi and Wold, 1998; Damania et
al., 2000; Neipel et al., 1997). Since some of these virus genes show a high degree of
sequence and/or functional similarity to some cellular genes, it is believed that they
may have been acquired by the virus during co-evolution with its host species
(Nicholas, 2000).
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1.1.1 Herpesvirus replication
Once herpesviruses have entered a cell, one of two outcomes follows. The virus may
undergo a lytic phase of replication, also described as productive infection, where a
cascade of virus gene expression is initiated and infectious virus particles are
produced. Alternatively, the virus will enter a latent state in which infectious virus
progeny are absent and there is only limited virus gene expression (Lehman and
Boehmer, 1999).
1.1.2 Herpesvirus lytic replication
Based on HSV-1 replication, infection begins with attachment of the virus
glycoproteins to cell surface receptors followed by fusion of the cell membrane and
virus envelope with subsequent release of the naked capsid into the cell. Heparan
sulphate proteoglycan on the cell surface is involved in binding of HSV-1 to the host
cell, although it is not the sole receptor. HSV-1 itself has 10 envelope glycoproteins
which are involved in a complex attachment and penetration process (Kasamatsu and
Nakanishi, 1998; Laquerre et al., 1998). In contrast, EBV uses one main glycoprotein
for attachment, gp350/220 which attaches to a B-lymphocyte surface protein called
CR2 (Gong and Kieff, 1990).
The HSV-1 naked capsid is transported to the nuclear pores in association with
microtubules and dynein, where DNA then enters the nucleus (Kasamatsu and
Nakanishi, 1998). Virus DNA is transcribed in the nucleus by host RNA polymerase
II and the mRNA is translated in the cytoplasm. The temporal pattern of gene
expression of herpesviruses is classified according to that of HSV-1. Gene expression
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in the lytic phase of virus replication occurs in a sequential manner, which can be
classified into three main stages: immediate early (IE), early (E) and late (L) which
are also named a, (3 andy respectively. Virus transactivator VP 16 and the cellular
octamer DNA-binding protein, Oct-1, activate the IE genes. The products of IE genes
are then involved in activating the E genes which encode proteins required for DNA
replication, for example DNA polymerase, single-stranded DNA-binding protein,
origin-binding protein and enzymes involved in deoxynucleotide metabolism such as
thymidine kinase (TK). These components of the DNA replication machinery are
conserved between bacteria, yeast, mammals and viruses. The L genes encode
proteins which provide the structural components of the virus (Lehman and
Boehmer, 1999).
When virus DNA enters the nucleus, it assumes a circular configuration which is
necessary for initiation of viral replication. The origin of replication can be oris, of
which there are two copies in the 'c' sequences (IRs, TRs) of the genome or oHl of
which there is one copy in the Ul region of the genome (see Figure 1.2). There are
inverted repeat sequences surrounding the origins to which the UL9 origin-binding
protein binds. Virus DNA replication occurs in the nucleus through a rolling circle
mechanism (Lehman and Boehmer, 1999). The replicated DNA is in the form of
head-to-tail concatemers which are cleaved at specific sites within the 'a' sequences
and packaged into capsids (Deiss et al., 1986; Vlazny et al., 1982).
Virus assembly occurs in the nucleus and the nucleocapsids have been observed
budding through the nuclear membrane. The mechanism of egress is not fully
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Figure 1.2: Herpesvirus genome structures
Schematic diagram of six Herpesviridae genome groups.
An example of a virus having each of these structures is listed.
(I) ictalurid herpesvirus 1 (channel catfish herpesvirus)
(II) saimirine herpesvirus 2 (herpesvirus saimiri)
(III) human herpesvirus 3 (varicella zoster virus)
(IV) human herpesvirus 1 (herpes simplex virus 1)
(V) human herpesvirus 4 (Epstein-Barr virus)
(VI) tupaiid herpesvirus 1 (tree shrew herpesvirus)
= unique or quasi-unique region.
= reiterated domains.
—► + ► = orientation of repeated sequence.
(I) LTR - left terminal repeat
RTR - right terminal repeat
(II) The terminal repeats are reiterated many times
and their number can vary.
(III) IR - internal repeat
TR -terminal repeat
(III) & (IV) UL - unique long region
Us - unique short region
These components invert giving the potential
for isomers (2 in group (III), 4 in group (IV)).
IRl - internal repeat long
IRS - internal repeat short
TRl -terminal repeat long
TRS - terminal repeat short
(VI) R1-R4 - repeat regions.
This diagram is a composite adapted from Davison (1991),

















understood. The nucleocapsids may then be transported to the cell surface and
exocytosed. It has also been suggested that de-envelopment and re-envelopment
processes occur such that the final envelope of HSV-1 is derived from a post-
endoplasmic reticulum compartment rather than the nuclear membrane as the first
model predicts (Whiteley et ah, 1999).
1.1.3 Herpesvirus latency
"The evolution of exquisite and diverse mechanisms for the
establishment and maintenance of latency and the reduced capacity
of herpesviruses to cause severe disease in their natural hosts as
compared to heterologous hosts suggests that herpesviruses have
evolved a relationship with their hosts that permits them to survive
and be perpetuated." (Roizman and Baines, 1991)
Latency is defined as a persistent infection where the virus genome is present without
production of infectious virus particles (Stevens, 1989). During latency the virus
DNA is in a circular episomal form and limited virus gene expression occurs. The
ability to establish a latent infection enables the virus to persist for the lifetime of the
host largely because the virus remains undetected by the host immune system. There
are various theories as to how and why latency may occur, which have been based
mainly on analysis of HSV-1 and EBV.
Skin, mucous membranes and corneal epithelium are the common primary sites of
HSV-1 infection. The virus can then infect neurons of the peripheral sensory ganglia.
Once it has entered it ascends the nerve axons by retrograde axonal transport to the
somas. Here the virus establishes the latent state and virus replication has to be
prevented. Latency associated transcripts (LATs) are the only transcripts expressed
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by latent HSV-1 (Wheatley et al., 1991; Steiner, 1996; Mellerick and Fraser, 1987).
LATs are encoded within the long repeats of the virus genome. However, studies
using mutant viruses have indicated that expression of LATs is not essential for
establishment or maintenance of latency or indeed for reactivation from latency.
Nevertheless, these studies did show that reactivation is greatly enhanced by the
LATs (Javier et al., 1988). All mutant viruses that have been studied are able to
establish latency albeit with different efficiency, therefore implying that no single
virus gene product is absolutely essential for the establishment of latency (Stevens,
1989). Establishment of latency of HSV-1 is associated with inefficient expression of
IE genes in neurons, which may arise through different pathways (Preston, 2000).
The function of LATs has been described in two alternative models:
1) If present in the nucleus, LATs may inhibit translation of the IE gene ICPO
thereby reducing lytic gene expression resulting in reduced virus replication
and establishment of latency.
2) If LATs are in the cytoplasm they may be translated and the resulting
products may stimulate replication and therefore encourage reactivation.
When and why either of these two models may occur is not clear and there is no
general consensus on LAT function (Millhouse and Wigdahl, 2000).
In contrast with HSV, EBV establishes latency in dividing cells and up to 11 EBV
genes are expressed. The maintenance of latency is therefore likely to involve a
different mechanism to that of HSV-1. The pattern of latent gene expression in
various EBV-associated tumours differs. Latent genes expressed are six Epstein-Barr
virus nuclear antigens (EBNAs) -1,-2, -3A, -3B, -3C and -LP, three latent membrane
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proteins (LMPs) 1, 2A and 2B and two non-polyadenylated (non-coding) RNAs
called EBERs 1 and 2. Three types of latent infection have been described. Latency
type I: EBNA-1 expression is observed in endemic and sporadic Burkitt's lymphoma.
Latency type II: EBNA-1 and the LMPs are expressed in nasopharyngeal carcinoma,
Hodgkin's disease and T-cell lymphomas. Latency type III: Expression of all six
EBNAs and the LMPs is detected in immunoblastic lymphomas. All EBV positive
tumours express the EBER RNAs (Young et al., 2000).
EBNA-1 is associated with chromatin and is involved in replication of the virus DNA
and its maintenance as an episome as well as its replication. It achieves this through
interaction with the origin of replication (oriP), which is distinct from that used in the
lytic cycle. EBNA-2 has a crucial role in the transformation process and can act as a
transcriptional activator of cellular and virus genes (Young et al., 2000). EBNA-3A
and EBNA-3C are essential in the process of lymphocyte transformation in vitro,
whereas EBNA-3B and EBNA-LP are not (Cohen et al., 1989; Tomkinson et al.,
1993). LMP-1 is important for cell transformation and cell phenotypic changes.
LMP-2 and -3, although not essential for transformation, appear to have roles in
signalling pathways (Young et al., 2000; Stevens, 1989).
1.1.4 Gammaherpesviruses
The main distinguishing characteristic of gammaherpesviruses (yHVs) is their ability
to achieve latency in lymphocytes. Gammaherpesvirinae are split into the yl and y2
genera, known formally as the Lymphocryptovirus (B-cell tropic) and Rhadinovirus
(B- or T-cell tropic) genera (Efstathiou et al., 1990). All yHVs causing significant
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veterinary diseases are in the Rhadinovirus genus. In ungulates and non-human
primates, yHVs have been identified which pose no threat to their natural host, but
cause lymphoproliferative diseases in related animals (Murphy et al., 1999).
1.2 Malignant catarrhal fever
Malignant catarrhal fever (MCF) is a lymphoproliferative and degenerative disease
which affects members of the Artiodactyla family such as cattle and deer. MCF is a
worldwide disease affecting domestic and exotic animals, predominantly ruminants,
which can be living freely or in captivity (Plowright et al., 1960; Floffman and
Young, 1989; Metzler, 1991; Howard, 1993; Jones et al., 1997; Reid, 2000). The first
description of MCF in Africa was in 1923 (Mettam, 1923) and work published in
1930 described the first reports of MCF in cattle in Europe (Goetze and Liesse,
1930).
1.2.1 Symptoms of MCF
MCF has a variety of symptoms and the affected animal can show many or
practically none. Some common symptoms are shown in Figure 1.3. The outcome
was thought to be almost always fatal. Subsequent work has revealed that
symptomless cases may occur, which had previously gone undetected (Reid et al.,
1984; Milne and Reid, 1990). There may also be more animals recovering than once
thought (OToole et al., 1997).
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Figure 1.3: Symptoms of malignant catarrhal fever.
a) Dry, cracked and encrusted appearance of muzzle, bilateral mucopurulent
nasal discharge and hypersalivation.
b) Corneal opacity.
c) Typical case with encrustation of muzzle, eye lesions, hypersalivation
and nasal discharge.
Reproduced with kind permission from Selman et al, (1974).
The symptoms of MCF have been categorised into four forms. These are :
(0 the peracute form with generalised disease,
(ii) the intestinal form,
(iii) the head and eye form,
(iv) the catarrhal form.
In the peracute form, which is the most severe, the animal initially exhibits a fever
and depression and can die within a few hours of these first visible symptoms
showing (Reid et al., 1984). In most cases the animals die within 2-12 days after the
onset of fever (Howard, 1993).
1.2.2 Clinical signs
Examples of the many symptoms include high fever, inflammation of conjunctival,
oral and nasal mucosa, lymphadenopathy and leukopenia (Metzler, 1991; Jones et al.,
1997). Rectal temperature can rise to 41-42°C (Selman et al., 1974; Pierson et al.,
1978; Reid et al., 1979). There is also nasal and ocular discharge which starts as clear
and watery but progresses to a mucopurulent secretion (Selman et al., 1978; Howard,
1993). The muzzle epidermis may become dry and cracked and bleeding occurs
(Selman et al., 1974; Liggitt et al., 1978). Depending on the type of MCF, diarrhoea
or constipation can occur (Florzinek, 1990). Necrosis and vasculitis as well as
lymphocyte proliferation and tissue infdtration are other features (Metzler, 1991).
The disease can involve the respiratory and alimentary tract where lesions or erosions
can occur as well as pneumonia and necrotic pharyngitis, laryngitis and tracheitis
(Florzinek, 1990). In addition, the lymphoid organs can be affected. A variety of skin
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lesions may also be observed (Howard, 1993). Extensive muscle tremors are seen,
along with incoordination, a twisted neck, random eye movements, ear-twitching and
aggressive behaviour (Florzinek, 1990).
1.2.3 Gross pathological changes
Many body systems are affected by MCF and autopsy exposes numerous gross
pathological changes. Necrosis and erosion of the epithelia can occur in the
alimentary tract, from the pharynx to all chambers of the stomach. Areas of the
intestine also exhibit congestion, fresh blood and mucus. Cellular infdtration into the
liver is observed as round foci and the liver is usually swollen (Daubney and Hudson,
1936).
Haemorrhaging occurs in the turbinates and septum in most of the head-and-eye
cases. Lesions found on the tongue and in the mouth and throat can be red erosions,
ulcers or areas of necrosis (Daubney and Hudson, 1936). Bronchopneumonia along
with congestion and edema occurs in the lungs of 40% of the fatal cases.
Dense cellular infdtration is observed in the swollen kidneys as mottled areas and
there are wedge-shaped areas of dead tissue. The cortical areas of the adrenal glands
have haemorrhaging. Haemorrhage and erosion also occurs in the urinary bladder
along with the congested mucosa in this area. Also, vaginitis is observed with
necrosis, mucosal erosion and mucopurulent discharge.
Generalised lymph node enlargement is observed in 80% of cases. This is most
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prominent in the lymph nodes around the head and neck area and also the bronchial
and renal areas. The spleen is usually slightly enlarged. Generalised synovitis is
observed in some cases (Selman et al., 1974; Liggitt et al., 1980). The cerebrospinal
and synovial fluid collected from an animal which had died from MCF were shown
to be cloudy and contained significantly higher amounts of protein and mononuclear
cells than normal (Pierson et al., 1978).
1.2.4 Histopathologv
MCF lesions are characterised by epithelial degeneration, vasculitis, hyperplasia and
necrosis of lymphoid organs and accumulation of lymphoid cells in non-lymphoid
tissues through interstitial infiltrations.
Destruction of small lymphocytes occurs in the germinal follicles of the lymph node
cortex and the cell debris is ingested by macrophages. Proliferation of lymphocytic
and lymphoblastoid cells occurs in distinct regions of the lymph node, namely the
interfollicular and paracortical areas.
Vasculitis is mainly observed in medium-sized arteries and is accompanied by
infiltration of lymphocytes, lymphoblasts and macrophages into the endothelial layer
of the blood vessels. As a result, the endothelial cells multiply excessively and/or are
enlarged. Due to the increased number of lymphoid cells and the multiplication of
endothelial cells the blood vessels can become blocked (Reid et al., 1979; Liggitt and
DeMartini, 1980a). Connective tissue and the smooth muscle surrounding the blood
vessels can undergo degeneration.
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The connective tissue of the lymph nodes and spleen are also subject to cell
infiltration and degeneration. This also occurs in the intestines where smooth muscle
degeneration occurs (Denholm and Westbury, 1982; Liggitt and DeMartini, 1980b).
The sites in which vascular lesions are most commonly observed are the kidney,
brain, meninges, lung, lymph nodes, adrenal glands and the carotid arteries (Liggitt et
al., 1978). Infiltration of lymphoid cells into the liver and kidney are characteristic of
MCF (Liggitt et al., 1978; Reid et al., 1979).
The main ocular lesion is inflammation of the cornea due to infiltration of lymphoid
cells and degradation of the corneal epithelium which leads to corneal opacity (Huck
et al., 1961).
In summary, the two key components of MCF pathology are tissue necrosis and T-
lymphocyte proliferation. T-lymphocyte proliferation is discussed further in section
1.5 below.
1.2.5 Socio-economic impact
The study of MCF is important because of the devastating economic losses the
disease can cause on individual farms. The disease occurs predominantly in African
and Indonesian cattle. However, it is also a problem in deer farms (Reid et al., 1984;
Dinter and Morein, 1990), and in zoos and wildlife parks (Reid et al., 1987; Bridgen
et al., 1989) where conservation and breeding programmes may be drastically
affected. The most recent estimate indicated that 33 different species have presented
with MCF (Gulland et al., 1989; Blake et al., 1990).
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The first report of MCF in deer occurred in 1976 (Anonymous, 1976) and from 1979-
1985 it was the most important disease of farmed deer in New Zealand (Orr, 1986).
When red deer (Cervus elaphus) farming in Europe and New Zealand was initiated
outbreaks of MCF occurred which in some cases affected as much as 50% of the
herd. This pattern has since changed and now sporadic incidents, affecting only a
single animal, are more common. There could be two reasons for this: either the deer
are being isolated from the carriers of the virus, or the virus and deer may be co-
evolving. Many projects trying to establish the farming of Pere David's deer
(Elaphurus davidianus) were abandoned in their early stages due to the devastating
losses which occurred as a result of MCF.
The disease has had increased relevance in South Africa in the last 10-20 years due to
increased game farming and game conservation. Some farms have reported a 20%
loss of cattle (Barnard and Pypekamp, 1988). This has also become a concern in
North America where bison farming is becoming more common and MCF is also
proving to be a significant disease of this species (Reid, 2000; Schultheiss et al.,
2000). Outbreaks have also occurred in swamp buffalo (Bubalus bubalis) (Hoffman
et al., 1984; Hill et al., 1993). There have been reported incidences of MCF in pigs in
Scandinavia and Europe, the first of these occurring in Germany in 1950 (Loken et
al., 1998; Reid, 2000). These cases expanded the host range because although pigs
belong to the Artiodactyla family they are non-ruminants.
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1.2.6 Incidence of MCF
Table 1.2: Examples of outbreaks of MCF.
Cattle
Total Deaths
Year no. Deaths (%) Location Reference
1960 500 100 20 Kenya Masailand Plowright, 1964
1970 10 000 700 7 Kenya Masailand Plowright etal., 1975
1973 231 87 38 Colorado Pierson et al., 1973
1984 20 5 25 Japan Taneichi et al., 1986
1987 320 49 15 Republic of Ireland Hamilton, 1990
1988 250 35 14 Republic of Ireland Hamilton, 1990
1988 500 100 20 Indonesia Daniels et al., 1988
Obtaining current figures for the number of MCF cases is a problem. In the UK if an
animal is suspected of having MCF, the animal is usually sacrificed without
diagnosis being confirmed. At the Moredun Institute, Edinburgh, there are -300
confirmed cases of MCF a year, the majority of which are from the UK. Most of
these cases are in cattle although there are also some in deer. Similarly, in Africa
there is no system in place for quantifying the number of cases of MCF although
there does seem to be an increased incidence.
There are several factors contributing to an increased incidence of MCF in Africa
including increased game fanning in South Africa and increased wildebeest
populations in East Africa - a six-fold rise in the last 30 years. In addition, the land
area available for use by the Masai for their cattle is decreasing due to expansion of
arable land. This forces them to occupy land which lies in the path of migrating
wildebeest, one of the natural carriers of an MCF-causing virus (H. Reid, pers.
comm.).
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1.2.7 Types of MCF
Until recently, three types of MCF had been identified, the two main ones being the
wildebeest-associated or wildebeest-derived forms of MCF (WA-MCF or WD-MCF)
and the sheep-associated or non-wildebeest-associated forms (SA-MCF or NWA-
MCF) (Metzler, 1991). WA-MCF is found in Africa and in zoos. Transmission
occurs from the black and blue wildebeest (Connochaetes gnu and Connochaetes
taurinus taurinus). SA-MCF is found outside Africa and predominantly affects cattle
and deer.
The blue wildebeest and sheep are the primary hosts and act as reservoirs of infection
but do not succumb to the disease themselves (Plowright et al., 1960; Plowright,
1968; Baxter et al., 1997). Both of these types of MCF can occur as isolated cases or
as epizootics, although SA-MCF is more likely to occur as the former (Reid et al.,
1984; Bridgen and Reid, 1991). Sheep and wildebeest are the main but not the sole
reservoirs as MCF has been found in areas in which neither are present (Mirangi,
1991a).
The third type of MCF is found in North America in feedlot cattle which have no
contact with sheep. This type is more difficult to transmit in experimental conditions
than the wildebeest-associated form and also has a longer incubation period but with
a shorter period exhibiting symptoms. The causative agent of this type of MCF is
unknown (Fenner et al., 1993; Pierson et al., 1979).
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1.3 Causal agents of MCF
The causal agents of MCF are a group of yHVs. WA-MCF is caused by alcelaphine
herpesvirus-1 (AfHV-1) (Plowright et al., 1960; Reid et al., 1984). SA-MCF is
caused by ovine herpesvirus-2 (OvHV-2). Although OvHV-2 has not been isolated, a
DNA clone from lymphoblastoid cells of diseased cattle, deer and rabbits has been
sequenced and shows similarity to other yHVs and particularly A1HV-1 (Bridgen and
Reid, 1991).
The data regarding types of MCF and the causal agents have become increasingly
convoluted due to the discovery of new MCF-causing viruses. For example, virus
recovered from roan antelope was named hippotragine herpesvirus-1 (HiHV-1). This
virus produced MCF in rabbits but disease caused by this virus in non-experimental
conditions has not been observed (Bridgen and Reid, 1991). A virus has been
discovered in hartebeest (AIcelaphus buselaphus) and topi (Damaliscus korrigum)
which has been named alcelaphine herpesvirus-2 (A1HV-2) (Seal et al., 1989;
Roizman and Baines, 1991). This virus has not been associated with any naturally-
occurring disease. However, it causes MCF in rabbits and cattle following
experimental transmission (Bridgen and Reid, 1991). Other authors have used the
term A1HV-2 to describe the virus from hartebeest and have classified the virus from
topi as A1HV-3. A highly virulent virus has been identified as the causal agent of
MCF in white-tailed deer and has been named MCFV-WTD. This is genetically
related to A1HV-1 and OvHV-2. The reservoir for this virus is not known (Li et al.,
2000a).
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Most recently an MCF-causing yHV has been discovered in goats; it has been named
caprine herpesvirus-2 (CpHV-2). Goats had been thought to be a source of OvHV-2
and OvHV-2 sequences have been found in a small percentage of goats studied. The
sequence of the DNA polymerase gene from CpHV-2 was compared to the
homologues in A1HV-1, OvHV-2 and MCFV-WTD and it was found to have 67%,
71% and 73% identity respectively. CpHV-2 has been noted as the causal agent of
chronic disease in Sika deer (Li et al., 2001).
The discovery of new viruses and the observation that there are more varied
presentations of the disease, such as undetected symptomless cases as previously
mentioned, have suggested that the survival rate may be higher than once thought
(O'Toole et al., 1997). These discoveries could assist in identifying natural hosts of
these viruses and therefore be of practical assistance in, for example, wildlife parks
with regard to determining which species can co-habit enclosures. Also these
emerging MCF viruses could solve some of the mysteries regarding the possible
sources for MCF which is neither sheep- nor wildebeest-associated. They provide an
added dimension to the study of MCF, and may prove useful in the future in
determining underlying causes and mechanisms of MCF.
1.3.1 Alcelaphine herpesvirus-1 - causal agent of WA-MCF
In 1960 the agent of MCF from wildebeest was described as a virus and showed
similarities to other known herpesviruses (Plowright et al., 1960). Further
characterisation of its growth and visualisation by electron microscopy was soon
carried out to confirm the initial findings (Plowright et al., 1963).
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A1HV-1 was originally named bovine herpesvirus-3 (BHV-3) but is now called
A1HV-1 because the carrier host, the wildebeest, is in the subfamily Alcelaphinae
(Blake et al., 1990; Castro et al., 1985; Mushi and Rurangirwa, 1981a). The full
classification of A1HV-1 is that it is in the family Herpesviridae, subfamily
Gammaherpesvirinae and genus Rhadinovirus (Ensser et al., 1997; Bridgen et al.,
1989; Bridgen, 1991).
In nature, A1HV-1 generally infects animals of the same family as the carrier host.
A1HV-1 can be passed to domestic cattle, gaur, greater kudu, ibex, white-tailed
wildebeest, white-bearded wildebeest, cape hartebeest (Shih et al., 1989), roan
antelope (Gulland et al., 1989), white-tailed deer (Castro et al., 1982), nilgai, sika
deer, axis deer (Castro et al., 1985) and Pere David's deer (Reid et al., 1987), to
name a few.
In wildebeest secretions A1HV-1 is both cell-associated (CA) and cell-free (CF)
whereas in cattle it is only CA. The virus from cattle, when cultivated in cell culture,
causes cells to form syncytia.
1.3.2 Sequencing of AIHV-1
At least 26 herpesviruses, including examples from each subfamily, have been
sequenced (Murphy et al., 1999). The sequence of the low passage C500 strain of
AIHV-1 was published in 1997 (Ensser et al., 1997) (Figure 1.4). The genome
consisted of a region of DNA, 130,608 bp in length, with low GC content (46.17%)





















































Figure1.4:OrganisationoftheAIHV-1enome Schematicdiagramoft eC500AIHV-1g nomedaptedfrEnss rel.(1997)byDR.Galzi l. TheORFsarnumb redndR1-R7indicatthrepetitivr gions. Thecoloursindicatethconserva ionfORFsbetw na,(3a dysubfamilies.
DNA) of 1113-1118 bp. The L-DNA sequence was analysed revealing 70 open
reading frames (ORFs), with 61 showing similarity to other herpesvirus genes. These
ORFs are arranged in blocks separated by non-conserved ORFs. The blocks are
collinear with the genomes of other Rhadinoviruses, such as herpesvirus saimiri
(HVS), equine herpesvirus-2 (EHV-2) and Kaposi's sarcoma-associated herpesvirus
(KSHV [human herpesvirus-8]) (Ensser et al., 1997) (Figure 1.5). In all
Rhadinoviruses there are some genes, mainly to the far right and far left of the
genome close to the repeat regions, which have homology to cellular genes.
Rhadinoviruses also have several unique genes and in this respect A1HV-1 is no
exception (Ensser et al., 1997).
A1FIV-1 has similar epidemiological and biological properties to the prototype
rhadinovirus, HVS. Both viruses are asymptomatic in their natural hosts, but cause
lymphoproliferative disorders in susceptible animals. A1HV-1 is also similar to many
other yHVs such as KSHV, murine gammaherpesvirus-68 (MHV-68), bovine
herpesvirus-4 (BHV-4), EHV-2, herpesvirus ateles (HVA) and the prototype
Lymphocryptovirus, EBV.
1.3.3 Attenuation of AIHV-1
Attenuation is defined as the reduced capacity of a pathogen to cause disease. It has
been observed that when AIHV-1 is passaged through bovine cell cultures, it changes
from being cell-associated and virulent to cell-free and virulent after approximately
10 passages and then becomes cell-free and attenuated after a further 20 passages.
Figure 1.6 shows the two forms of cytopathic effect (CPE) caused by virulent and by
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Figure1.5:Genomeorganisationfthefullyseq enc dgammaherpesviruses (a)herpesviruss imiri(HVS ,Albrechtetal.1992) (b)herpesvirusatele(AtHV-3),Albr chtt.2000). (c)rhesusmonkeyhadinoviru(RRV ,Searlest.1999). (d)Kaposi'ssarcoma-a sociatedherpesviru(KSHV ,Ru tl.1996). (e)alcelaphineherpesvirus-1AIHV- ),Enssertl.(1997). (f)murineherpesvirus-68(MHV-68),Virgtal.1997) (g)equineherpesvirus-2EHV-2 ,T lfordtal.(1995). (h)Epstein-Barrv rusEBV ,Baeretal.(1984) ORFsareshownsrectangles. ORFsthatareconservedmongllg mmaherp sviru essh d dbl ck. ORFsthathavecounterpartsisomb tnollg mmaherpesviru esrindi dwi hmediumsha ing. ORFsthatareuniqueopart cularvi unotshad ddh vbeenassigncorr spondingprefixes: HVSandAtHV-3-S,RRVKSH-AI -1MH 68E 2-.




Figure 1.6: Cytopathic Effects of Virulent and Attenuated Virus on
Bovine turbinate cells
1(a)- subconfluent BT cells; 1(b) - confluent BT cells;
2-4 - BT cells infected with virulent AIHV-1;
5-7 - BT cells infected with attenuated AIHV-1.
attenuated viruses. Both viruses cause rounding of the cells and thinning of the
monolayer but only the virulent form induces formation of syncytia. (These images
were taken within this project). In the case of A1HV-1, attenuation is measured as the
loss of ability to cause disease symptoms in the laboratory model, the rabbit.
Genomes from the virulent and attenuated forms of the virus have been analysed and
it was proposed that an alteration had occurred in the genome (Handley et al., 1995).
Since the report by Handley et al. (1995), further work has been carried out to
determine the nature of the alteration (H. Wright pers. comm.). A few ORFs were
proposed to be affected by the genome alteration, including ORF50, which is
predicted to encode an R-transactivator (EBV) homologue (Ensser et al., 1997).
Northern blot analysis showed ORF50 mRNA to be present in LGLs containing the
cell-associated virulent form of the virus and also in bovine turbinate (BT) cells
infected with this virus, but not in BT cells infected with the cell-free attenuated form
of the virus. Southern blots and PCR have been used to investigate the rearrangement
that occurs. (H. Wright, pers. comm.). In the published sequence of A1HV-1, ORF50
is present near the middle of the genome at 70-80 kb. Analysis placed ORF50
sequences adjacent to or flanked by repeat sequences and it was suggested that the
ORF50 sequence had been removed from the middle of the genome and inserted
close to the terminal repeat sequences. Further investigation has led to the suggestion
that more than one rearrangement had occurred (H. Wright, pers. comm.).
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1.3.4 Ovine herpesvirus-2 - causal agent of SA-MCF
SA-MCF was first recognised as a cattle disease in Europe (Goetze and Liesse, 1930;
Baxter et al., 1997) but has since been observed worldwide in several susceptible
species, in particular Bali cattle, Asian swamp buffalo and deer, the latter being more
susceptible than cattle to SA-MCF (Floffman and Young, 1989).
Initially, only circumstantial evidence connected sheep to the disease (Reid et al.,
1984). The observation of herpesvirus particles in a sample obtained from a rabbit
with experimental SA-MCF suggested that a herpesvirus was the causative agent
(Schuller et al., 1990). Also, sheep sera were found to contain antibodies, which were
reactive to A1HV-1 although they were not virus neutralising (Rossiter, 1981). In
fact, >95% of sheep from many different countries have antibodies that react with
antigens of A1HV-1 in immunofluorescence tests (Florzinek, 1990). In addition,
cattle with SA-MCF had antibodies that were reactive to A1HV-1 although they too
were not virus neutralising (Rossiter, 1983). These studies suggested that SA-MCF
and WA-MCF were caused by two very similar, but not identical, agents. This
evidence implicated OvHV-2 as the causal agent of SA-MCF (Baxter et al., 1993).
Unlike A1HV-1, OvHV-2 has not been isolated though it has been partially
characterised (Baxter et al., 1997).
Screening of a genomic library obtained from a lymphoblastoid cell line from an SA-
MCF infected cow using probes from A1HV-1 DNA showed that OvHV-2 DNA had
high homology to A1HV-1 DNA (Bridgen and Reid, 1991). A PCR test has since
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been developed to detect OvHV-2 specifically. The primers do not amplify DNA
from A1HV-1 or other related viruses and can be used to diagnose clinical cases.
Evidence that sheep are the carriers of the causal agent was strengthened when sheep
peripheral blood leukocytes were tested by PCR and shown to contain OvHV-2 DNA
(Baxter et al., 1993).
Recent work has been carried out during which almost the entire OvHV-2 genome
has been cloned into cosmids. Sequence analysis of these should resolve some of the
mystery surrounding OvHV-2 and they also provide the possibility of having an
infectious clone of OvHV-2, which could be used in further studies (J. Rosbottom,
R.G. Dalziel and J.P. Stewart, pers. comm.).
1.4 Transmission
1.4.1 Transmission of WA-MCF
Wildebeest are infected with A1HV-1 while in utero and A1HV-1 has been shown to
be present in foetal spleen but not in wildebeest foetal membranes and fluid released
during parturition, making it unlikely that these substances are the source of infection
for cows as had been thought. Also, scavengers remove these substances from
pastures (Rossiter et al., 1983). A1HV-1 has been isolated from nasal and ocular
secretions and from nasal turbinate cells harvested from wildebeest calves. The
calves display viraemia during the first three months of life, when virus particles are
secreted, but overcome it at a time coincident with production of neutralising IgA
antibodies (Mushi et al., 1980a; Barnard and Van de Pypekamp, 1988). It is likely
that pastures which are grazed by cattle are contaminated by the secretions of young
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wildebeest calves. Alternative explanations of transmission, such as droplet
inhalation, are unlikely when the wildebeest and cattle are far apart (Rossiter et al.,
1983). Nevertheless, some cases have occurred where there is substantial distance
between the natural and susceptible hosts, for which there is still no explanation.
The seasonal occurrence of WA-MCF is in accordance with wildebeest calves being
the source of infection (Mushi et al., 1980a). An interesting exception to this
seasonal pattern is seen in South Africa where the disease has been reported to have
occurred through non-direct contact and when wildebeest calves are 8-10 months old,
not under 3 months. Climatic conditions and bad diet resulting in stress and
subsequent virus reactivation in the calves have been implicated, as have vectors
such as flies which may act as intermediates in virus transmission (Barnard and
Pypekamp, 1988). At the moment there is no evidence to support this last suggestion
and indeed there is some to discount it. Although African face flies (Musca
xanthomelas) were able to carry A1HV-1-infected material after feeding on
wildebeest tears, they would have to regurgitate into the eyes of cattle within 30
minutes for transmission of the virus to occur. Furthermore, the titre of the virus they
could carry was so low that transmission was deemed to be highly unlikely (Barnard
et al., 1990).
1.4.2 Transmission of SA-MCF
Seasonal occurrence of SA-MCF has been noted in a similar fashion to WA-MCF. A
high incidence of the disease is associated with the lambing season (Buxton and
Reid, 1980; Baxter et al., 1997). As with WA-MCF, the virus is transmitted from the
natural host, the sheep, to susceptible hosts such as cows and deer but not between
the susceptible hosts (Reid, 2000).
In conclusion, there appears to be more than one mode of transmission of MCF. The
theory of intermediate vectors has not been totally discounted and a mystery remains
on how transmission occurs over large distances.
1.4.3 Experimental transmission
A variety of experiments have been carried out to determine transmissibility of MCF-
causing viruses to various species. Unlike natural transmission which usually occurs
as a result of close proximity of susceptible species to host species, experimental
transmission involves inoculation of blood products or cell suspensions derived from
the spleen, lymph nodes, kidney, brain and tonsils of the carrier animal.
In one such experiment inocula consisting of lymph node or peripheral blood
leukocyte suspensions from SA-MCF-affected cattle were administered to calves,
rabbits and deer. To assess whether the disease had been transmitted, typical signs of
MCF such as fever followed a few days later by catarrhal discharge and diarrhoea
were used. All the cases in rabbits were confirmed by histology. The results showed
that transmission from cattle to calves was possible but not consistent and from cattle
to deer was unsuccessful. In one case where transmission to a calf was successful, it
was able to be subpassaged to another calf and a rabbit. Transmission from affected
deer to unaffected deer and to rabbits was successful. Transmission to calves was still
unsuccessful even when subpassaging the virus from these rabbits and infecting with
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suspensions as described. Incubation times varied from around 50-90 days in the
calves to 5-17 days in the rabbits. Also subpassaged virus from rabbits was used to
infect Syrian hamsters which reacted within 24-45 days; virus continued to be
passaged in this species. It is not clear why the transmission success varies between
cattle and deer to such an extent (Reid et al., 1986).
Perinatal lambs have been tested for presence of OvHV-2. The results showed that
perinatal lambs were largely uninfected with OvHV-2 and lambs removed from the
flock at 2.5 months of age could be OvHV-2-free. (Li et al., 1998). With a view to
determining whether OvHV-2-free sheep could remain so, studies were carried out to
investigate experimental transmission of SA-MCF in adult sheep and lambs. They
showed that both were susceptible to OvHV-2 infection. Transmission was carried
out by intravenously injecting leukocytes or whole blood from OvHV-2-positive
sheep or by housing OvHV-2-free sheep with sheep infected with the virus. In fact,
the efficiency of transmission of the virus was more successful by horizontal means
than by direct inoculation of whole blood. Successful infection was measured by
PCR. Furthermore, injection of peripheral blood leukocytes did not result in
infection. The authors have conjectured that this may mean the virus infection in the
leukocytes is largely unproductive (Li et al., 1999; Li et al., 2000b).
Rabbits have been important as experimental models of both WA-MCF and SA-MCF
as when they are infected with the virus or virally-infected material, they show
similar symptoms to those seen in the natural disease (Buxton and Reid, 1980). The
use of rabbits along with cows and monolayer tissue culture was used for propagation
of A1HV-1 ultimately leading to its isolation (Plowright et al., 1960). Rabbits have
since been used in the investigations of the symptoms, transmission and molecular
basis of the disease (Buxton and Reid, 1980; Reid et al, 1984).
Alternative animal models for MCF were also investigated. Hamsters are highly
susceptible to both WA-MCF and SA-MCF and show typical signs of the disease
whereas mice do not show any symptoms. Rats and guinea-pigs are susceptible to
WA-MCF but resistant to SA-MCF (Jacoby et al., 1988a and b; Dinter and Morein,
1990; Bridgen et al., 1992).
1.5 Target cells
Much work has been carried out to examine the target cells involved in MCF,
particularly SA-MCF. Lymphoblastoid cell lines have been derived from both A1HV-
1- and OvHV-2-infected animals, including cattle, deer and rabbits, which have the
characteristics of large granular lymphocytes (LGLs). LGLs can be natural killer
(NK) cells or cytotoxic T-cells as the latter type can also assume the granular
morphology (Abbas et al., 1994). Cultures of this cell type can be obtained from a
range of tissues, such as thymus, spleen, lymph node or cornea from MCF-infected
animals. The generation of these cell lines is difficult but can be improved by the
addition of feeder cells and rIL-2 to the medium. The derived cell line can lose the
requirement for these over time (Reid et al., 1989).
LGLs cultured from infected red deer and cattle were shown to be cytotoxic for both
primary cell cultures and for established cell lines. Examples of the cells used were
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bovine and ovine kidney cells, BT cells and deer testes cells. This activity was not
directed only to histocompatible target cells but also to heterologous cells. This led to
the suggestion that these cells have NK cell-like activity and are not classical
cytotoxic T-cells (Reid et al., 1989).
The LGLs have been described as having similar properties to lymphokine-activated
killer (LAK) cells which are NK cells with enhanced cytotoxicity due to cytokine
stimulation. Also, following addition of IL-2, the LGLs acquire T-cell markers. The
difference between LGLs obtained from a cow with MCF and similar cell
populations obtained from a healthy animal is not the ability to kill, but the ability of
the cells from a diseased animal to be propagated in culture for long periods of time.
It has been extrapolated from this that infection by the virus may therefore enhance
the cell's ability to proliferate (Cook and Splitter, 1988).
T-lymphocytes involved in mediating the immune reponse can be classified
according to their surface markers. Cytotoxic T-lymphocytes are CD8+ and CD4-
whereas helper T-lymphocytes have the opposite marker profile. Monoclonal
antibodies and a fluorescent activated cell sorter (FACS) are used to detect and
analyse the surface markers on the LGLs. In one study, the LGLs from three cows
were classified as cytotoxic lymphocytes on the basis that they were CD8+/CD4-
although one other cow did have LGLs with the opposite marker profile and thus
were classified as helper lymphocytes. Two cell lines derived from infected deer in
this study were found to be CD4-/CD8-. Both sets of LGLs, from the cattle and the
deer, were classified as NK cells and all contained virus DNA sequences. Only the
deer cell lines could transmit the disease to both deer and rabbits. The bovine LGLs
could not transmit the disease. Thus this study suggests that there are three T-cell
subsets, CD4+/CD8-, CD4-/CD8+ and CD4-/CD8-, and only the latter is involved in
the pathogenesis of MCF (Burrells and Reid, 1991). However, this conclusion may
be misleading because the ability to transmit the disease may be associated with the
species of the infected animal and not the marker profile of the LGLs. As has been
mentioned (Li et al., 2000b; Reid et al., 1989) transmission by leukocytes does not
always occur efficiently or at all.
The pathogenic mechanism of the virus is thought to be indirect as only one cell in
100 000 was positive for virus DNA or virus antigen in a lymph node examination.
Immunohistochemical examination utilising monoclonal antibodies for CD43, a pan
T-cell marker and proliferating cell nuclear antigen (PCNA) demonstrated extensive
T-cell hyperplasia in the spleen and lymph nodes. Analysis of the spleen and lymph
nodes in rabbits infected with A1HV-1 showed the T-cell hyperplasia was due to
CD8+ T-cell expansion (Nakajima et al., 1992; Schock and Reid, 1996). Since there
is very little virus gene expression in MCF lesions, it has been proposed that the virus
infection of LGLs disrupts their normal function and leads to polyclonal T-cell
expansion (Cook and Splitter, 1988).
Lymphocytes are thought of as the main target cell for MCF infection in rabbits.
Virus replication has been observed in the lymphocytes of the spleen followed by
other lymphoid organs (Edington and Patel, 1981; Patel and Edington, 1981).
However, some infectivity has been detected in macrophages and monocytes
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(Rurangirwa and Mushi, 1982). It is possible that these may be carrier cells involved
in the spread of virus throughout the body but which do not support productive virus
replication themselves. They may also be the underlying cause of
immunosuppression of the infected animal because their usual functions such as
phagocytosis and antigen presentation may be compromised by the presence of the
virus (Mushi and Rurangirwa, 1981b).
Administration of cyclosporin-A, a potent T-lymphocyte suppressor, before infection
prevents lymphoproliferation. However, necrosis of tissues still occurs therefore
implying that the polyclonal T-lymphocyte proliferation is not directly involved in
tissue degradation (Buxton et al., 1984). If the T-cell proliferation in normal disease
progression is due to dysregulation of an aspect of the immune system, it is feasible
that other aspects of the immune system are also affected so leading to the other
symptoms characteristic of MCF.
1.5.1 MCF disease model
A model developed to explain the pathogenesis of MCF, which is both a
lymphoproliferative and degenerative disease, is that it is a result of an immune
dysfunction caused by virus infection. The traditional roles of the LGLs are to act as
NK cells by killing virally infected and transformed cells and suppressing excessive
T-lymphocyte responses. If these cells are disrupted by virus infection then in theory
unchecked T-cell proliferation and non-specific cell killing would ensue. Indeed,
both T-cell hyperplasia and non-specific tissue destruction are seen in MCF (Reid et
al., 1984). The normal function of these cells is to kill virally-infected cells, but they
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themselves are infected and being 'controlled' by the virus. Dysregulation of the IL-2
cellular messenger has been implicated in having possible involvement in the acute
stages of the disease mechanism. The suggestion is that proliferation and necrosis
occur in different phases of the disease. The lymphocyte proliferation is due to
increased IL-2 production which is as a result of dysregulation of NK cells. The
necrosis occurs through a more severe NK cell dysregulation and the destruction of
host cells results (Schock and Reid, 1996).
1.6 Treatment and immunisation
There is presently no effective treatment available for MCF. Current advice involves
distancing susceptible hosts from reservoir hosts by keeping animals in separate
housing or using land not grazed by reservoir hosts. However, this is not always
possible for economic or practical reasons. Also the increasing numbers of viruses
and potential reservoir hosts may mean that this approach will not always be
effective.
Levamisole, a powerful antihelmintic, which works by restoring T-cell function in
immunocompromised individuals, was used to successfully treat a gaur with MCF.
However, it had no effect on the course of infection in rabbits (Mushi et al., 1980b).
MCF is a serious enough problem in some parts of the world to warrant interest in
vaccine development. To date, no suitable vaccine has been developed. One of the
first attempts used an avirulent strain of A1HV-1, called WC11, both in a live form
and in a formalin-inactivated form, to vaccinate cattle. A formalin-inactivated form
of the virulent C500 form has also been used. Although high levels of virus-
neutralising antibodies were produced in every case, this did not confer protection to
challenge from virulent virus by exposure to wildebeest herds, implying that humoral
mechanisms are not sufficient to confer resistance (Plowright et al., 1975).
This was corroborated by a study investigating MCF in immunosuppressed versus
immunostimulated rabbits. There was no change in the course of the disease in the
two sets of rabbits, irrespective of the presence of antibodies, implicating the
involvement of cell-mediated immunity in protection from virus infection
(Rurangirwa and Mushi, 1984).
More successful approaches towards vaccination have involved the use of inactivated
virulent cell-free virus as the vaccine. This protected rabbits against challenge by
cell-free virulent virus but not cell-associated virus administered in the form of a
rabbit lymph node suspension (Edington and Plowright, 1980; Russell, 1980). There
has been success against challenge with virus infected rabbit lymphoid cells after
immunisation with virus-infected cultured rabbit kidney cells although the immunity
diminished after 47 weeks. This is a significant improvement (relative to the lifetime
of the rabbit), but potential difficulties are highlighted in previous vaccination
experiments that showed some success in rabbits but not in cattle. Moreover, the
method used was complex, expensive and therefore impractical (Rossiter, 1982).
There has also been success in immunising cattle with the virulent 707K herpesvirus
isolate from MCF-affected cattle in the USA. Two inoculations conferred immunity
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in 3 out of 4 cows up to 9.5 months. A disadvantage with this approach was that
while one inoculation was not sufficient, repeated inoculations increased the risk of
the animal developing the disease (Mirangi, 1991a; Mirangi, 1991b).
Further investigation of the immune response to these viruses as well as more
information on the general pathogenesis of MCF is needed to enable an efficient
vaccine to be developed.
1.7 Gene expression in gammaherpesviruses
The diversity of cell types and cell function within higher organisms results from the
strict regulation of their extensive genetic information. This regulation is achieved by
a variety of mechanisms including the organisation of chromosomes into highly
condensed, transcriptionally inactive heterochromatin and potentially
transcriptionally active euchromatin. Also, methylation of the DNA is associated
with transcriptionally inactive regions. In addition, there is control at the sequence
level including promoter sequences upstream of the coding sequence and also
enhancer sequences that may be position and orientation independent.
In contrast, viruses have a size constraint imposed on their genome. They exploit the
cellular regulatory processes to their own advantage. For example, viruses use a wide
variety of mechanisms to promote or repress cellular gene expression, in order to
create a more favourable cellular environment for replication of its nucleic acid. The
main purpose of virus gene expression is to facilitate the production of multiple
copies of the virus genome and infectious virions. Despite the constraints on genome
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size, virus gene expression is a highly regulated process. The genome sequence is
used in a highly efficient manner, with multiple overlapping ORFs and
transcriptional control sequences for one gene contained within the sequence of an
adjacent gene.
1.8 R-transactivator homoloaues in qammaherpesviruses
Herpesviruses code for several trans-acting factors, which regulate the gene
expression cascade. The sequence of A1HV-1 has shown that A1HV-1 ORF50 has
weak homology to other herpesvirus genes such as the BRLF1 gene encoding the
Epstein-Barr virus R-transactivator protein (Rta), and the ORF50 genes of HVS,
KSHV, MHV-68, BHV-4 and EHV-2 (Ensser et al., 1997). Fortunately, yHV gene
nomenclature is largely co-ordinated between different viruses, so in all cases other
than EBV this open reading frame is called ORF50. The Rta nomenclature referring
to the gene product of BRLF1 has been adopted for the gene products of HVS,
KSHV and MHV-68 ORF50.
1.8.1 Epstein-Barr Virus
The Epstein-Barr virus, a human herpesvirus, was discovered in 1964 in tumour
samples during a search for the causal agent of endemic (African) Burkitt's
lymphoma (Epstein et al., 1964). It is now known that EBV infects the majority of
the world's adult population and persists throughout life without causing serious
illness. However, if primary infection is delayed, teenagers may suffer from
infectious mononucleosis. More significantly, EBV is associated with many human
malignant proliferations including lymphomas and oral hairy leucoplakia in
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immunocompromised individuals such as AIDS patients, endemic Burkitt's
lymphoma in children, where falciparum malaria is hyperendemic, and
nasopharyngeal carcinoma in Chinese and Inuit adults. EBV is also a powerful
immortalizing agent in vitro (Epstein and Crawford, 1998).
1.8.2 EBV transactivators
EBV has several transactivators, namely R, Z, M and EBNA-1 and -2. The gene
transcripts for BZLF1 which encodes the Z-transactivator (also known as Z, Zta,
ZEBRA or EB1) and BRLF1 which encodes the R-transactivator (also known as R or
Rta) are the only IE RNAs (Biggin et al., 1987). The products of BZLF1, BRLF1 and
BMLF1 (Zta, Rta and Mta, respectively) are key EBV gene expression regulators
(Farrell, 1989). Rta and Mta homologues are present in all yHV family members
whereas Zta homologues are absent or are not well conserved (Ragoczy et al., 1998).
Zta and Rta both seem to function in a cell-specific manner, sometimes working in
synergy (Holley-Guthrie et al., 1990). Zta is expressed from two promoters, one
giving a monocistronic mRNA and one as a bicistronic mRNA along with Rta
(Ragoczy et al., 1998).
The EBV R-transactivator was identified in 1988 and shown to activate several virus
promoters including one promoter producing a cytoplasmic early antigen which is
homologous to the Bcl-2 oncogene (Hardwick et al., 1988). Rta also transactivates
the promoter for the BMLF1 gene which encodes the Mta transactivator (Gruffat et
al., 1992). Rta-responsive elements have been identified in the promoters of genes
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induced by Rta. The transcriptional activation domain is located in the C-terminus of
Rta. In vitro, Rta has been shown to bind as a homodimer to an Rta responsive
element (Manet et al., 1991). In contrast, it can autoregulate itself as well as the EBV
DNA polymerase gene through an indirect mechanism (Zalani et al., 1992; Liu et al.,
1996). Rta activates the Zta promoter (Ragoczy and Miller, 1999) and has also been
shown to activate the human c-myc promoter in transient transfection assays (Gutsch
et al., 1994). In turn, Rta itself can be activated by the Spl cellular transcription
factor mechanism (Zalani et al., 1992). Thus, Rta acts as a transactivator for both
cellular and virus genes and can itself be activated by both cellular and virus
transcription factors.
Zta is a sequence-specific DNA-binding transcription factor which binds as a dimer
(Lieberman and Berk, 1990). It is a member of the c-Jun/c-Fos/GCN4 family of
proteins which bind AP-1 consensus sequences (Chang et al., 1990). Zta interacts
directly with TFIID, an essential component of the transcriptional complex and
stabilises the interaction of TFIID with DNA (Lieberman and Berk, 1991). Zta
activates the promoters for ORFs BMLF1 (Mta) and BMRL1, which codes for a
subunit of DNA polymerase, and downregulates promoters encoding latent products
(Kenney et al., 1989a). It also activates the Mta promoter although this is probably
via an indirect mechanism mediated through the Rta transactivator which is a direct
target of Zta (Kenney et al., 1989b). Since Rta induces expression of Zta, both
transactivators stimulate their own expression (Sinclair et al., 1991; Flemington et
al., 1991). Different domains of the Zta protein are required for the different
functions (Kenney et al., 1989a).
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1.8.3 EBV transactivators in latent to lytic switch
Both Zta and Rta have been implicated in reactivation of the virus from the latent
phase to a lytic cycle. Expression of Zta in latently infected B-lymphocytes induced
the lytic cycle (Countryman and Miller, 1985; Chevallier-Greco et al., 1986; Takada
et al., 1986). Previous studies had shown that Rta alone was unable to disrupt latency
in a lymphocyte cell line and it was thought that both Zta and Rta may be required
(Cox et al., 1990). However, it has since been shown that Rta can disrupt latency in a
B-cell line as well as in epithelial cells (Ragoczy et al., 1998; Zalani et al., 1996).
Thus either protein appears to be sufficient for reactivation.
1.8.4 EBV transactivators - interaction with the cell cycle
A common strategy of DNA viruses is to interfere with the regulation of the cell
cycle to enable their propagation to continue (Swenson et al., 1999). Rta has been
shown to bind in vivo to the retinoblastoma protein (pRB), a cell cycle regulator,
after lytic cycle intitiation. This binding occurs in conjunction with the release of
E2F, a transcription factor, from the RB-E2F complex (Zacny et al., 1998). Zta has
been shown to bind in vivo to p53, a tumour suppressor protein, thereby inhibiting
the transactivation ability of p53. This interaction also prevents Zta from inducing a
latent to lytic switch (Zhang et al., 1994). Zta has been shown to induce a growth
arrest (Rodriguez et al., 1999), which could be beneficial to the virus as EBV
replication occurs most efficiently in growth-arrested cells. Paradoxically, Rta has
been shown to induce S-phase in contact-inhibited fibroblasts.
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Caution should be taken when investigating these interactions in isolation. Clearly,
complex mechanisms are occurring involving the two key EBV transactivators and
host cell cycle regulating proteins, either as a strategy by the virus or as a result of
reaction by the host cell, and there may be opposing strategies in different cell types.
1.8.5 Herpesvirus saimiri
The natural host of herpesvirus saimiri (HVS, saimirine herpesvirus-2) is the squirrel
monkey (Saimiri sciureus) which is apparently unaffected by the virus. When passed
to susceptible species such as other new world primates, HVS can cause T-cell
lymphomas. It can also transform simian and human T-lymphocytes in tissue culture.
The HVS genome has been sequenced (Albrecht et al., 1992) and much work has
been carried out on determining the genes responsible for the transforming ability of
this virus and on its transactivators.
1.8.6 HVS transactivators
There are two stable IE transcripts detected in HVS-infected cells treated with
cycloheximide. These are transcribed from genes homologous to the EBV BRLF1
and BMLF1 genes encoding the R and M transactivators respectively. Initial studies
using transient transfections and an HVS delayed-early promoter showed that these
gene products also behaved as transactivators and were therefore functionally
equivalent to Rta and Mta of EBV. Subsequent analysis of their amino acid sequence
indicated that they shared common protein domains with the EBV transactivators
(Nicholas et al., 1991). This was the first report to identify an Rta homologue.
39
The HVS Rta homologue is encoded by HVS ORF50. This ORF encodes for two
transcripts; ORF50a is a spliced transcript expressed in the early stages of replication,
ORF50b is expressed from a promoter located in the second exon of ORF50a and is
expressed later in the lytic cycle. Both products can activate the ORF6 promoter,
encoding a component of the major DNA binding protein, but the product of ORF50a
is five-fold more effective (Whitehouse et al., 1997a). ORF50 responsive elements
have been identified in the ORF6 promoter through deletion analysis and gel
retardation assays (Whitehouse et al., 1997b). The ORF50 response elements will be
discussed further in Chapter 5.
The Mta homologue of HVS, encoded by ORF57, can either activate or repress
promoters depending on the absence or presence of an intron within the coding
region. The ORF57 gene product activates expression when there is no intron
(Whitehouse et al., 1998a). The mechanism underlying this action may involve the
redistribution of the spliceosome complex by the ORF57 gene product (Cooper et al.,
1999). ORF57 therefore controls gene regulation through a post-transcriptional
mechanism (Whitehouse et al., 1998b). The domains of ORF57 required for these
various functions have been identified. A hydrophobic domain is involved in
transactivation and nuclear localisation and a zinc finger-like domain is required for
the transactivation, repression and the spliceosome redistribution functions (Goodwin
et al., 2000).
Similar to the situation in EBV, in which Rta activates Mta expression, the ORF50a
gene product of HVS activates the ORF57 gene. In turn the ORF57 gene product
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downregulates expression of ORF50a therefore creating a negative feedback
mechanism. In contrast, the ORF57 gene product enhances the transactivation ability
of ORF50b (Whitehouse et al., 1998a and b). The C-terminus of ORF50b is essential
for transactivation. This activation domain contains essential hydrophobic residues
and is necessary for interaction with the TATA-box binding protein (TBP). These
hydrophobic residues are commonly found in activation domains, for example in the
herpes simplex VP 16 protein and in EBV Rta (Hall et al., 1999).
A very recent study investigating the mechanism of the latent-lytic switch in HVS
has reported that the HVS ORF50a protein under the control of the CMV IE
promoter, though not its own promoter, can reactivate the virus in the A549 cell line
in which HVS is maintained as an episome. The lytic replication cycle is induced
resulting in infectious virus particles (Goodwin et al., 2001).
1.8.7 Kaposi's Sarcoma-associated herpesvirus
Kaposi's sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 (HHV-8)
was discovered in 1994 (Chang et al., 1994). KSHV is associated with Kaposi's
sarcoma, primary effusion lymphoma (PEL) and multicentric Castleman's disease
(MCD) (Schulz, 1998). Since its discovery there has been intense research on KSHV
and it too has been sequenced (Russo et al., 1996). The genome has several genes
which are homologues of genes encoding cell cycle regulatory proteins and
signalling molecules such as IL-6, CC chemokines, interferon response factor, OX-2
(N-CAM transmembrane protein), Bcl-2, cyclin D2 and G-protein coupled receptor
homologue IL-8R (Russo et al., 1996; Neipel et al., 1997).
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1.8.8 KSHV Transactivators
KSHV has homologues of ORF50 and ORF57 (Russo et al., 1996). Also, K8, which
was first thought to be a unique KSHV gene, is a Zta positional homologue (Lin et
al., 1999). One IE transcript of KSHV that was identified encoded ORF50 and K8
(Zhu et al., 1999; Seaman et al., 1999). KSHV ORF50 is classified as an IE gene,
being expressed 4 h after chemical induction in the presence of cycloheximide. K8 is
classified as an early gene, which appeared 8-13 h after stimulation. ORFK8 is not
always expressed with ORF50 (Sun et al., 1999). For KSHV the gene product of
ORF50 is referred to as KSHV/Rta.
The KSHV Zta homologue is called K-bZIP because like EBV Zta, it belongs to the
basic-leucine zipper (bZIP) family of transcription factors. There are several spliced
variants of the K-bZIP protein. The C-terminus of full-length K-bZIP is involved in
forming homodimers (Lin et al., 1999). In one study K-bZIP could not
heterodimerise with other members of the bZIP family, such as c-Jun and c-Fos, and
likewise EBV Zta only formed homodimers. K-bZIP is a structural homologue of Zta
but it is not yet known whether it is a functional homologue (Gruffat et al., 1999). No
Zta homologue has been found in the other yHVs (Zhu et al., 1999).
In transient transfection reporter assays, KSHV/Rta activated the early promoters for
polyadenylated nuclear RNA (PAN-RNA [also called nut-1]), TK, DNA binding
protein (DBP) and kaposin. Two late promoters for the assembly protein and
glycoprotein B genes were not activated by KSHV/Rta (Lukac et al., 1998).
KSHV/Rta was also capable of auto-activation as shown both by reporter assays and
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by induction of ORF50 from latent viral genomes after transfection of an ORF50
expression plasmid (Deng et al., 2000).
The activation of PAN RNA by KSHV/Rta was investigated further. PAN-RNA is a
novel non-coding RNA. It is also the most abundant (80%) of all KSHV poly-A
transcripts. An Rta-responsive element in the PAN-RNA promoter was identified and
purified. KSHV/Rta was shown to bind very stably to this element (Song et al.,
2001).
Recent work has proposed that KSHV/Rta activates two classes of lytic promoters: 1)
highly responsive promoters activating other virus regulatory proteins such as K-
bZIP and ORF57 and 2) less responsive promoters driving genes such as PAN-RNA
and kaposin. Two different response elements have been identified to which
KSHV/Rta binds either directly or indirectly through a cellular complex (Lukac et
al., 2000). The response elements will be discussed further in Chapter 5.
The ORF57 gene product of KSHV acts through post-transcriptional regulation to
enhance accumulation of certain virus transcripts, including ORF50, ORF59 and
PAN-RNA. The product of ORF57 seems to enhance the activity of KSHV/Rta such
that when ORF50 and ORF57 are co-expressed ORF50-responsive promoter activity
is enhanced (Kirshner et al., 2000).
The ORF57 gene product localises to the nucleus in a specific punctate distribution
and co-localises with the cellular splicing factor SC-35. ORF57 thus shares
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properties with ORF57 of HVS and with ICP27 of HSV-1 (Bello et al., 1999).
1.8.9 KSHV transactivators in latent to lytic switch
The KSHV ORF50 gene product, KSHV/Rta, is a potent activator able to activate E
and L genes. In a study to investigate the ability of several virus genes to activate
lytic gene expression in a B-cell line derived from a PEL tumour, only KSHV/Rta
was able to activate the expression of ORF59 (DNA processivity factor) and K8.1
(glycoprotein), two markers for lytic gene expression. This was specific for
KSHV/Rta since ORF57, K3 and K5 gene products did not activate these lytic genes.
(Lukac et al., 1998).
A similar study was carried out using different lytic gene expression markers. The
expression of KSHV lytic genes induced by KSHV/Rta included PAN RNA, viral
IL-6, the K8 gene and the K4 gene encoding viral macrophage inflammatory protein
II (vMIPII). In this same study the activation of EBV and KSHV lytic genes by
KSHV/Rta or EBV Rta or EBV Zta were tested. Each transactivator only activated
genes from its parent virus (Sun et al., 1999; Ragoczy et al., 1998).
The lytic cycle is thought to be important for tumour pathogenesis because Kaposi's
sarcoma is an endothelial tumour and usually the patient will have had a latent
KSHV infection before having a KS tumour. Therefore, reactivation from the B-cells
containing latent virus is thought to be necessary (Lukac et al., 1998). If KSHV/Rta
controls the entry into the lytic cycle it may therefore be a key factor in tumour
development (Sun et al., 1998) and could become a target for therapy. It has been
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proposed that since the cellular signalling molecules, which could conceivably be
involved in tumour development, are only expressed by KSHV during its lytic cycle,
reactivation may be a prerequisite for KS tumours to develop (Lukac et al., 1999).
This is not the case for EBV, which is associated with lymphoid tumours, and may
not be the case for the other KSHV-associated neoplasia, MCD and PEL.
KSHV/Rta contains phosphorylation sites for protein kinase C. Activators of protein
kinase C also activate the lytic cycle. The C-terminus of KSHV/Rta contains an
activation domain. Removal of this domain results in a protein that acts in a dominant
negative manner and which is able to form multimers with full-length KSHV/Rta.
When this truncated form is expressed in latently infected cells the lytic cycle is no
longer induced by usual chemical stimulation. Reactivation and virus replication are
both suppressed. These experiments indicate that KSHV/Rta plays an essential role
in lytic replication and it is thought to be a molecular switch controlling transition
from latency to a lytic cycle (Lukac et al., 1999).
Another study reported the ability of KSHV/Rta to activate virus interferon
regulatory factor (vIRF) and virus DNA polymerase promoters in three cell types
(Chen et al., 2000). This contradicts a previous study, which stated that KSHV/Rta
did not activate the DNA polymerase promoter (Lukac et al., 1999). Chen et al. also
deleted two putative nuclear localisation signals (NLS) from ORL50, which
abolished its transactivation ability. Functional Spl binding sites were identified in
the vIRF promoter and it was suggested that they might be involved in its
transactivation by ORF50 (Chen et al., 2000).
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A recent study using the HH-B2 PEL cell line showed that a plasmid expressing
ORF50 was able to initiate the lytic cycle as measured by determining lytic virus
DNA replication, late gene expression and virus release (Gradoville et al., 2000). The
other studies mentioned had not examined whether the lytic cycle goes to
completion. This study suggests KSHV/Rta alone has the capacity to initiate the lytic
cycle, which then goes to completion.
1.8.10 Murine aammaherpesvirus-68
MHV-68, a natural pathogen of rodents, is used as a small animal model to study the
pathogenesis and immunology of yHV infection. This small animal model is
preferable to the primate models used for HVS (Virgin et al., 1997; Nash et al.,
2001).
1.8.11 MHV-68 transactivators
The MHV-68 genome has been sequenced by two groups (Virgin et al., 1997; Nash
et al., 2001) and has revealed the presence of an Rta homologue, encoded by ORF50,
which is expressed as an IE gene. MHV-68 also has an Mta homologue (ORF57).
The ORF50 promoter has been identified and there are two ORF50 transcripts
produced. The ORF50 gene product has been shown to activate the ORF57 promoter
(Liu et al., 2000).
In vitro the Rta of MHV-68 is capable of disrupting latency and activating virus
replication resulting in a complete lytic cycle and production of infectious virus
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particles from the SI IE cell line (derived from a mouse B-cell lymphoma), which is
latently infected with MHV-68 (Wu et al., 2000).
1.9 Project Background
ORF50 has been implicated as one of the genes affected by the deletion and/or
rearrangement of the genome that occurs in A1HV-1 following prolonged passage
through tissue culture.
The ORF50 homologues of other herpesviruses have been shown to be of major
importance both in the crucial mechanism of reactivation, in inducing the cascade of
gene expression and in affecting cell cycle regulation. Many functions are conserved
through members of the same family of viruses and this is true of the key roles of
ORF50 homologues. There is currently a dearth of information on the functions of
specific A1HV-1 genes. The potential importance of the ORF50 gene product in the
virus life cycle, reactivation and pathogenesis of MCF makes it an excellent
candidate with which to engage in functional molecular studies. In keeping with the
nomenclature of the other yHVs, the A1HV-1 ORF50 gene product will be referred to
as A1HV-1/Rta throughout.
"The (MCF) disease process is one of the most devastating in
nature and its elucidation at the molecular level will provide
fundamental information on immunological control mechanisms
and viral pathogenesis." (Reid, 2000)
1.10 Project Aim
The aim of this project is to characterise A1HV-1 ORF50.
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2.4 Mammalian cell and virus work
2.5 RNA work
2.6 Protein work
2.7 Electrophoretic mobility shift assays
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2.1 Materials
2.1.1 Chemicals and solutions
Unless otherwise stated, all chemicals were obtained from Sigma (Sigma-Aldrich
Company Ltd., Fancy Road, Poole, Dorset, BH12 40H, England) or ICN
Biochemicals (ICN Pharmaceuticals Ltd., 1 Elmwood, Chineham Business Park,
Basingstoke, Hampshire, RG24 8WG).
All solutions were made using Milli-Q deionised water (dH20) (Millipore).
General solutions













6x Loading buffer 10% (w/v) Ficoll
0.25% (w/v) bromophenol blue
0.25% (w/v) xylene cyanol
0.4% (w/v) orange G
10 mM Tris-HCl pH 7.5
50 mM EDTA
Solutions for small scale preparation of plasmid DNA
Resuspension solution 50 mM glucose
25 mM Tris-HCl pH 8.0
10 mM EDTA
Denaturation solution 0.2 M NaOH
1% (w/v) SDS
Neutralisation solution 3 MKAc
2 M acetic acid
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Bacterial growth medium
Luria-Bertani (LB) broth: 10 g/1 bactotryptone
5 g/1 bacto yeast extract
10 g/1 NaCl
LB Agar: LB broth plus 15 g/1 bacto-agar




Solutions for preparation of DNA from cell-associated virus
RSB 10 mM NaCl
(resuspension solution buffer) 1 mM MgCl2
10 mM Tris-HCl pH 7.5
TNE 10 mM Tris-HCl pH 8.0
100 mM NaCl
1 mM EDTA
Solution for mammalian cell work
Versene 200 pg/ml EDTA
(pH 7.2) 1% phenol red
sterile PBS
Solutions for RNA work
20x SSPE 3 M NaCl
(pH 7.4) 0.2 M NaH2P04.H20
20 mM EDTA
20x SSC 3 M NaCl
(pH 7.0) 0.3 M sodium citrate
50x Denhardt's solution 1% (w/v) Ficoll
1% (w/v) polyvinylpyrrolidone
1% (w/v) BSA
lOx RNA gel-running buffer 0.2 M 3-(N-Morpholino)propanesulfonic acid (MOPS)
(pH 7.0) 80 mM sodium acetate
10 mM EDTA
lOx RNA gel-loading buffer 50% (v/v) glycerol
1 mM EDTA pH 8.0
0.25% (w/v) bromophenol blue
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RNA marker staining 0.2% (w/v) methylene blue
solution 0.4 M acetic acid
0.4 M sodium acetate
Solutions for protein work
12% (v/v) acrylamide*
0.375 M Tris-HCl pH 8.8
0.1% (w/v) SDS
0.1% (w/v) ammonium persulphate**
0.04% (v/v) TEMED**
5% SDS-PAGE 5% (v/v) acrylamide*
stacking gel 0.125 M Tris-HCl pH 6.8
0.1% (w/v) SDS













0.2% (w/v) bromophenol blue
Solutions for electrophoretic mobility shift assays





0.25 mM DTT (added just prior to use)
0.5 mM PMSF (added just prior to use)




0.25 mM DTT (added just prior to use)







4% non-denaturing 4% (v/v) acrylamide*
polyacrylamide gel 0.5x TBE
0.1% (w/v) ammonium persulphate**
0.2% (v/v) TEMED**
*Molar ratio of acrylamide:N,N'-methylenebisacrylamide is 29:1 (BioRad).
** Added just prior to pouring gel.























Clontech 4700 Kan/Neo CMV IE
pGL3-Basic vector Promega 4818 Amp None
pGL3-Promoter vector Promega 5010 Amp SV40
pRL-SV40 vector Promega 3705 Amp SV40
pcDNA3.1(-)/
myc-His A,B.
Invitrogen 5500 Amp/Neo CMV IE
Abbreviations used in table:
LTR - long terminal repeat, MMLV - Moloney murine leukaemia virus, CMV IE -
human cytomegalovirus immediate-early promoter, SV40 - simian virus 40.
E.coli drug selection: Amp - Ampicillin, Kan - Kanamycin.
Mammalian cell selection: Neo - Neomycin.
EGFP - enhanced green fluorescent protein.
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2.2 Molecular techniques
2.2.1 Polymerase chain reaction
The polymerase chain reaction (PCR) was carried out in a total volume of 50 pi
including 1 pi of 1 U/pl Taq polymerase (Boehringer Mannheim/Roche), 5 pi of lOx
reaction buffer (100 mM Tris-HCl, 15 mM MgCl2, 500 mM KC1 (pH 8.3)), 10 ng of
template, 100 ng of each primer, 10 mM dNTP mix (Sigma), 1.5 mM MgCl2 and
dH20.
A Hybaid Omnigene PCR machine or Hybaid PCR Sprint thermal cycler was used.
The standard PCR programme was 1 cycle of 96°C for 2 min; 40 cycles of 96°C for 1
min, 50°C for 1 min and 72°C for 1 min and finally 1 cycle of 72°C for 7.5 min. The
annealing temperature was varied and is stated for individual primer pairs. PCR
products (25 pi) were analysed on an agarose gel and in some instances bands were
excised from the gel for purification.
All primers were obtained from MWG-Biotech. The annealing temperature for each
primer was calculated as follows:
[(Number of Gs + Cs) x 4] + [(Number of As + Ts) x 2)] - 5 = annealing temperature
(Suggs et al., 1981)
If a restriction endonuclease recognition site was present in the oligonucleotide
primer, its sequence was not included in this equation. Reactions were optimised by
varying annealing temperature, MgCl2 concentration, pH or by adding DMSO or
glycerol (Pomp and Medrano, 1991).
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2.2.2 Reverse transcriptase-polymerase chain reaction (RT-PCR)
DNase I (Gibco BRL Life Technologies) was used to remove DNA from the RNA
preparation. To 1 pg of RNA, 1 pi of lOx DNase I buffer (200 mM Tris-HCl pH 8.4,
20 mM MgCl2, 500 mM KC1) and 1 pi of DNase I (1 U/pl) was added and the
mixture made up to 10 pi with RNase-free dH20. This was incubated at room
temperature for 15 min. The DNase I was inactivated by addition of 1 pi of 25 mM
EDTA and incubation at 65°C for 10 min.
Superscript II RNase H" Reverse Transcriptase (Gibco BRL Life Technologies) was
used for the reverse transcription reaction. To 1 pg of RNA, which had been treated
with DNase I, 1 pi of oligo d(T) primer (500 pg/ml) was added along with 1 pi of
dH20 to make a final volume of 12 pi. This sample was incubated at 70°C for 10
min. To the mixture, 4 pi of 1st strand buffer (250 mM Tris-HCl (pH 8.3), 375 mM
KC1, 15 mM MgCl2), 2 pi of 0.1 M DTT and 1 pi of 10 mM dNTP mix was added.
The sample was then incubated at 42°C for 2 min followed by addition of 1 pi (200
U) of Superscript II reverse transcriptase and a further incubation at 50°C for 50 min.
The enzyme was inactivated by incubating at 70°C for 15 min. PCR was carried out
as in section 2.2.1. One tenth of the reverse transcribed sample was used in a PCR
reaction.
2.2.3 Restriction endonuclease digest of DNA
Restriction enzymes were purchased from New England Biolabs. Reactions were
carried out in a volume of 20 pi - 50 pi with 1 U of enzyme per 1 pg of DNA. The
buffers used were those supplied by the manufacturer. Reactions were incubated at
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37°C for at least 2 h. Digested DNA (20 pi) was analysed on an agarose gel.
2.2.4 Agarose gel electrophoresis of DNA
Samples were loaded onto a horizontal 1% agarose (Bioline) gel made using lx TAE
buffer and containing 1 pg/ml ethidium bromide. The gel was submerged in lx TAE
buffer and samples electrophoresed at a constant voltage (13 cm x 15 cm gels at 100
V or 6 cm x 7 cm gels at 80 V). Loading buffer (6x) was added to PCR products or
products of analytical restriction endonuclease digests. The DNA markers used were
EcoRI and Hind\\\ fragments of bacteriophage lambda DNA (sizes in bp: 21226,
5148, 4973, 4268, 3530, 2027, 1904, 1584, 1375, 947, 831, 564, 125) (Promega) and
a 100 bp DNA Ladder (sizes in bp: 1500, 1000, 900, 800, 700, 600, 500, 400, 300,
200, 100) (Promega). DNA was visualised using a UV transilluminator (UVP inc.) at
a wavelength of 302 nm.
2.2.5 Gel extraction of DNA from agarose gels
DNA fragments were extracted from agarose gels using the QIAquick gel extraction
kit (QIAGEN). The gel slice containing the band of interest was excised and placed
in a micro-centrifuge tube. The addition of proprietary Buffer QG and incubation at
50°C for 10 min with occasional vortexing resulted in solubilisation of the gel. The
sample was added to a QIAquick column containing a silica membrane to which the
DNA bound. Salts were washed through the column by addition of proprietary
Buffer PE, which contains ethanol. The DNA was eluted in 10 mM Tris-HCl pH 8.5.
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2.2.6 Dephosphorvlation of DNA
The 5' phosphates of linear vector fragments were removed prior to ligation by direct
addition of 5 U of shrimp alkaline phosphatase (SAP) (USB Life Science Research
Products) to the restriction digest mix. The mixture was incubated at 37°C for 1 h.
SAP was heat inactivated by incubating the reaction mix at 65°C for 15 min.
2.2.7 Filling in recessed ends of DNA
DNA fragments with 3'-recessed ends were filled in for use in blunt-end ligations
using Klenow polymerase (DNA polymerase 1 large fragment) in reaction buffer (50
mM Tris-HCl pH 8.0, 10 mM MgCl2, 50 mM NaCl) (Gibco BRL Life Technologies)
with 33 pM dNTPs (Sigma). This mixture was incubated at 37°C for 20 min.
2.2.8 Ligation of DNA
Ligations involving the pGEM-T Easy vector contained T4 DNA ligase (3 U) and 1
pi of the lOx T4 DNA ligase buffer (300 mM Tris-HCl pH 7.8, 100 mM MgCl2, 100
mM DTT, 10 mM ATP) and were incubated at 4°C overnight. Ligations involving
other vectors contained T4 DNA ligase (3 U) and 1 pi of lOx T4 DNA ligase buffer
(660 mM Tris-HCl pH 7.5, 50 mM MgCl2, 10 mM dithioerythritol, 10 mM ATP)
(Boehringer Mannheim/Roche) and were incubated at 16°C overnight. For blunt-
ended ligations, T4 DNA ligase (3 U) and 2 pi of 5x T4 DNA ligase buffer (250 mM
Tris-HCl pH 7.6, 50 mM MgCl2, 5 mM DTT, 5 mM ATP, 25% (w/v) polyethylene
glycol-8000) (Gibco BRL Life Technologies) were used. The inclusion of
polyethylene glycol-8000 in the buffer improves the efficiency of blunt-end ligations.
All ligations were carried out in a volume of 10 pi with the exception of those
56
involving pBeloBACll, which were carried out in a 20 pi volume using the Gibco
BRL Life Technologies T4 DNA ligase and buffer.
2.2.9 Quantification of plasmid DNA
Plasmid DNA was quantified using a CECIL spectrophotometer. To 98 pi of water, 2
pi of plasmid DNA was added and optical density (OD) measured at 260 nm and 280
nm. The figure obtained at 260 nm was multiplied by 50 to account for the dilution
of the DNA and by 50 again to obtain the concentration per ml. This is based on the
fact that 1 OD unit is equivalent to approximately 50 pg/ml of double-stranded DNA.
The ratio of OD values at 260 nm to 280 nm indicated the purity of the DNA. A ratio
of 1.8-2.0 indicates that the DNA is pure (Sambrook et al., 1989).
2.2.10 Sequencing of plasmid DNA
Sequencing of all constructs was carried out by Mr. Ian Bennet by automated
sequencing using a LI-COR DNA sequencer model 4000L (MWG-Biotech). The
primers used were: RVprimer3 (5'-CTA GCA AAA TAG GCT GTC CC) designed
for sequence analysis clockwise across the multiple cloning site (MCS) of pGL3
reporter vectors; GLprimer2 (5'-CTT TAT GTT TTT GGC GTC TTC CA) designed
for sequence analysis counter-clockwise across the MCS of pGL3 reporter vectors;
pUC/M13 forward sequencing primer (5'-GTT TTC CCA GTC ACG AC) and
pUC/M13 reverse sequencing primer (5'-CAG GAA ACA GCT ATG AC).




2.3.1 Escherichia coli strains
JM109 competent cells (Promega) were used for transformation of plasmid DNA by
heat-shock. ElectroMAX DH10B Cells (Gibco BRL Life Technologies) were used
for transformation of the bacterial artificial chromosome pBeloBACll vector by
electroporation. The genotypes for these two strains are shown in Table 2.2.
Table 2.2: Genotypes of bacteria used for transformations
Strain Genotype
JM109 endAl, recAX, gyrA96, thi, hsdRll (r"k~, mk+), relAX, supE<\4,
A(lac-proAB), [F', traD36, proAB /ocqZAM15]
DH10B F", rncrA, A(mrr-hsdRMS-mcrBC), <j)80d/acZAM15, AIacX74,
endAX, recAX, deoR, A(ara, leu)7697, araD139, galU, galK,
nupG, rps L, X
2.3.2 Bacterial growth medium
All bacteria were grown in sterilised Luria-Bertani (LB) medium (Sambrook et ah,
1989) with addition of appropriate antibiotics. Agar plates were made with 15 g/1
bacteriological agar (ICN Biochemicals) in LB medium.
2.3.3 Transformation of competent E.coli cells with plasmid DNA
To 4 pi of ligation mix, 50 pi of JM109 cells (Promega) were added and placed on
ice for 20 min. The cells were then heat-shocked for 45 seconds at 42°C and
quenched on ice for 2 min. SOC medium (800 pi) was added to the cells and the
mixture was incubated at 37°C for 1.5 h with shaking (250 rpm). The cells were then
centrifuged in a micro-centrifuge at 3500 xg for 2 min, resuspended in 200 pi of
SOC medium and spread on agar plates containing appropriate antibiotics. All
plasmids contained genes encoding either ampicillin or kanamycin resistance.
Ampicillin and kanamycin were used at final concentrations of 100 pg/ml and 50
pg/ml, respectively. The plates were inspected after -18 h at 37°C.
For transformations involving the pGEM-T Easy vector, IPTG (isopropylthio-P-D-
galactoside) and X-gal (5-bromo-4-chloro-3-indolyl-P-D-galactoside), both from
Bio-Gene Ltd., were spread on to agar plates containing ampicillin before use. X-gal
(50 mg/ml stock dissolved in dimethylformamide (AnalaR)) was used at 20 pi per
plate and IPTG (0.1 M stock, filter-sterilised) was used at 100 pi per plate.
The pGEM-T Easy vector contains the a-peptide coding region of the enzyme P-
galactosidase, which allows identification of recombinant clones by blue/white
selection. In the presence of IPTG (a lac analogue that permits expression of P-
galactosidase) and X-gal (a substrate for p-galactosidase), blue colonies are
produced. Insertion of a PCR product into the vector disrupts the P-galactosidase
gene, resulting in white colonies.
2.3.4 Small scale preparation of plasmid DNA
After transformation, colonies were picked and grown in 5 ml of liquid LB medium
with appropriate antibiotic selection. Preparation of plasmid DNA was carried out
using a QIAprep Spin Miniprep kit (QIAGEN). The bacterial cells were harvested
by centrifugation at 600 xg for 5 min. The bacterial pellet was resuspended in Buffer
PI (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 pg/ml RNase A) and then
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incubated in Buffer P2 (200 mM NaOH, 1% SDS) to lyse the bacterial cells. Buffer
N3 (3 M KAc pH 5.5) was added to precipitate the genomic DNA, proteins, cell
debris and SDS. The supernatant containing the plasmid DNA was separated from
the precipitate by centrifugation in a micro-centrifuge, and then passed through a
column containing an anion-exchange resin. Addition of proprietary Buffer PB
followed by ethanol-containing proprietary Buffer PE to the column removed RNA,
proteins and low molecular weight impurities. Plasmid DNA was then eluted in 50 pi
of Buffer EB (10 mM Tris-HCl pH 8.5).
2.3.5 Large scale preparation of plasmid DNA
Large preparations of plasmid DNA were made using QIAGEN Plasmid Midi and
Maxi kits (QIAGEN). The principle of these kits is the same as the QIAprep Spin
Miniprep kit described above, except that the column is first equilibrated with Buffer
QBT (750 mM NaCl, 50 mM MOPS pH 7.0, 15% isopropanol, 0.15% Triton X-100)
before addition of the supernatant containing the plasmid. Impurities were then
removed by 3 washes with Buffer QC (1 M NaCl, 50 mM MOPS pH 7.0, 15%
isopropanol). The plasmid DNA was eluted in Buffer QF (1.25 M NaCl, 50 mM
Tris-HCl pH 8.5, 15% isopropanol) and precipitated with isopropanol. The pellet was
then washed once with 70% ethanol to remove excess isopropanol, air-dried and
resuspended in TE buffer.
2.3.6 Transformation of competent E.coli cells with BAC DNA
(electroporation)
This method was used for the pBeloBACll vector. The ligation (section 2.2.8) was
carried out in 20 pi, which was made up to 200 pi with TE buffer. Phenol/chloroform
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and chloroform extractions were carried out (Sambrook et al., 1989). The sample
was then desalted using a microcon-30 column (Amicon) to give a final volume of
10 jul. From the sample, 4 pi was added to 40 pi of electrocompetent DH10B cells.
These cells have a higher transformation efficiency for use with larger plasmids. The
mixture was transferred to a chilled 2 mm electroporation cuvette (Flowgen) and
electroporated (2500 V, 25 pF, 156 Q, 0.004 ms pulse). SOC medium (1 ml) was
immediately added and the sample was incubated in a shaker (250 rpm) for 1 h at
37°C. From this, 100 pi of the mixture was spread on an LB agar plate containing 15
pg/ml chloramphenicol, as a gene encoding chloramphenicol resistance is present in
the pBeloBACl 1 vector.
2.3.7 Small scale preparation of BAC DNA
Single bacterial colonies were grown overnight at 37°C with shaking in 20 ml of LB
medium containing 15 pg/ml chloramphenicol. The cultures were then centrifuged at
6000 xg for 10 min. The pellet was resuspended in 200 pi resuspension solution
containing 70 pg/ml lysozyme, added just before use, and transferred to a 1.5 ml
micro-centrifuge tube. The tube was incubated for 5 min at room temperature. To
lyse the bacteria, 400 pi of denaturation solution was added and the sample was
placed on ice for 5 min after mixing by inversion. Ice-cold neutralisation solution
(300 pi) was added and after inversion the sample was again placed on ice for 5 min.
The sample was centrifuged for 5 min in a micro-centrifuge at 9500 xg. The
supernatant was transferred to a new micro-centrifuge tube containing 500 pi of
isopropanol and this mixture was placed on ice for 15 min. The sample was
centrifuged for 5 min in a micro-centrifuge at 9500 xg. The supernatant was removed
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and the pellet was air-dried then resuspended in 200 pi TE to which 100 pi of 7.5 M
sodium acetate was added. The sample was placed on ice for 15 min then centrifuged
for 5 min at 9500 xg. The supernatant was transferred to a new tube to which 600 pi
of ethanol was added and the mixture was incubated at -70°C overnight. The sample
was centrifuged at 9500 xg for 10 min and the pellet was air-dried and resuspended
in 50 pi TE buffer.
2.3.8 Large scale preparation of BAC DNA
A QIAGEN Plasmid Maxi kit was used, the principle of which has been described in
sections 2.3.4 and 2.3.5. The "Protocol for Very Low-Copy Plasmid Purification"
was used. This has several modifications to the standard maxi-prep protocol, namely
that the culture volume is increased to 2.5 litres, as compared with 100 ml for high-
copy plasmids, and the volume of the three buffers used to resuspend the pellet, lyse
the cells and precipitate the genomic DNA, proteins and cell debris, is increased from
10 ml to 125 ml. In addition, five columns are used instead of one.
2.4 Mammalian cell and virus work
2.4.1 Mammalian cells
Bovine turbinate (BT) cells were grown in Iscove's medium (Gibco BRL Life
Technologies) containing 10% foetal calf serum (FCS) (Globepharm), 70 pg/ml
penicillin (Merck BDH), 10 pg/ml streptomycin, 2 mM L-glutamine (Merck BDH)
and 250 pg/ml Amphotericin B (an anti-fungal agent) (Merck BDH). BT cells were
used up to passage 12, after which time their growth rate was substantially reduced.
BT cells were provided by Miss Irene Pow, Moredun Research Institute, Edinburgh.
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Baby hamster kidney (BHK) cells and thymidine kinase deficient (TIC) BHK cells
were grown in Glasgow Modified Eagle's Medium (GMEM) containing 10%
tryptose phosphate broth (TPB) (Gibco BRL Life Technologies), 10% newborn calf
serum (NBCS) (Harlan SeraLab), 70 pg/ml penicillin, 10 pg/ml streptomycin and 2
mM L-glutamine. BHK-21 cells are a continuous fibroblastoid cell line from a Syrian
golden hamster (Stoker and Macpherson, 1961). The TIC BHK cells used were the
tk~ ts 13 BHK-21 cell line (ATCC CRL-1632) (Talavera and Basilico, 1977), a
temperature sensitive (ts) derivative of BHK-21, which was provided by Dr. H.
Marsden, MRC Virology Unit, Glasgow.
HeLa (human cervical epithelial cell line) cells were grown in Dulbecco's modified
Eagle's medium (DMEM) containing 10% FCS, 70 pg/ml penicillin, 10 pg/ml
streptomycin and 2 mM L-glutamine.
To harvest BT, BHK and HeLa adherent cell lines, the medium was removed and the
monolayers were washed in 5 ml of 0.02% versene (BT cells) or sterile PBS (BHK
cells and HeLa cells). The monolayers were then incubated with 5 ml of 0.25%
trypsin/EDTA solution (Gibco BRL Life Technologies) until they detached from the
flasks. The cells were resuspended in media by pipetting and seeded into new flasks.
BT cells were seeded at 1 x 106-3 x 106 and BHK cells and HeLa cells were seeded
at 2 x 106-6 x 106 per 175 cm2 (T175) flask.
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2.4.2 Long-term storage of mammalian cells
After trypsinisation of exponentially growing cells, cells were counted using a
haemocytometer. Cells were centrifuged at 4500 xg for 10 min and the pellet was
resuspended in freezing mix (90% FCS, 10% DMSO) at 1 x 106 cells/ml. Aliquots (1
ml) were stored in cryovials, frozen at -70°C overnight in cotton wool and then
stored in liquid nitrogen.
2.4.3 Preparation of virus stocks
The C500 strain of A1HV-1 was obtained from Dr. Hugh Reid and Miss Irene Pow,
Moredun Research Institute, Edinburgh. This virus was isolated from a blue
wildebeest and passaged several times through rabbits. To a T175 flask of BT cells at
80% confluence, 0.3 ml of very low passage virus stock (A1HV-1 C500 20/5/96) was
added. Virus-infected BT cells were grown in medium containing 2% FCS. Cells
were incubated until signs of CPE were observed (~7 days), at which time they were
harvested and pelleted by centrifugation at 4500 xg for 10 min. The pellet was
resuspended in 2 ml of medium and 1.8 ml of this was used to infect ten T175 flasks
of BT cells. The cells were incubated for 8 days and then harvested and pelleted by
centrifugation at 4500 xg for 10 min. The pellets were resuspended in 90% FCS and
10% DMSO, pooled and aliquoted into cryovials (0.5 ml), which were stored in
liquid nitrogen.
2.4.4 Preparation of virus DNA from cell-associated virus
Cell-associated virus (A1HV-1 C500 strain) was used to infect five T175 flasks of BT
cells, which were harvested when 80% CPE was visible. Since the infected cells
were loosely attached to the flask they were harvested by addition of sterile glass
beads to the flask with rocking. The cells were pelleted by centrifugation at 5000 xg
for 10 min, washed in PBS, resuspended in a total of 5 ml RSB with 0.5% (v/v)
Triton X-100 and Dounce homogenised. To remove cell debris, the cells were
centrifuged at 4500 xg for 10 min. Virus particles were separated from cellular DNA
by centrifugation through a 25% sucrose cushion in RSB at 114,000 xg for 30 min at
room temperature. The pellet containing virus particles was resuspended in TNE and
digested with 100 pg/ml proteinase K in the presence of 1% SDS in a final volume of
5 ml. This was incubated overnight at 55°C. An equal volume (5 ml) of
phenol/chloroform/isoamyl alcohol (25:24:1) was used to carry out four 10 min
extractions followed by two 10 min extractions with chloroform/isoamyl alcohol
(24:1). The sample was then made up to 15 ml volume with TE buffer and
centrifuged in Centriplus 10°S concentrators (microcon columns) (Amicon) at room
temperature for 25 min at 5000 xg. This step was repeated until the volume equalled
1 ml.
2.4.5 Transfection of mammalian cells by electroporation
Cells were harvested as described in section 2.4.1, resuspended in medium lacking
FCS or NBCS and 800 pi aliquots of this cell suspension were added to 1.5 ml
micro-centrifuge tubes containing DNA in a 50 pi volume. BT cells were used at 5 x
105 to 1 x 106 cells per sample and BHK cells and HeLa cells were used at 2 x 106
cells per sample. The DNA-cell mixture was placed in a 4 mm electroporation
cuvette (Flowgen) and electroporated at a capacitance of 1050 pF and a voltage of
300 V in an EquiBio EasyjecT Plus electroporator. After electroporation, cells were
65
plated immediately onto 60 mm dishes containing 3 ml of medium with FCS or
NBCS and assayed after incubation at 37°C for 48 h.
2.4.6 Superinfection of transfected cells
In some experiments, cells were infected with virus 24 h after transfection with
promoter constructs, and assayed 24 h subsequently.
2.4.7 Transfection of mammalian cells by SuperFect
SuperFect (QIAGEN) is an activated-dendrimer transfection reagent. Dendrimers are
branched spherical molecules with a defined size and shape. Activated dendrimers
result from removal of amines from dendrimers, which gives them a flexible
structure. They assemble DNA into compact structures in a similar manner to
histones with eukaryotic DNA. The complexes have a positive charge, which enables
them to bind to negatively-charged molecules on the cell surface, and they are then
taken up by non-specific endocytosis.
Plasmid DNA was made up to 150 pi with medium containing no serum or
antibiotics, and 15 pi of SuperFect transfection reagent was then added. The mixture
was vortexed and incubated at room temperature for 5-10 min. During this
incubation the pre-seeded cells, at -70% confluence, were washed with PBS. Cell
culture medium (1 ml) containing serum and antibiotics was added to the tube
containing the transfection mix. This was added to the plated cells, which were then
incubated for 2 h at 37°C. The medium was removed, cells were washed with PBS
and fresh medium was added. The cells were assayed 48 h later.
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2.4.8 Luciferase assays
The Luciferase Assay System (Promega) was used to assay transfected cells that had
no internal transfection control. The cells were washed in sterile PBS and 250 pi of
lx Reporter Lysis Buffer (25 mM Tris-phosphate, pH 7.8, 2 mM DTT, 2 mM 1,2-
diaminocyclohexane-N,N,N',N'-tetra-acetic acid, 10% glycerol, 1% Triton X-100)
(Promega) was added to each plate and incubated at room temperature for 15 min.
Lysates were harvested and transferred to a 1.5 ml micro-centrifuge tube and
centrifuged for 2 min at 3500 xg. The luciferase activity was assayed immediately
using a Luminoskan RT luminometer and the proprietary luciferase assay reagent.
2.4.9 Dual-luciferase reporter assays
The Dual-Luciferase Reporter Assay System (Promega) was used when the pRL-
SV40 Renilla expression plasmid was used as an internal control in each sample
along with the firefly luciferase reporter vectors that were being tested. Cells were
washed with sterile PBS and incubated for 15 min in 400 pi of proprietary lx Passive
Lysis Buffer. Lysates were harvested and transferred to a 1.5 ml micro-centrifuge
tube and centrifuged for 2 min at 3500 xg. The samples were assayed using
proprietary firefly Luciferase Assay Reagent II. Proprietary Stop & Glo Reagent was
then added which quenches the firefly luciferase signal and provides the substrate for
the Renilla luciferase. The luciferase activities were assayed using a Luminoskan RT
luminometer.
2.4.10 Methods to screen for potential virus recombinants
To screen for recombinant virus after using the strategy described in section 4.3.5,
cells exhibiting CPE were analysed using two methods, DNA hybridisation and PCR.
Cells were harvested, transferred to a 1.5 ml micro-centrifuge tube and centrifuged at
12000 xg for 1 min. The cells were resuspended in 200 pi of PBS then freeze-thawed
three times and briefly sonicated in a water-bath sonicator to complete cell lysis. The
cell extract (50 pi) was spotted on to a nitrocellulose membrane, which was then
placed successively on three filter papers soaked for 3 min each in 0.5M NaOH, Tris-
HC1 pH 7.5 and 2 x SSC, respectively. The membrane was baked for 2 h at 80°C. It
was then incubated for 4 h at 65°C in 6x SSC and 5x Denhardt's solution and
hybridised with radioactive probe (see section 2.5.6) for 12-18 h at 65°C. The
membrane was washed twice for 15 min each in 2x SSC, 0.1% SDS at 65°C and
twice for 15 min each in 0.2x SSC at 65°C. The membrane was air-dried and exposed
to Biomax MS Kodak scientific imaging film.
To screen virus recombinants using PCR, cells were resuspended in 400 pi PBS and
freeze-thawed and sonicated as above. The cells were disrupted by heating at 95°C
for 5 min then placed on ice. The PCR was set up (see section 2.2.1) using 3 pi of the
disrupted cell extract.
2.4.11 Microscopy and photography
Cells were routinely examined by light and fluorescence microscopy and










e.g. (12.5) x (10) x (1.25) x (0.32) = 50
i.e. the cell magnification is 50x.
2.5 RNA Work
2.5.1 Extraction of total RNA from mammalian cells
Total RNA was extracted from cells using the RNAzol B reagent (Biogenesis).
Medium was removed from cell monolayers and they were washed with sterile PBS.
To lyse the cells, 0.2 ml of RNAzol B per 1 x 106 cells was added directly into the
culture flask and the mixture passed through a pipette several times before
transferring to a micro-centrifuge tube. To 2 ml of cell homogenate, 0.2 ml of
chloroform was added. The samples were then vigorously shaken and incubated on
ice for 5 min. The suspension was centrifuged at 12000 xg for 15 min. The upper
aqueous phase was transferred to a micro-centrifuge tube, mixed with an equal
volume of isopropanol and incubated for 15 min at 4°C. Samples were again
centrifuged for 15 min at 12000 xg. The RNA precipitate was washed with 0.8 ml of
75% (v/v) ethanol, centrifuged at 7500 xg for 8 min and resuspended in 200 pi of 1
mM EDTA pH 7.0.
2.5.2 Treatment of cells to obtain RNA from AIHV-1-infected cells
RNA representing the three temporal classes of gene expression in AIHV-1 was
obtained. To obtain RNA from expression of IE genes, Iscove's medium containing
2% FCS with cycloheximide (100 pg/ml) was added to BT cell monolayers 30 min
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prior to addition of virus and maintained throughout the infection. The cells were
harvested 8 h after addition of virus. To obtain RNA from expression of E genes,
Iscove's medium containing 2% FCS with phosphonoacetic acid (PAA) (0.1 mg/ml)
was added at the time of virus addition and maintained throughout infection. Cells
were harvested 24 h later. Addition of PAA, a herpesvirus DNA polymerase
inhibitor, prevents DNA synthesis. To obtain RNA from expression of L genes, virus
was added with no supplement and harvested 24 h later. In all cases, virus was added
in 5 ml of medium and left for 1 h before the volume was increased to 30 ml. In
preparation for this experiment, 15 T175 flasks of BT cells were infected with
A1HV-1 and a further 15 T175 flasks of subconfluent BT cells were prepared. To
each flask of subconfluent BT cells, the cells from one virus-infected flask exhibiting
50-70% CPE were added. RNA was harvested as described in 2.5.1.
2.5.3 Electrophoresis of RNA
This was carried out by the method in Sambrook et al. 1989. RNA samples were
electrophoresed in a 1.2% agarose gel containing 2.2 M formaldehyde and ethidium
bromide (1 pg/pl) made with lx RNA gel-running buffer. The RNA samples were
made up to 5.5 pi with dH20. To this was added 1 pi lOx RNA gel-running buffer,
3.5 pi formaldehyde and 10 pi formamide. The 0.24-9.5 kb RNA ladder (Gibco BRL
Life Technologies) or the RNA Molecular Weight Marker I (Roche) was prepared in
the same manner. All samples were denatured at 65°C for 15 min, cooled on ice and
mixed with 2 pi lOx RNA gel-loading buffer. The horizontal gel was submerged in
lx RNA gel-running buffer and electrophoresed overnight at 35 V with recirculation
of the buffer.
2.5.4 Northern hybridisation
The gel was washed in 50 mM NaOH, 150 mM NaCl for 30 min and then in 0.1 M
Tris-HCl pH 7.5, 150 mM NaCl for a further 30 min. The gel was rinsed with Milli-
Q water and soaked in 20x SSC for 45 min. Two pieces of 3MM paper were cut to
the size of the gel tank and placed over the platform so that both ends were
submerged in the wells of the tank, which were filled with 20x SSC. The gel was
placed on the paper. Hybond-N nylon transfer membrane (Amersham), cut to the size
of the gel, was soaked in 20x SSC and placed on top of the gel. Two sheets of 3MM
paper, cut to the size of the gel, were soaked in 20x SSC and placed on top of the
membrane followed by a stack of blotting paper and a 500 g weight. Transfer of
RNA from the gel to the membrane took place overnight.
The RNA was cross-linked to the membrane by placing it in a 'Stratalinker'
(Stratagene) for 45 seconds, which exposes the membrane to UV with a wavelength
of 254 nm.
The marker track was cut from the rest of the membrane after cross-linking and air-
dried. It was then incubated in 1 M acetic acid for 10 min at room temperature and
then in RNA Marker staining solution for 10 min. Finally, it was washed in sterile
distilled water until the blue background disappeared.
2.5.5 Probe labelling
To label a double-stranded DNA probe, 25 ng of DNA in 11 pi dF^O was boiled for
10 min and quenched on ice. To this, 5 pi of [a-32P] dCTP (10 mCi/ml) (Amersham)
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followed by 4 pi of High Prime, containing random oligonucleotide primers, 0.125
mM each of dATP, dGTP and dTTP, Klenow enzyme (4 U) and reaction buffer
(Boehringer Mannheim/Roche) were added. This was incubated at 37°C for 30 min.
To stop the reaction, 5 pi of 2 M NaOH was added. This was followed by the
addition of 100 pi of TE buffer. Labelled DNA was separated from unincorporated
radiolabeled nucleotides by gel fdtration on NICK columns (Amersham Pharmacia
Biotech).
2.5.6 Probing the membrane
The membrane was incubated for 1 h at 45°C in 50 ml of pre-hybridisation buffer.
The pre-hybridisation buffer was 5x SSPE buffer, 5x Denhardt's solution, 50% (v/v)
formamide, 0.5% (w/v) SDS and 100 pg/ml denatured salmon sperm DNA. The pre-
hybridisation buffer was replaced with hybridisation buffer (pre-hybridisation buffer
plus 10% (w/v) dextran sulphate and 200 pg/ml instead of 100 pg/ml denatured
salmon sperm DNA). The labelled probe was then added and incubated with the
membrane overnight at 45°C.
Following hybridisation, the membrane was washed twice in 2x SSC, 1% SDS for 15
min at room temperature and twice in 0.5x SSC, 1% SDS for 15 min at 65°C. The
membrane was then washed with TE, excess liquid was removed using 3MM paper,
and the membrane was wrapped in clingfdm and placed in a phosphorimager
cassette. This was analysed using a phosphorimager (Molecular Dynamics).
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2.5.7 Slot blots
Slot blots were carried out using a filtration manifold consisting of a Lucite block
containing numerous slots and a suction platform. A piece of nitrocellulose
membrane cut to the size of the block was moistened in water briefly then soaked in
20x SSC for 1 h at room temperature. Two pieces of 3MM paper, cut to size, were
moistened with 20x SSC. The nitrocellulose membrane and 3MM paper were placed
between the block and platform, which were clamped together and connected to a
vacuum unit. All slots were filled with lOx SSC, which was suctioned through the
membrane and then the slots were refilled with lOx SSC. The RNA samples (0.1 pg
and 10 pg) were made up to 10 pi in dFBO, and 20 pi formamide, 7 pi formaldehyde
and 2 pi 20x SSC were added. The samples were heated to 68°C for 15 min then
placed on ice. Two volumes of 20x SSC were added to the samples. The lOx SSC in
the slots was suctioned through the membrane. The samples were suctioned on to the
membrane followed by two rinses with lOx SSC. Suction was continued for 5 min,
the membrane was air-dried at room temperature and baked for 2 h at 80°C. The
membrane was then probed with labelled DNA as described in section 2.5.6.
2.5.8 5'-rapid amplification of cDNA ends
The 5'-Full Rapid Amplification of cDNA Ends (5'-RACE) Core Set from TaKaRa
Biomedicals was used. The principles of 5'-RACE can be found in Frohman et al.
(1988) and Maruyama et al. (1995). The method and result are presented in Figures
3.18 (a) and (b). Reverse transcription was carried out with 5 pg of total RNA using
a 5'-end phosphorylated RT primer specific to the ORF57 mRNA, 5'-ATA AAC
ACA CGC CGC TTG GC (corresponding to Nt 84761-84742 in the A1HV-1
genome). The DNA-RNA hybrid was treated with RNase H to remove the RNA,
leaving the single-stranded cDNA. T4 RNA ligase was used to enable the cDNA to
form concatemers. PCR was carried out to amplify the DNA straddling the upstream
non-translated region. The primary PCR primers used were SI, 5'-GAG AGT GTG
GAC GAT TGC AT (Nt 84673-84692) and Al, 5'-CTC CAG GTG AAA GGA
GTC AT (Nt 84672-84653). The secondary PCR primers used were S2, 5'-GCA
AAC CAA ACA ATC GCC CTA (Nt 84701-84721) and A2, 5'-GAA TCC TCT
GCA GAG ATG TCT (Nt 84650-84630). The PCR product was inserted into the
pGEM-T Easy vector and sequenced.
2.6 Protein work
2.6.1 Protein sample preparation
Transfected cell monolayers were washed in PBS and lysis buffer was added. The
plates were heated at 80°C for 30 min. The cells and lysis buffer were mixed by
pipetting, placed in micro-centrifuge tubes and boiled for 3 min before loading onto
an SDS-PAGE gel. The Low Molecular Weight Calibration Markers from Pharmacia
Biotech were used to estimate sizes of proteins.
2.6.2 SDS-polyacrvlamide gels for protein separation
Electrophoresis was carried out using a 12% resolving gel and a 5% stacking gel.
The resolving gel was poured first and a layer of n-butanol was added to smooth the
surface and to prevent air reaching the gel, therefore accelerating polymerisation.
Once the resolving gel was polymerised the n-butanol was removed and the stacking
gel was poured on. The gel was run vertically at 100 V for 1-1/2 h in SDS-PAGE
running buffer (Sambrook et al., 1989).
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2.6.3 Protein ael staining
The protein gels were fixed and stained using brilliant blue G-colloidal concentrate
(Sigma). The gels were fixed for 1 h in a solution containing 7% (v/v) glacial acetic
acid and 40% (v/v) methanol. The staining solution was prepared by adding 1 part of
methanol to 4 parts of lx Brilliant Blue G-Colloidal Concentrate working solution
and mixed by vortexing. The gel was placed in the staining suspension for 2 h and
then destained for 60 seconds in 10% (v/v) glacial acetic acid/25% (v/v)methanol.
Finally the gel was rinsed and then soaked in 25% (v/v) methanol for up to 24 h.
2.6.4 Western blots
Proteins separated by SDS-PAGE were transferred onto nitrocellulose membranes
using a semi-dry electroblotter. The nitrocellulose membrane, gel and 6 pieces of
3MM paper were soaked in transfer buffer (25 mM Tris-HCl/20% (v/v) methanol).
Three pieces of 3MM paper were placed on the blotter, followed by the
nitrocellulose membrane, the gel and three more pieces of 3MM paper. Transfer was
carried out at 120 mA for 2 h. The protein marker tracks were removed from the rest
of the membrane and stained in amido black (working solution: 0.2% (w/v) amido
black, 10% (v/v) glacial acetic acid, 90% (v/v) methanol) for 5 min and then
destained in 50% (v/v) methanol/5% (v/v) acetic acid. The remainder of the
nitrocellulose membrane was blocked in 5% (w/v) non-fat milk powder/0.2% (v/v)
Tween 20/PBS for 1 h at room temperature. Primary rabbit antibodies were diluted
1/500 in 1% (w/v) non-fat milk powder/0.1% (v/v) Tween 20/PBS, added to the blot
and incubated overnight at 4°C. The membrane was washed 5 times in 0.1% (v/v)
Tween 20/PBS and then incubated at room temperature for 1 h in the presence of an
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alkaline phosphatase secondary antibody (DAKO pig anti-rabbit) diluted 1/1000 in
1% (w/v) non-fat milk powder/0.1% (v/v) Tween 20/PBS. Five washing steps were
carried out as before. The membrane was developed by washing very quickly in 0.1
M Tris-HCl pH 9.5, and then incubated in an alkaline phosphate substrate (Sigma
fast 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium) to allow bands to
develop.
2.7 Electrophoretic mobility shift assays
2.7.1 Preparation of whole cell extracts
To prepare whole cell extracts, 8 x 107 transfected BHK cells were washed with
PBS, harvested then centrifuged. The pellet was then subjected to three cycles of
freeze/thawing at -70°C. An equal volume of Buffer C was added to the pellets,
which were then Dounce homogenised 10 times in a micro-centrifuge tube. Debris
was removed by centrifugation at 9500 xg for 5 min. The supernatant was frozen in
100 pi aliquots at -70°C.
2.7.2 Preparation of labelled double-stranded oligonucleotides
To make a 500 ng/pl stock of double-stranded oligonucleotides, equal amounts (-50
pi) of each single-stranded oligonucleotide (1 pg/pl) were mixed and boiled for 10
min, and allowed to cool slowly to room temperature. The stock was diluted 1:5 with
buffer D100 to make a working solution. Radioactive labelling of double stranded
oligonucleotides was carried out by adding 100 ng of double stranded
oligonucleotides, 1 pi of Klenow fill-in buffer, 1 pi of Klenow enzyme (see section
2.2.7), 1 pi of 10 mM dATP, dTTP, dGTP, 1 pi of [a32P] dCTP (10 mCi/ml)
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(Amersham) and 5 pi of water. The mixture was incubated for 15 min at room
temperature. The concentration of the oligonucleotide was made up to 0.75 pg/pl
with tRNA in a total volume of 30 pi. Unincorporated [a-32P] dCTP was removed
using Chromaspin-10 columns that are based on gel filtration chromatography
(Clontech). The columns were placed, with a 2 ml collection tube, inside a 15 ml
centrifugation tube and centrifuged for 5 min at 700 xg to remove the equilibration
buffer. The collection tube was replaced and the labelled double-stranded
oligonucleotide sample was placed in the column, which was again spun for 5 min at
700 xg. The collection tube contained the purified labelled probe.
2.7.3 EMSA reactions and acrvlamide gel electrophoresis
Reactions were carried out with a final concentration of 100 mM NaCl. Samples
contained labelled probe (1 ng), cell extract (1-3 pi), dldC (0.5, 1, 2.5, 5 or 10 pg),
loading buffer (1 pi) and buffer D100 to make a final volume of 5 pi. All
components were added to the sides of a 0.5 ml micro-centrifuge tube, which was
centrifuged to initiate all reactions simultaneously. Samples were incubated at room
temperature for 10 min and analysed on a 14 cm x 16 cm non-denaturing 4%
polyacrylamide gel. While samples were incubating, the gel was pre-run at 100 V.
Wells were rinsed out using lx TBE buffer before and after the gel was pre-run.
Samples were loaded at 100 V and gels were electrophoresed, in a vertical gel tank in
lx TBE buffer, for 75 min at 250 V. After electrophoresis gels were dried on to
3MM paper at 80°C for 2 h and analysed by exposing to Biomax MS Kodak
scientific imaging film in a cassette at -70°C or by using a phosphorimager
(Molecular Dynamics).
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3.1 Introduction
As discussed in the introduction, R-transactivators of yHVs have a role in
reactivation of the virus from latency and also act as transactivators. Continued
passage of the cell-associated C500 virulent strain of A1HV-1 in BT cells results in
the virus becoming cell-free and attenuated (Handley et al., 1995). Concomitant with
this attenuation is alteration of the genome affecting ORF50, the homologue of the
Rta-encoding genes. The aim of this section of work was to characterise the ORF50
gene product, A1HV-1/Rta.
3.2 Expression of QRF50
3.2.1 Amplification and subcloning of AIHV-1 QRF50
To initiate characterisation of AIHV-1 ORF50, the coding sequence was amplified
by PCR with primers 5' - AAGAATTCA TGA GTG CCA ACA ACC (Nt 72825-
72840) and 5' - TTG GAT CCA CTC CCA AAT ATG G (Nt 74904-74918), which
are illustrated in Figure 3.5 as A and B, respectively. These primers were based on
the sequence of the AIHV-1 genome published by Ensser et al. 1997 and
incorporated EcoK\ and BamW\ restriction sites respectively (underlined) for
convenient cloning of the PCR product. The start and stop codons are shown in bold.
AIHV-1 DNA (see section 2.4.4) was used as a template for PCR. The programme
used was: 1 cycle of 2 min at 96°C; 2 cycles of 1 min at 96°C, 1 min at 40°C and 2
min at 72°C; 2 cycles of 1 min at 96°C, 1 min at 45°C and 2 min at 72°C; 36 cycles
of 1 min at 96°C, 1 min at 50°C and 2 min at 72°C and finally 1 cycle of 7.5 min at
72°C. The PCR product was inserted into the pGEM-T Easy TA cloning vector,
deriving pGEM-T Easy-ORF50 (Figure 3.1(a)).
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Figure 3.1 (a): Amplification and subcloning of AIHV-1 QRF50
(i) PCR amplification of the AIHV-1 ORF50 sequence.
(ii) Two EcoRI and BamHI digests (lanes 1 and 2) of pGEM-T Easy-ORF50
releasing the ORF50 sequence.
(iii) Diagram of pGEM-T Easy-ORF50. Insertion of the ORF50 sequence
disrupts the LacZ gene (arrows)
Ampr- ampicillin resistance gene
3.2.2 Construction and analysis of pLXSN-QRF50 expression construct
To generate a construct that allowed expression of ORF50 in mammalian cells, the
2078 bp ORF50 sequence was excised from pGEM-T Easy via the EcoRI and
BarnWl sites and subcloned into these sites in the pLXSN expression vector
(Clontech) to derive pLXSN-ORF50 (Figure 3.1(b)). In the pLXSN vector, gene
expression is driven from the MMLV LTR.
A Northern blot was carried out to test for transcription from this expression
construct. pLXSN-ORF50 (2 pg) or pLXSN (2 pg) was transfected by
electroporation into HeLa cells and total cellular RNA extracted 48 h later (see
section 2.5.1). The samples (30 pg) were loaded onto a formaldehyde gel,
electrophoresed and transferred onto a membrane. The membrane was hybridised
with a probe derived from the ORF50 sequence excised from the pGEM-T Easy-
ORF50 vector (see section 2.5.3-2.5.6). A band of 8 kb was detected on the Northern
blot, which differed from the expected size of 2 kb (Figure 3.2). The most likely
explanation for this is that the RNA was contaminated with pLXSN-ORF50 plasmid
DNA, which is 7978 bp.
Western blots were also carried out using crude extract from HeLa cells transfected
with pLXSN-ORF50 (see section 2.6.1-2.6.4). The antibody used to detect A1HV-
1/Rta was raised in rabbits to a truncated protein expressed from a construct
containing nucleotides 73059-74903 of A1HV-1 ORF50 (obtained from Sandi Swa,
Moredun Research Institute, Edinburgh). Initial results showed a band indicating the












Figure 3.1(b) Construction of pLXSN-QRF50
(i) EcoRI and SamHI digest of pLXSN-ORF50 releasing the ORF50
sequence insert.
(ii) Diagram of pLXSN-ORF50.
Ampr- ampicillin resistance gene.
Neor- neomycin resistance gene.
1 2
Figure 3.2: Transcription from pLXSN-QRF50
Lane 1 - RNA from cells transfected with 2 pg of pLXSN plasmid.
Lane 2 - RNA from cells transfected with 2 pg of pLXSN-ORF50 plasmid.
Each lane contains 30 pg of total cellular RNA.
The membrane was probed with ORF50 sequence (arrow indicates band).
Days after transfectionProtein





Figure 3.3: Protein Expression of oLXSN-QRFfin
Western blot of crude protein extract from cells transfected with
pLXSN-ORF50. The negative lane contains crude extract from
cells transfected with pLXSN. The blue arrow indicates a band
that is present in the samples containing pLXSN-ORF50 and
absent in the sample containing pLXSN.
background was high. It is possible that the protein was below the level of detection
or that the antibody titre was too low.
3.2.3 Northern analysis of QRF50 aene expression in AIHV-1 infected cells
The transcriptional expression pattern of ORF50 in AIHV-1 infected cells was
investigated. The following questions were addressed: (1) when is the transcript
expressed in the virus life cycle? (2) are there multiple transcripts? (3) is the
transcript(s) spliced? The transcriptional expression pattern of ORFA6 was also
investigated since it is adjacent to ORF50 in the AIHV-1 genome. ORFA6 is a
positional homologue of the gene encoding EBV Zta although the two proteins have
limited sequence homology (Ensser et al., 1997).
Total RNA containing transcripts from each temporal class of expression (IE, E or L)
was harvested from virus-infected BT cells (see section 2.5.1 and 2.5.2) and
examined by Northern blot analysis; 30pg of total RNA was used (see section 2.5.3-
2.5.6). The ORF50 sequence excised from the pGEM-T Easy-ORF50 plasmid was
used as a probe. An ORF50 transcript was not detected in any of the samples. The
quality of RNA had been verified by agarose gel electrophoresis and ethidium
bromide staining, which showed that the RNA was intact. Thus, the level and
stability of the transcript were deemed to be the two most likely problems to explain
the lack of detection. As is observed in Figure 3.17, P-actin transcripts were detected
when 30 pg of total RNA was used, but were not detected when 5 pg of total RNA
was used. It is highly likely that the ORF50 transcript is much less abundant than the
P-actin transcript and therefore was below the level of detection.
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Two approaches were taken to address this problem:
(1) Slot blots (Figure 3.4).
Total RNA (0.1 pg and 10pg) from virus-infected BT cells was spotted onto a
nitrocellulose membrane using a slot blot apparatus. As positive controls, the pGEM-
T Easy-ORF50 and pGEM-T Easy-ORFA6 plasmid DNAs (0.1 and 10 pg) were
used. The membrane was probed with either the ORF50 sequence or the ORFA6
sequence excised from the appropriate pGEM-T Easy plasmid. The results indicated
that ORF50 and ORFA6 are transcribed as IE genes but not as E genes (Figure 3.4).
The results are unusual because it may be expected that IE transcripts would also be
transcribed with the E transcripts. In addition, despite the fact that the RNA appeared
to be intact by agarose gel electrophoresis and ethidium bromide staining,
hybridisation with a p-actin probe was not successful. Thus, no absolute conclusions
can be made from this experiment.
(2) PolyA+ mRNA purification.
mRNA accounts for a very small proportion (1-2%) of total RNA. Thus, polyA+
mRNA was purified from total cellular RNA for Northern blot analysis in order to
increase the total amount of mRNA loaded on the gel. This approach was
unsuccessful and no ORF50 transcripts were detected by this method.
3.2.4 RT-PCR analysis of QRF50 gene expression
Due to the lack of sensitivity of the Northern Blots that were carried out, RT-PCR














Figure 3.4: QRF50 and 0RFA6 expression in AIHV-1
IE and E total RNA was harvested from AIHV-1-infected BT cells and
analysed using slot blots. Total RNA from uninfected cells was used as
a negative control. Plasmid DNAs containing either ORF50 or 0RFA6
sequence were used as positive controls.
Positions 1 and 2 contain 10 pg and 0.1 pg, respectively, of either total RNA
or plasmid DNA.
a) Slot blots probed with ORF50 sequence.
b) Slot blots probed with ORFA6 sequence.
PCR primers were designed to test if and when ORF50 and 0RFA6 were expressed,
if the splice site predicted by Ensser et al. 1997 within ORF50 was used and if
0RFA6 was co-transcribed with ORF50 (Figure 3.5). The primers used for ORF50
were the same as those used to initially amplify the ORF50 sequence (A and B).
Other primers were 5' - AAG AAT TCC ATT TTA CAG AGG AGA C (Nt 73109-
73125) (E) and 5' - AAG AAT TCG AAC TGC TTG ATA GAG ACA G (Nt
74709-74728) (F). The sequences of the primers used for ORFA6 (C and D) are
given in section 3.7.1.
As templates for RT-PCR analysis, RNA from each class of temporal transcript of
virulent (Vir) and attenuated (Att) A1HV-1 was used (section 2.5.2). In Figure 6(a)
and (b) they are referred to as Vir IE, Vir E, Vir L and Att IE, Att E and Att L. The
RNA from attenuated virus was harvested by L. Devi. RNA was also harvested from
mock-infected BT cells referred to as BT. RNA harvested from BHK cells
transfected with an ORF50 or ORFA6 expression plasmid, referred to as BHK-
ORF50 and BHK-ORFA6 in Figure 3.6(a) and (b), and mock-transfected BHK cell
RNA, referred to as BHK, were also analysed.
The RNA samples were treated with DNAse and reverse transcribed using an oligo
d(T) primer (see section 2.2.2). Reverse transcribed RNA (RT+) samples were used
as templates in the PCR and RNA that had not been reverse transcribed (RT-) was
used as a negative control. Water was also used as an additional negative control, and
pGEM-T Easy-ORF50 and pGEM-T Easy-ORFA6 plasmids were used as positive
controls. Primers were used to amplify adenosine triphosphatase (ATPase) or p-actin
83
Position in the AIHV-1 genome:
72825 74903
ORF50



























Diagram showing ORF50 and ORFA6 and their nucleotide positions in the AIHV-1
genome taken from Ensser et at. (1997). The PCR primers used in the RT-PCR
analysis are indicated, as are the putative PCR products.
PCR products 1 and 2, if obtained, would indicate transcription of ORF50.
PCR products 3 and 4, if obtained, would indicate whether ORF50 is spliced.
PCR product 5, if obtained, would indicate if ORF50 and ORFA6 are co-transcribed.
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Figure 3.6 (a): RT-PCR
RT-PCR analysis was performed using primers to amplify ATPase and
ORF50. RNA samples were obtained from BT cells infected with virulent
or attenuated virus at IE,E or L stages of infection (Vir IE, Vir E, Vir L,
Att IE, Att E and Att L), or from BHK cells transfected with an ORF50
expression plasmid (BHK-ORF50). Reverse transcribed samples of
mock-infected BT cells (BT) and mock-transfected BHK cells (BHK)
were used as controls as well as RNA from all of the above samples,
which were not reverse transcribed. All reverse transcribed samples are
labelled RT+ and all non-reverse transcribed samples are labelled RT-.
As positive controls ATPase and ORF50 plasmid DNA were included
as templates for the PCR reaction.
(i) and (ii) show RT-PCR analysis with ATPase primers.
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Figure 3.6 (b): RT-PCR
RT-PCR analysis was performed using primers to amplify p-actin and
0RFA6. RNA samples were obtained from BT cells infected with virulent
or attenuated virus at IE,E or L stages of infection (Vir IE, Vir E, Vir L,
Att IE, Att E and Att L), or from BHK cells transfected with an ORFA6
expression plasmid (BHK-ORFA6). Reverse transcribed samples of
mock-infected BT cells (BT) and mock-transfected BHK cells (BHK)
were used as controls as well as RNA from all of the above samples,
which were not reverse transcribed. All reverse transcribed samples are
labelled RT+ and all non-reverse transcribed samples are labelled RT-.
As a positive control ORFA6 plasmid DNA was included as a template
for the PCR reaction.
(i) and (ii) show RT-PCR analysis with p-actin primers.
(iii) and (iv) show RT-PCR analysis with ORFA6 primers.
transcripts to confirm the presence and quality of intact RNA in the samples. The
ATPase primers used were 5'-CAA GAC CAG GAG GAA TTC CG-3' and 5'-
GGG CAG TAG GAA AGG AAA GC-3'. The |3-actin primers used were 5'-CGT
AGA TGG GCA CAG TG and 5'-CTC CGG CAT GTG CAA AG.
Figure 3.6(a) (i) and (ii) show the results of RT-PCR analysis with ATPase primers.
The ATPase plasmid gave a 200 bp band as did all RT+ samples. All the RT-
samples and the water control did not show a product. This indicated that the RNA
was intact and that the reverse transcriptase reactions had worked.
Figure 3.6(a) (iii) and (iv) show the results of RT-PCR analysis with ORF50 primers
(A and B). A product of 2078 bp should have been amplified. In agreement with this,
the centre of the smeared band obtained when using the ORF50 expression plasmid
as a template, was of this size, suggesting that the primers and conditions used were
working. No product was seen in the negative controls, the RT- samples or the water
control. A band of the correct size, also smeared, was observed in all of the Vir RT+
samples. The mock-infected BT cells and mock-transfected BHK cells also contained
a smeared band, however the centre of the band did not correspond to those in the
Vir RT+ samples or the positive control suggesting it was an alternative product. It
was also noticed that the smeared bands obtained in the Att RT+ samples did not
correspond to the positive control band suggesting that they too were alternative
products. ORF50 expression therefore appears to be expressed at all times in the
virulent virus life cycle but not at all in the attenuated virus life cycle. However, it
was reasoned that there might have been some non-specific priming taking place
84
hence the products being observed as a smear rather than a defined product. Primers
to amplify a smaller region of ORF50 were designed and more stringent conditions
were used. The primers used for this were the 5' primer used for the full-length
ORF50 sequence (A) and 5'- AAG GAT CCC CAT TTG TCA GTG TGC (Nt
73478-73463) (G) to amplify 653 bp of the ORF50 sequence. In the time available
successful RT-PCR amplification of ORF50 was not achieved.
Figure 3.6(b) (i) and (ii) show the results of RT-PCR analysis with P-actin primers.
Again this showed that all RT+ samples gave a positive band of 500 bp indicating
that the RT reactions had worked and the RNA was intact. All of the RT- samples
and water gave no band therefore no contamination had occurred.
Figure 3.6(b) (iii) and (iv) show the results of RT-PCR analysis with ORFA6 primers
(C and D). All Vir and Att RT+ samples were positive. The mock-transfected BHK
cells and mock-infected BT cells gave no product as expected. The only products
that gave cause for concern were those obtained with templates Att IE RT-, Att L
RT- and Vir IE RT-, which were used as negative controls. Overall, it could be
suggested that ORFA6 is expressed at all times during virus replication of virulent
and attenuated virus. However, in order to be conclusive these experiments would
have to be repeated to ensure that all controls worked satisfactorily. Considering that
a master mix was used for each group of reactions, it is clear that it was not
contaminated since not all negative samples have a product. Also the RT-
preparations cannot have been contaminated with virus DNA since not all of the RT-
samples yielded a product.
85
In the time available the transcription pattern of ORF50 and ORFA6 within the virus
life cycle was not elucidated.
3.3 Investigating the function of the AIHV-1/Rta
Transient transfection reporter assays were used to determine if A1HV-1/Rta could
act as a transactivator. The principle of this technique is that vectors containing
promoter sequences linked to a reporter gene are co-transfected with a plasmid
expressing the predicted transactivator. If the product of the expression vector
activates the specified promoter, this can be detected by measuring the activity of the
reporter gene. The promoters of three candidate A1HV-1 ORFs were chosen to test
the transactivation potential of A1HV-1/Rta.
The action of A1HV-1/Rta on promoters from the three different temporal classes of
transcripts was examined. No detailed transcript mapping of A1HV-1 had been
carried out previously, and so by comparison with other yHVs, ORF57 was chosen as
a representative IE gene, TK as an E gene and ORF6 as a delayed early (DE)/L gene.
In other yHVs, ORF57 encodes a transcriptional regulator, ORF6 codes for the
single-stranded DNA-binding protein and TK codes for thymidine kinase. Constructs
containing putative promoters for each of these ORFs were generated.
3.3.1 Construction of reporter constructs with putative AIHV-1 promoter
sequences
To ensure that the putative promoter sequences from the AIHV-1 genes were
represented in the constructs, approximately 800-900 bp of sequence upstream of the
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predicted start codon and ~50 bp downstream of this was amplified from A1HV-1
virus DNA. (Figure 3.7(a)). These figures were estimated by assessing other HV
promoters. For example, in HVS the ORF6 and ORF57 promoters required up to 259
bp and 764 bp, respectively, upstream of the transcription initiation site for activation
by HVS/Rta (Whitehouse et al., 1997b; Whitehouse et al., 1998a).
The A1HV-1 ORF57 promoter was amplified by PCR using primers 5' - AAG AGC
ICT GGT AGA GGA AGG TC (Nt 83700-83714) and 5'- AAG CTA GCT CTT
ACC CTC CAT GG (Nt 84519-84505) with Sacl and Nhel sites incorporated,
respectively (underlined).
The A1HV-1 TK promoter was amplified by PCR using primers 5'- AAG GTA CCG
TGG TGA GAT AGT CG (Nt 37540-37559) and 5' - AAC TCG AGC TTT GGG
CAC ATC G (Nt 38408-38395) with Kpnl and Xhol sites incorporated, respectively
(underlined).
The A1HV-1 ORF6 promoter was amplified by PCR using primers 5' - AAG GTA
CCG CCA GTA AAT GGA CC (Nt 10435-10449) and 5' - AAG CTA GCA GAT
GAA GCC GCA GG (Nt 11341-11327) with Kpnl and Nhel sites incorporated,
respectively (underlined).
The PCR programme used for amplification of the ORF6 promoter sequence was: 1
cycle of 2 min at 96°C; 40 cycles of 1 min at 96°C, 1 min at 60°C and 1 min at 72°C
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Figure 3.7 (a) Diagrammatic representation of AIHV-1 putative promoter
constructs
57prom, TK prom and 6prom are AIHV-1 putative promoter sequences inserted
upstream of the firefly luciferase gene in the pGL3-Basic vector. The pGL3-Basic
vector is represented indicating the position and contents of the multiple cloning
site relative to the luciferase gene.
The restriction enzymes used in the subcloning procedure, the location of the
sequences in the AIHV-1 genome, taken from Ensser et al. (1997), and their
positions relative to their predicted translational start sites within the virus are
all shown. Also shown are the predicted temporal classes of the ORFs.
the ORF57 and TK promoters, except that an annealing temperature of 50°C was
used. All PCR products were inserted into the pGEM-T Easy vector.
pGL3-Basic is a luciferase reporter vector encoding the firefly luciferase gene but
has no promoter or enhancer sequences, allowing testing of potential promoter
sequences. To make promoter reporter constructs, each of the amplified and
subcloned putative promoter sequences was inserted upstream of the firefly
luciferase coding region in the pGL3-Basic vector, thus deriving 57prom, TKprom,
and 6prom (Figure 3.7(a) and (b)).
Sections 3.3.2 to 3.3.10 below describe preliminary experiments used to establish a
transient transfection reporter assay system with an appropriate cell line, a
background control and an internal control for transfection efficiencies of individual
samples. Initially BT cells were used but were found to have poor transfection
efficiencies. BHK cells were subsequently concluded to be the most appropriate cell
line owing to higher transfection efficiencies. Initially the pLXSN-ORF50 expression
vector was used but an expression construct with ORF50 being driven by the CMV
promoter was then generated to improve expression. Thereafter, in subsequent
sections, this system is used for assessing the transactivating abilities of A1HV-1/Rta.
The actual luciferase values obtained are termed 'raw' values and they are measured
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Figure 3.7 (b) Construction of putative AIHV-1 promoters
(i) Sac I and Nhe I digests of pGEM-T Easy containing the ORF57 promoter sequence
(lane 1) and pGL3-Basic (lane 2).
(ii) KpnI and Xho\ digests of pGL3-Basic (lane 1) and pGEM-T Easy containing the
ORFTK promoter sequence (lane 2) and Kpn\ and Nhe\ digests of pGL3-Basic
(lane 3) and pGEM-T Easy containing the ORF6 promoter (lane 4).
(iii) Digests of 57prom, TKprom and 6prom with Sacl and Nhe I, Kpn\
and Xho\, and Kpn\ and Nhe\, respectively.
3.3.2 Activity of 57prom. TKprom and 6prom following virus superinfection
To determine if the promoter constructs were functional, their activity during
productive virus infection was tested. BT cells were transfected by electroporation
with 2 pg of 57prom, TKprom, 6prom or pGL3-Basic and then superinfected with
A1HV-1 (C500 virulent isolate) 24 h later. BT cells were used, as they are the cell
line used to propagate the virus. The amount of virus used per sample was equivalent
to 5 x 105 cells exhibiting 70% CPE. Luciferase activity was determined 24 h after
superinfection (see section 2.4.8). The pGL3-Basic vector was used as a background
control since it contains no promoter sequences. Cells were also transfected with
promoter constructs but were not infected with A1HV-1.
To assess whether activation of the promoter had occurred, the luciferase values
obtained from the samples infected with virus were divided by the values obtained
from uninfected samples to give the fold induction of promoter activity:
Luciferase value obtained from cells transfected with
promoter constructs and superinfected with virus
= Fold Induction
Luciferase value obtained from cells transfected with
promoter constructs alone
Both the TK promoter and the ORF6 promoter were up-regulated in the presence of
virus (Figure 3.8(a) and Appendix 1), 12-fold and 18-fold, respectively. The ORF57
promoter showed no significant activity under the conditions used. Since ORF57 is
most likely to be an IE gene, from studies of its functional homologues in other
yHVs, a possible explanation could be that at 24 h post-infection there is no longer





















Figure 3.8: Activation of AIHV-1 putative promoters
(a) BT cells were transfected with promoter constructs and 24 h later
infected with the C500 isolate of AIHV-1 or left uninfected. The
samples were assayed 24 h following infection. Results show the fold
induction of activity of samples with virus over those without virus.
(b) BT cells were transfected with promoter constructs with or without
co-transfection of pLXSN-ORF50. Results show the fold induction of







The results shown are from one experiment.
single experiment and repeat experiments using virus superinfection were not
successful, possibly owing to slow growth of the virus.
3.3.3 Activation of putative AIHV-1 promoters bv pLXSN-QRF50 in BT cells
Transient transfections and reporter assays were employed to assess if any of the
AIHV-1 promoters could be activated by A1HV-1/Rta. BT cells were co-transfected
with the ORF50 expression vector, pLXSN-ORF50 (2 pg) and 2 pg of pGL3-Basic,
57prom, TKprom or 6prom. The promoter constructs were also transfected alone to
allow fold induction values to be calculated (Figure 3.8(b)).
The luciferase value of each sample was measured to obtain the relative level of
promoter activity. The fold induction of activation of the promoters was calculated
by dividing the activity obtained from samples transfected with pLXSN-ORF50 by
the activity obtained in samples without pLXSN-ORF50:
Luciferase value obtained from cells transfected with
a promoter construct and pLXSN-ORF50
= Fold Induction
Luciferase value obtained from cells transfected with
a promoter construct alone
The ORF57 promoter appeared to be activated by the A1HV-1/Rta. The activation of
the ORF57 promoter was ~4-fold compared to the fold induction of pGL3-Basic
which was ~l-fold. In contrast, the other promoters were not activated by A1HV-
1/Rta (Figure 3.8 (b) and Appendix 1). However, the 'raw' values obtained in this
experiment were unsatisfactorily low and were all below 1.4 RLU (0.037-1.366).
Such low values were not thought to be sufficiently accurate.
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To address this issue two strategies were pursued:
a) The transfection efficiency of BT cells was examined.
b) A new ORF50 expression construct was made with the intention of improving
transcription and therefore the overall yield of A1HV-1/Rta protein.
3.3.4 Optimisation of the transfection efficiency of BT cells
The method of transfection used in the laboratory at the time was electroporation. To
optimise this method for BT cells the method of Baum et al., (1994) was used
whereby a single parameter, the voltage, is changed. The voltage used was varied
across a range from 220-300 V. BT cells were transfected with 2 pg of pCMVluc and
the luciferase activity measured 48 h after transfection (Figure 3.9 and Appendix 2).
Dr. P. Harrison constructed pCMVluc by inserting the CMV IE promoter, excised
from the pEGFP-Nl vector, upstream of the firefly luciferase coding region in pGL3-
Basic. The efficiency of transfection did not vary greatly between 220-280 V with
'raw' luciferase values ranging from 163-243 RLU. However, at 300 V the luciferase
activity was 428 RLU implying that transfection efficiency was almost twice as great
at this voltage. In previous experiments, 280 V had been used as the standard
condition. Following this optimisation experiment, 300 V was used subsequently.
The values obtained when using pCMVluc are significantly higher than when using
the A1HV-1 promoter constructs because of the strength of the CMV IE promoter.
3.3.5 Construction of an QRF50 expression construct - pCMVQRF50
In order to improve the expression of ORF50, the 2078 bp ORF50 sequence was
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Figure 3.9: Optimisation of electroporation conditions in BT cells.
BT cells were transfected with 2 pg of pCMVluc plasmid and
luciferase activity was measured 48 h later.
subcloned into the EcoRI and Xbal sites of the pEGFP-N 1 vector downstream of a
CMV IE promoter. The EGFP sequence of this vector was replaced with the ORF50
sequence deriving pCMVORF50 (Figure 3.10).
3.3.6 Activation of putative AIHV-1 promoters by pCMVQRF50 in BT cells
The luciferase assay values obtained when using pCMVORF50 in BT cells were still
unsatisfactorily low and so were not thought to be sufficiently accurate.
3.3.7 Use of an alternative cell line - BHK cells
At this point it was decided that an alternative cell line that would give high
transfection efficiencies was required. Since BHK cells were known to have high
transfection efficiencies and since AIHV-1 had been shown to infect hamsters
(Jacoby et al., 1988a and b), BHK cells were considered. To determine their
suitability, the ability of AIHV-1 to infect BHK cells was tested. It was shown that
BHK cells could support AIHV-1 replication, as determined by propagation of the
virus through serial monolayer cultures (Figure 3.11). BHK cells were therefore
considered suitable for use in the transient transfection assays.
3.3.8 Optimisation of the transfection efficiency of BHK cells
Transfection of BHK cells was optimised in a similar manner to that for BT cells
using a range of conditions including double pulse as well as single pulse (Baum et
al., 1994) (Figure 3.12 and Appendix 3). Each sample was transfected with
pCMVluc (2 pg), a constitutively active luciferase promoter construct, and luciferase
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Figure 3.10: Construction of pCMVQRF50
(i) Restriction enzyme digests of pCMVORF50. Arrows indicate
clones containing the ORF50 sequence (lanes 4 and 6).
(ii) Diagram of pCMVORF50.
Kanr- kanamycin resistance gene.
x50 H
Figure 3.11: BHK cells infected with AIHV-1
A-C - Uninfected BHK cells. D-H - infected BHK cells. CPE is
observed as thinning of the monolayer and rounding of cells.
A, D and F are higher magnifications of B, E, and G,respectively.
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Figure 3.12: Optimisation of electroporation of BHK cells.
BHK cells were transfected with 2 |ag of pCMVluc at different voltages and
assayed for luciferase activity after 48 h.
Cells were subject to electroporation with either a single or a double pulse:







The results shown represent a single experiment.
from 366-415 RLU, and single pulse values from 1297-2468 RLU. The highest value
was obtained using a single pulse of 300 V and this was therefore chosen as the
optimal voltage to use with BHK cells. When comparing the single pulse values
obtained with BHK cells to those obtained with BT cells there is a 5-10 fold
improvement in transfection efficiency when using BHK cells. Table 3.1 shows the
'raw' values and the calculations to support this.
Table 3.1: Comparison of the transfection efficiencies of BT cells and BHK
cells.
Luciferase values
using single pulse BHK cell value
Voltage electroporation (RLU) BT cell value
BT cells BHK cells Fold difference
220 240 1297 5.4
240 162 1733 10.7
260 223 1877 8.4
280 242 1777 7.3
300 428 2468 5.8
3.3.9 Activation of putative AIHV-1 promoters by pCMVQRF50 in BHK cells
Assays were carried out by transfecting 2 pg of the promoter reporter constructs
alone or with 2 pg pCMVORF50 into BHK cells. The fold induction of activation of
the promoters was calculated by dividing the activity obtained from samples
transfected with pCMV-ORF50 by that obtained in samples without pCMV-ORF50
(Figure 3.13 and Appendix 4). This experiment was carried out on three separate
occasions using single samples and the same trend was obtained each time. The
































Figure 3.13 : Activation of AIHV-1 promoters by pCMVQRF50 in BHK cells
BHK cells were transfected with 2 pg of pGL3-Basic, 57prom, TKprom or 6prom with
or without 2 pg pCMVORF50. Results show the fold induction of activity of each
promoter in the presence and absence of pCMVORF50. The results from three
separate experiments are shown.
The A1HV-1/Rta appeared to strongly induce 57prom between 179-fold to 395-fold.
The activation of 6prom was induced to a much lesser degree, and ranged from 13-
fold to 22-fold. The activity of TKprom was not considerably higher than that of
pGL3-Basic, which lacks promoter sequences, and therefore it was concluded that
the putative TK promoter region is not activated by A1HV-1/Rta.
3.3.10 Inclusion of more controls
The experiments outlined above identified an appropriate and efficient cell line for
use in these studies and revealed that 57prom and 6prom were activated by the
A1HV-1/Rta. However, the system did not include an internal control to account for
variations in transfection efficiency between samples. Thus, an internal control was
included which made use of the Dual-luciferase Reporter System (Promega). In each
transfection mixture, the pRL-SV40 vector (0.2 pg) was added in addition to the
promoter construct or promoter construct and expression construct. The pRLSV40
vector contains a gene encoding Renilla luciferase under the control of the simian
virus 40 (SV40) promoter. 57 prom, TK prom and 6prom, constructed using the
pGL3-Basic vector, contain the firefly luciferase gene. These two luciferase enzymes
use different substrates and so it is possible to discriminate between their
bioluminescence reactions. The activity of the firefly luciferase reporter constructs
can thus be normalised against the values obtained in the same sample for Renilla
luciferase. The fold-induction of the samples with and without pCMVORF50 may
then be calculated from the following formula:
(Firefly valudRenilla value) in the presence of pCMVORF50
= Fold Induction
(Firefly valudRenilla value) in the absence of pCMVORF50
94
3.3.11 Activation of putative AIHV-1 promoters by pCMVQRF50 in BHK
cells using the Dual-luciferase Reporter System
In the experiments described in Figure 3.14, 3.15, 3.16, 3.19(b) and (c) and 3.21(b),
BHK cells were transiently transfected with one of the promoter constructs or the
empty vector, pGL3-Basic, in the presence of the pRLSV40 control plasmid, with or
without pCMVORF50. The average fold induction of activity of pGL3-Basic in the
presence of pCMVORF50 for all of these experiments was 3.69+/-2.28 (standard
deviation) (Appendix 14). The pGL3-Basic fold induction value was used as the
background value in each of the experiments shown.
Figure 3.14 shows the results of three independent experiments using single samples.
Figure 3.15 shows the mean of results from an additional experiment performed in
triplicate. Standard deviations were calculated and are shown on the graph as error
bars (Figure 3.15). All 'raw' luciferase data for these experiments can be found in
Appendices 5 and 6.
The results presented in Figures 3.14 and 3.15, which made use of the pRLSV40
internal control, reproduced the findings obtained in Figure 3.13, in that the ORF57
promoter is greatly induced, the ORF6 promoter is moderately induced, and the TK
promoter is not induced in the presence of pCMVORF50.
The trends are the same in all sets of experiments although the fold induction values
varied. Thus, in Figure 3.14 A1HV-1/Rta activated 57prom from 49-67 fold and
6prom from 12-19 fold. In Figure 3.15 A1HV-1/Rta activated 57prom from 15-36
fold and 6prom from 4-8 fold. One explanation for the range of fold induction values
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Figure 3.14: Activation of AIHV-1 promoters by pCMVQRF50 in BHK cells
with a pRLSV40 internal control.
BHK cells were transfected with 2 pg of pGL3-Basic, 57prom, TKprom or
6prom and 0.2 pg of pRLSV40, with or without 2 pg of pCMVORF50. The
activity of each promoter was normalised using the Renilla luciferase value.
The fold induction of activity of each promoter was calculated using the values
obtained in the presence and absence of pCMVORF50. The results from
























Figure 3.15: Activation of AIHV-1 promoters by pCMVQRF50 in BHK cells
with a pRLSV4Q internal control, in triplicate.
BHK cells were transfected with 2 pg of pGL3-Basic, 57prom, TKprom or
6prom and 0.2 pg of pRLSV40, with or without 2 pg of pCMVORF50. The
experiment was performed in triplicate. Results show the average fold
induction of each promoter in the presence or absence of pCMVORF50.
Error bars indicate the standard deviation. Before calculating fold induction
the activities were normalised to the Renilla value.
could be variation between samples, as each transfection mix was prepared
independently and each sample was electroporated individually.
Moreover, it became clear when using the Dual-luciferase Reporter System (section
2.4.9) that the 'raw' luciferase values obtained with a new kit were higher than the
values obtained after repeated use, despite the fact that components were stored as
recommended.
From these experiments, using a cell line that gives high transfection efficiency and
includes an internal control that accounts for variations between individual sample
transfection efficiency, the conclusion is that A1HV-1/Rta can act as a transactivator.
A1HV-1/Rta can strongly activate the A1HV-1 ORF57 promoter and to a lesser extent
the A1HV-1 ORF6 promoter but does not activate the TK promoter.
3.3.12 Co-transfection of pCMVQRF50 with luciferase reporter
plasmids containing CMV. SV40 and HSV TK promoters
To establish whether A1FIV-1/Rta could act as a promiscuous transactivator,
pCMVORF50 was used in transient transfection assays with various non-AlHV-1
virus promoters. The CMV IE promoter, the SV40 promoter and the FISV-1 TK
promoter as well as pGL3-Basic were all used with or without pCMVORF50. The
experiment was carried out on triplicate. The constructs used were pCMVluc (CMV
IE promoter driving expression of the firefly luciferase gene; described in section
3.3.4), pRL-SV40 (SV40 promoter driving Renilla luciferase; Promega) and pTKluc
(HSV-1 TK promoter driving firefly luciferase; constructed by Louise King by
inserting the HSV TK promoter from pRLTK into pGL3-Basic).
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The results (Figure 3.16 and Appendix 7) showed that A1HV-1/Rta had no effect on
the CMV IE, HSV-1 TK or SV40 promoters. All activities measured were less than
that of pGL3-Basic, an empty vector with no promoter sequences. It was therefore
concluded that A1HV-1/Rta did not act as a promiscuous transactivator.
3.4 Analysis of the AIHV-1 ORF57 promoter
3.4.1 Transcription of 57prom
As the most significant effect of A1HV-1/Rta was on the ORF57 promoter, this
promoter was analysed further. The ORF57 promoter sequence used in the luciferase
reporter assays mentioned above was putative. Before it was investigated further,
transcription from the construct was analysed to determine where its transcriptional
start site was located in relation to the translational start site predicted by Ensser et
al. (1997).
pCMVORF50 (2 pg) and 57prom (2 pg) were transfected into BHK cells and total
cellular RNA was extracted after 48 h (see section 2.5.1). Aliquots of 5 pg or 30 pg
of total RNA from transfected or untransfected BHK cells were loaded onto a
formaldehyde agarose gel and subjected to Northern blot analysis (section 2.5.3-
2.5.4) (Figure 3.17). Digestion with restriction endonucleases within the ORF57
promoter sequence generated two fragments of 353 bp and 466 bp corresponding to
the left-hand and right-hand sections of the promoter sequence, respectively (Figure

























Figure 3.16: Effect of pCMVQRF50 on non-AIHV-1 virus
promoters
BHK cells were transfected with 2 pg of pGL3-Basic, pHSV-Tkluc,
pRLSV40 or pCMVluc with or without 2 pg of pCMVORF50.
The results show the average fold induction of activity of each
promoter in the presence or absence of pCMVORF50. The
experiment was performed in triplicate and error bars show the
standard deviation.
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Figure3.17:Transcriptionof57prom a)NorthernblotfRNAext act dfromBHKc ls co-transfectedwith57promandpCMVORF50.Duplicate RNAsampleswerelectrophoresedonaform ldehyde agarosegelandblottntnylonmembra .O e samplewasprobediththe353blefhandsecti no theORF57promotersequencandthotherprobwit the466bprighthandsectionoft eORF57pr mot r. b)5pgand30poft talRNAusedina)hybridis dwith ap- ctinprobe. c)Diagramindicatingthepositionsoftwoprobes usedrelativetoheORF57promot r.TATGindicat d representsthtranslationalst tcodopredictedby Enssereta\.(1997).
As can be seen in Figure 3.17(a), a band was observed when using the 466 bp (RH)
probe but no band was visible using the 353 bp (LH) probe. Aliquots of the same
RNA samples were electrophoresed on a second gel and the blot was incubated with
a (3-actin probe as a positive control (Figure 3.17(b)). (3-actin transcripts were
detected, showing that the RNA was intact. The Kpn 1 site used to dissect the
promoter was 409 bp upstream of the translational start codon. Since the transcript
was only detected by the 466 bp (RH) probe this indicated that the ORF57
transcriptional start site must be located no more than 409 bp 5' of the translational
start codon, otherwise it would have been detected by both probes.
3.4.2 Locating the ORF57 transcriptional start site and splice sites
To further analyse transcription from the ORF57 promoter, this time in the context of
the virus, the 5'-RACE method was chosen. A diagrammatic representation of the 5'-
RACE method is shown in Figure 3.18(a). Total cellular RNA extracted from virus-
infected BT cells treated with cycloheximide (section 2.5.1 and 2.5.2) was used for
5'-RACE. The data presented (Figure 3.18(b)) shows that the transcriptional start site
of ORF57 is located at position 84438 in the A1HV-1 genome. Ensser et al. (1997)
predicted the translational initiation codon of ORF57 to be at position 84462 and the
TATA box to be at position 84408. The transcriptional start site identified in this
study is therefore 24 bp upstream of the predicted translational start site and 30 bp
downstream of the predicted TATA box. The cDNA obtained by 5'-RACE also




















b) 84388 tttaggaaactatcactgccataaattagtttgaataacttcatttttca 84437
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(J^ start codon
84438 tcacttctcctgcatctcaaaaacatggctcagcaggcaattgtgactat 84487
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tttcagactcaggagatgtcagtatagacatct
84638 ctgcagaggattc 84650 AIHV-1 genome sequence
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ctgcagaggattc 5 -RACE product sequence
Figure 3.18 - Results of 5'-RACE of AIHV-1 ORF57.
(a) Diagrammatic representation of the 5'-RACE method. The diagram
shows the mRNA transcript of ORF57 and position of the complimentary
phosphorylated RT primer relative to it. The reverse transcription reaction
results in cDNAs with a phosphate group at one end allowing
concatemerisation. The concatemerised cDNAs are used as a template for
a PCR reaction with primers S1 and A1 to generate the primary PCR
product. This product was used in turn as a template for the second round
of PCR using primers S2 and A2, The secondary PCR product was
subcloned into the pGEM-T Easy vector to permit sequencing with the
pUC/M13 primer. The PCR products span the upstream non-translated
region.
(b) A sequence comparison of the secondary PCR product (lower line), and
the AIHV-1 genome (Genbank accession number AF005370) (upper line) is
shown. The location of the A2 primer is shown. The transcriptional start site
has been determined to be 24 bp upstream of the predicted translational
start site and 30 bp downstream of the predicted TATA box. Also clearly
seen are the splice donor (SD) and splice acceptor (SA) sites of ORF57.
3.4.3 Further analysis of the ORF57 promoter
Several of the Rta-responsive genes in other yHVs have specific sequences in their
promoters that act as Rta response elements (REs) (Gruffat and Sergeant, 1994;
Whitehouse et al., 1997b; Song et al., 2001; Lukac et al., 2001). Investigations were
undertaken to locate possible A1HV-1/Rta REs in the ORF57 promoter. It was
thought that identification of REs could lead to the discovery of other potential
A1HV1/Rta-responsive genes.
3.4.4 Construction of truncated ORF57 promoters
Deletion constructs of the ORF57 promoter, shown in Figure 3.19(a) and (b), were
made using appropriate restriction enzymes or PCR. All constructs were named
according to their size in bp.
Construct 57p(768) comprises a fragment amplified using the sense primer 5' -
AAG AGC TCT GGG CAG CTA GAG AG (Nt 83751-83765) containing a Sacl site
(underlined) and the same antisense primer used to amplify the initial ORF57
promoter sequence (5' - AAG CTA GCT CTT ACC CTC CAT GG (Nt 84519-
84505) containing an NheI site (underlined)). The PCR programme was the same as
that used for the ORE6 promoter (section 3.3.1). The fragment was inserted into
pGL3-Basic using Sad and NheI restriction sites to generate 57p(768).
Construct 57p(686) was generated by digestion of 57prom with Hindlll/Nhel. The
fragment was inserted into pGL3-Basic digested with Sad/Nhel to generate
57p(686). The Sad and HindlU sites were filled in (section 2.2.7) to allow a blunt-
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end ligation at the 5' end of the fragment (section 2.2.8).
Construct 57p(579) comprises a fragment amplified using the sense primer, 5'-
AAG AGC TCT CAG AAG CAG CTT CC (Nt 83940-84519) containing a Sacl site
(underlined) and the same antisense primer and PCR programme used to generate
57p(768). The fragment was inserted into pGL3-Basic using Sad and NheI
restriction sites to generate 57p(579).
Construct 57p(466) was generated by digestion of 57prom with Kpnl/Nhel. The
fragment was inserted into pGL3-Basic using Kpnl and Nhel restriction sites.
Construct 57p(180) was generated by digestion of 57prom with Sau3Al. The
fragment was inserted into the Sad and NheI restriction sites of pGL3-Basic by
blunt-end ligation to generate 57p( 180). All sites were filled in to allow blunt-end
ligation at both the 5' and 3' end of the fragment.
Construct 57p(194) was generated by digestion of 57prom with Sau3AHNhel. The
fragment was inserted into pGL3-Basic using Sad and Nhel restriction sites to
generate 57p(194). The 5aw3AI and Sacl sites were filled in to allow blunt-end
ligation at the 5' end of the fragment.
Construct 57p(133) was generated by digestion of 57prom with Sad/Hindlll. The
fragment was inserted into the Sacl and Nhel restriction sites of pGL3-basic to
















Figure 3.19 (a) Restriction Digests of ORF57 promoter
truncations
Restriction digests of the ORF57 promoter constructs, generated
using pGL3-Basic, to confirm the sizes of the inserts.
57prom, 57p(768), 57p(686) and 57p(579) were digested with Sacl
and NheI. 57p(466) was digested with Kpn\ and Nhe\.
ligation at the 3' end of the fragment.
3.4.5 Activity of truncated ORF57 promoters
Figure 3.19(b) shows the 57prom promoter and the position of the deletion constructs
relative to it. BHK cells were transfected with pGL3-Basic or an ORF57 promoter
construct both with and without pCMVORF50. The ability of A1HV-1/Rta to
transactivate each promoter is indicated by a plus or minus symbol in Figure 3.19(b).
As before, pGL3-Basic was used as the background control and any fold induction
value above that obtained with this plasmid was regarded as activation. The 'raw'
luciferase and fold induction values for the effect of A1HV-1/Rta on these constructs
are given in Appendix 8. Constructs were tested as they were made and the data is
therefore represented as four separate graphs in Figure 3.19(c) and in a summarised
form in Figure 3.19(b).
Constructs 57p(768), 57p(686) and 57p(579) were all activated by A1HV-1/Rta
whereas constructs 57p(466), 57p( 133), 57p(180) and 57p( 194) were not. The results
suggest that the sequence present in 57p(579) but absent in 57p(466), 409-522 bp
upstream of the translational start codon, is important for activation since 57p(579) is
activated by A1F1V-1/Rta and 57p(466) is not activated by A1HV-1/Rta.
To confirm this finding, 57p(466), the largest construct that was not activated by
A1HV-1/Rta, was remade and tested, and named 57p(466)B. This experiment is seen
in Figure 3.19(c) (iv) and the 'raw' luciferase values are in Appendix 8. The
construct 57p(466)B was not activated by A1HV-1/Rta thereby confirming the
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Figure 3.20 Construction and analysis of Prom57p(155)
(a) Diagram of Prom57p(155). The 155 bp of sequence from the
ORF57 promoter is inserted upstream of a luciferase reporter gene
driven by an SV40 promoter.
(b) BHK cells were transfected with 2 ^g of Prom57p(155) or pGL3-
Promoter with or without 2 p.g of pCMVORF50 and in the presence
of 0.2 jag of pRLSV40 control plasmid.
The average fold induction of activity of samples in the presence and
absence of pCMVORF50 is presented. Error bars show standard
deviation.
original observations.
3.4.6 Analysis of the sequence between 57p(579) and 57p(466) for AIHV-
1/Rta specific activity.
Since the 113 bp sequence (409-522 bp 5' of the ATG) present in 57p(579) and
absent from 57p(466) was thought to be important for activation by A1HV-1/Rta it
was analysed further. There was a possibility that an AlHV-l/Rta-responsive element
was contained within this sequence or within close proximity. Indeed, a sequence
corresponding to the HVS Rta RE (Whitehouse et ai, 1997b) was present in this
sequence. This will be discussed further in Chapter 5. A 155 bp sequence consisting
of the 113 bp plus 42 bp downstream was amplified by PCR using the following
primers; 5' - AAG CTA GCG AGA ACT GCT GCA GT (Nt 84081-84095), which
contains an NheI site (underlined) and the 5' primer used to generate 57p(579) (see
section 3.4.4). This fragment was inserted into the pGEM-T Easy vector, then
subcloned via SacU and Nhel sites into the pGL3-Promoter vector, thus deriving
Prom57p(155). The pGL3-Promoter vector contains an SV40 promoter driving a
firefly luciferase gene and allows testing of sequences, which have potential
enhancer properties (Figure 3.20(a)). Prom57p(155) and the pGL3-Promoter vector
were used in transient transfection assays with or without pCMVORF50. The pGL3-
Promoter vector was used as a background control.
Results showed that Prom57p(155) was not activated with the addition of
pCMVORF50 and so it was concluded that the 155 bp sequence did not have AlHV-
l/Rta-responsive activity in this system (Figure 3.20(b) and Appendix 9).
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3.4.7 Activity of an additional truncated ORF57 promoter
Since the sequence present in 57p(579) and absent in 57p(466) did not appear to
function in isolation as an AlHV-l/Rta-responsive enhancer (section 3.4.6), the
ORF57 promoter was investigated further. Upon examination of the raw data (Table
3.2 and Appendix 8) it was noticed that 57p(180) appeared to have some minimal
promoter activity in the absence of pCMVORF50. For example, without A1HV-1/Rta
the values obtained for 57prom, 57p(466) and 57p(686) were 1-2 RLU whereas the
value with 57p(180) was -14 RLU. It was therefore possible that the 180 bp with
potential minimal promoter activity was important, in addition to the 155 bp tested in
section 3.4.6, to facilitate AlHV-l/Rta-responsive transactivation.
Table 3.2 Luciferase values for 57p(180)
This table shows the average luciferase values obtained when
BHK cells were transfected with the constructs shown in the
absence of pCMVORF50.
Average luciferase





An ORF57 promoter construct was made (Figure 3.21(a)) to investigate if sequences
important for AlHV-l/Rta-responsiveness were present within the 180 bp region.
Even though the region had no increased activity with A1HV-1/Rta when studied
alone, it was considered that it may interact with sequences upstream. This 180 bp
region in the middle of the 57p(579) construct was removed by digestion with
Sau3AI and the flanking sequences religated to form 57p(399). This construct was
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Figure 3.21 (a) Construction of 57p(399)
(i) Diagrammatic representation of the construction of 57p(399) via removal
of the central 180 bp from 57p(579).
(ii) Sacl and Nhe\ restriction digest of 57p(399).
half that of the 57p(579) construct (Figure 3.21(b) and Appendix 10). This indicated
that although the deleted region was not essential for activation by A1HV-1/Rta, it
did exert a positive influence on A1HV-1/Rta transactivation potential. There are two
ways this region may be involved in activation: 1) it may contain a specific sequence
used for the activation of the promoter; 2) the distance between the two regions on
either side of the 180 bp may be important.
Another factor that may have contributed to the activity of 57p(399) is a second
sequence within the ORF57 promoter corresponding to the FIVS Rta RE
(Whitehouse et al., 1997b). As well as one being within the 133 bp 409-522 bp
upstream from the start codon, there is another sequence located in the 194 bp
sequence at the 3' end of the promoter. Thus, 57p(194), 57p(466) and Prom57p(155),
each containing one potential RE, are not activated by A1HV-1/Rta, whereas
57p(399) contains both potential REs and is activated by A1HV-1/Rta. This is
discussed further in Chapter 5.
Other deletion constructs of 57prom could be constructed to narrow down the
regions of importance for AlHV-l/Rta-responsiveness. Owing to time constraints
these constructs were not generated.
3.5 Electrophoretic mobility shift assays
3.5.1 EMSA design and oligonucleotides
Since the 113 bp region between 57p(579) and 57p(466) was deduced to be









Figure 3.21 (b): Effect of pCMVQRF50 on 57p(399)
BHK cells were transfected with 2 of 57prom, 57p(579) or 57p(399) with
or without 2 |ag of pCMVORF50. All samples were also transfected with 0.2
jag of pRLSV40 as an internal transfection control. Cells were harvested 48 h
post-transfection and assayed for luciferase activity. The average fold
induction of activity of each promoter was calculated using the values
obtained in the presence and absence of pCMVORF50. The experiment was
carried out in triplicate. Error bars indicate standard deviation.
investigated further. It is possible that the A1HV-1/Rta binds to this region directly or
indirectly. Electrophoretic mobility shift assays (EMSAs) were used to determine if
this was the case.
The region to be investigated was expanded to 140 bp because of the possibility that
an important sequence could be straddling the region between 57p(579) and
57p(466). Oligonucleotides were designed to cover the potential A1HV-1/Rta-
responsive region. For use in EMSAs, four double-stranded oligonucleotides of 35
bp were designed to span the region and three double-stranded oligonucleotides of 35
bp were designed, which overlapped them (Figure 3.22, Table 3.3). All of the
double-stranded oligonucleotides had single-stranded overhangs, which were fdled in
during labelling. The complimentary regions are in bold in Table 3.3.
105
ORF57 promoter constructs
57prom 57p(768) 57p(686) 57p(579)





















Figure3.22:LocationfEMSAdouble-strandedoligonucleotides Schematicdiagr moft er gionexaminedbyEMSAs,showingloc tt seven double-strandedoligonucleotidesla elE1 E7.A lORF57prom t rc structsene at d areinclud dnthdi g amforreference.
Table 3.3: Oligonucleotides used for EMSAs.
Each single-stranded oligonucleotide indicated in the table forms half of a
complementary pair (e.g. e1a and e1b) used to make double-stranded
oligonucleotides (e.g. E1) for use in EMSAs as indicated in Figure 3.22. NS -
non-specific.
Single-Stranded







GTA TAA ACA TAC GCA GAA GCA GCT TCC TGT CAA GC
GAT GCT TGA CAG GAA GCT GCT TCT GAG TAT GTT TA
ATG AGG CAG TTA TCC CCT CCA TCG AGC GCC TCT TG





GAC ACC AGC TTA AAC TGG TTC TTA CTT TCA AAA GT




CTG GCC CAA GTG TTT TGG TAC CAT CAG GTC TTA CA




GCA GCT TCC TGT CAA GCA TGA GGC AGT TAT CCC CT




GCA TCG AGC GCC TCT TGG ACA CCA GCT TAA ACT GT
GAA ACA GTT TAA GCT GGT GTC CAA GAG GCG CTC GA
E6
e7a GTC TTA CTT TCA AAA GTC TGG CCC AAG TGT TTT GG E7
e7b GTA CCA AAA CAC TTG GGC CAG ACT TTT GAA AGT AA
nsla TCG AAT CCC TTT AAA TTT GCG AGC NS
nslb TCG AGC TCG CAA ATT TAA AGG GAT
3.5.2 EMSA results
Figures 3.23-3.29 show the results of the EMSAs. Whole cell extract was made
(section 2.7.1) from BHK cells that had been electroporated with pCMVORF50 and
from BHK cells that had been electroporated with p-EGFP-Nl, the vector used to
construct pCMVORF50.
Experiments were designed to determine if there was a specific interaction between
A1HV-1/Rta and any of the double-stranded oligonucleotides. Whole cell extract was
mixed with a labelled double-stranded oligonucleotide (El - E7) (section 2.7.2) and
the mixture, after incubation at room temperature for 10 min, was electrophoresed on
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an acrylamide gel (section 2.7.3). To optimise conditions, varying concentrations of
whole cell extract and dldC were used.
The presence of a band indicates that the labelled double-stranded oligonucleotide is
bound to a protein(s) in the cell extract. To determine if this binding was specific,
excess unlabelled specific and non-specific double-stranded oligonucleotides were
added as competitors at three concentrations (10 ng, 50 ng and 100 ng). Specific
binding is defined as a band that can only be competed out by the specific competitor
oligonucleotide and not by the non-specific competitor oligonucleotide. Figures 3.23-
3.29 show the results for each double-stranded oligonucleotide analysed. Due to time
limitations only a few of the oligonucleotides (El, E3, E4 and E5) were repeated
with optimised conditions. When repeated, extract minus pCMVORF50 and extract
plus pCMVORF50 were electrophoresed on the same gel to allow comparison
between them.
In summary, the results suggest that proteins in the cell extract bound specifically to
oligonucleotides El, E2, E6 and E7 but not E3, E4 and E5. The pattern of bands
observed in the extracts minus pCMVORF50 and extracts plus pCMVORF50 was
similar in most cases, suggesting that cellular proteins bound to the double-stranded
oligonucleotides. None of these bands could be attributed to specific binding
between A1HV-1/Rta and the oligonucleotides. In other cases, for example in Figure
3.29 with E7, the pattern of bands in the two extracts differed, suggesting that A1HV-
1/Rta may be involved in binding that oligonucleotide, either directly or indirectly.
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Extract plus pCMVQRF50
(a) Extract minus pCMVQRF50
(b)
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Figure 3.23: EMSAs using E1
Labelled oligonucleotide E1 was incubated with whole cell extract prepared
from BHK cells transfected with pCMVORF50 or a control plasmid.
10-, 50- and 100-fold excess competitor was added to the appropriate reactions
as indicated (NS - non-specific, S - specific).
In (a) the samples were analysed on two different gels. The samples in (b) were
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Figure 3.24: EMSAs using E2
Labelled oligonucleotide E2 was incubated with whole cell
from BHK cells transfected with pCMVORF50 or a control
10-, 50- and 100-fold excess competitor was added to the
reactions as indicated (NS - non-specific, S - specific).
(a) Extract minus pCMVQRF50 Extract plus pCMVQRF50
I W m IM «
a
s NS
10 50 100 10 50 100 S NS
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(b)
Extract minus pCMVQRF50 Extract plus PCMVQRF50
I
S NS
10 50 100 10 50 100
S NS
10 50 100 10 50 100
Figure 3.25 : EMSAs using E3
Labelled oligonucleotide E3 was incubated with whole cell extract prepared
from BHK cells transfected with pCMVORF50 or a control plasmid.
10-, 50- and 100-fold excess competitor was added to the appropriate reactions
as indicated. (NS - non-specific, S - specific)
In (a) the samples are run on two different gels. The samples in (b) are
on the same gel to allow comparison between samples with or without
pCMVORF50.
Extract minus PCMVORF50 Extract plus pCMVQRF50
Figure 3.26: EMSAs using E4
Labelled oligonucleotide E4 was incubated with whole cell extract prepared
from BHK cells transfected with pCMVORF50 or a control plasmid.
10-, 50- and 100-fold excess competitor was added to the appropriate reactions
as indicated (NS - non-specific, S - specific).
The samples shown are on the same gel.
Extract minus pCMVQRF50 Extract plus pCMVQRF50
S NS 10 50 100 10 50 100
10 50 100 10 50 100
Figure 3.27: EMSAs using E5
Labelled oligonucleotide E5 was incubated with whole cell extract prepared
from BHK cells transfected with pCMVORF50 or a control plasmid.
10-, 50- and 100-fold excess competitor was added to the appropriate
reactions as indicated (NS - non-specific, S - specific).
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Figure 3.28: EMSAs using E6
Labelled oligonucleotide E6 was incubated with whole cell extract prepared
from BHK cells transfected with pCMVORF50 or a control plasmid.
10-, 50- and 100-fold excess competitor was added to the appropriate reactions
as indicated (NS - non-specific, S - specific).










Figure 3.29: EMSAs using E7
Labelled oligonucleotide E7 was incubated with whole cell extract prepared
from BHK cells transfected with pCMVORF50 or a control plasmid.
10-, 50- and 100-fold excess competitor was added to the appropriate reactions
as indicated (NS- non-specific, S - specific).
A square bracket indicates a region on the gel, which has a different pattern
from that obtained with cell extract minus pCMVORF50. This region may
therefore contain a band representing AIHV-1/Rta binding. The lowest of the
three bracketed bands is competed out by specific competitor.
The samples shown are on different gels.
To deduce if the cellular proteins that could bind to oligonucleotide E7 also bound to
common consensus sequences, cellular extracts were incubated with labelled E7
oligonucleotide in the presence or absence of excess unlabelled competitor
oligonucleotides containing consensus E-box or Oct-1 motifs. The oligonucleotides
containing these sequences were available in the laboratory. Many eukaryotic
promoter and enhancer regions contain sequences related to the octamer sequence
(ATGCAAAT) to which proteins bind (Sturm et al., 1987). E-boxes (CANNTG) are
also a common motif to which proteins bind (Gilmour et al., 1991). The unlabelled
competitor probes used were, NS, E7, E-box and Oct-1 (see Figure 3.30 and Table
3.4).
Table 3.4: Oct-1 and E-box oligonucleotides
Each single-stranded oligonucleotide indicated in the table is half of a
complementary pair used to make double-stranded oligonucleotides for use
in EMSAs. Note that since these oligonucleotides were only used as
competitors and were therefore not labelled, there was no requirement for
them to have single-stranded overhangs. The Oct-1 double-stranded
oligonucleotide does not have overhangs whereas the E-box double-












TCC CCT AAA TGT AAA ACA AAC CTG CC
GGC AGG TTT GTT TTA CAT TTA GGG GA
TCG AGG AGA GTG TCA CGT GGC TCT CC
TCG AGG AGA GCC ACG TGA CAC TCT CC
Oct-1
E-Box
In this experiment, all samples had 250 ng of non-specific double-stranded
oligonucleotide added to reduce the amount of background. Figure 3.30 shows that
the only unlabelled oligonucleotide able to compete with the band was the specific
double-stranded oligonucleotide E7. The negative extract and positive extract gave
108
Figure 3.30: EMSAs using E7 with several competitors
Labelled oligonucleotide E7 was incubated with whole cell extract
prepared from BHK cells transfected with pCMVORF50 or a control
plasmid.
All samples had 250 ng of NS primer in them to reduce background.
10-, 50- and 100-fold excess competitor was added to the
appropriate reactions as indicated (S - specific, NS - non-specific,
E-box and Oct-1).
Block arrows indicate a single band which is only competed out with
the specific competitor.
the same result suggesting that the band represented a cellular protein rather than
A1HV-1/Rta. The fact that the E-box and Oct-1 oligonucleotides did not compete
suggests that the cellular protein does not bind to the E-box or Oct-1 consensus
motifs.
The original aim of the EMSAs was to investigate whether A1HV-1/Rta bound to the
region which was suspected to be AlHV-l/Rta-responsive. It is possible that this
does happen, but the results obtained indicate that the use of whole cell extract is not
satisfactory as there appear to be several cellular proteins that bind to the
oligonucleotides tested. Suggestions of how to progress the EMSA analysis with
respect to A1HV-1/Rta binding are discussed in Chapter 5.
3.6 Analysis of functional domains of AIHV-1/Rta
Since A1HV-1/Rta was discovered to be a transactivator, studies were initiated to
investigate different domains of the protein. Published studies of EBV Rta showed
that it contains DNA-binding and transactivation domains (Manet et al., 1991).
Analysis of the EBV Rta transactivation domain revealed hydrophobic residues
conserved with VP 16 of HSV-1 and the Rta of HVS. Substitution of the hydrophobic
residues in EBV Rta resulted in loss of transactivation ability (Hardwick et al.,
1992). The A1HV-1/Rta amino acid (aa) sequence was analysed using a
hydrophilicity plot (Figure 3.31). A point on the plot was chosen to divide the protein
into two approximately equal sizes. This point was located between two discernible
sequence structures. As can be observed in Figure 3.31, the N-terminal sequence is a





























Figure3.31:HydrophilicitvplotftheAIHV-1/Rtaaminocidseq e c . TheKyte-Doolittlemethodofcalculatinghydrop licitywasusedtgenera eiph AIHV-1/Rtaaminocidseque cefroEnssertl.(1997). Alsoshownarethrelativepo itionsferoductenc d dbycon tru spcDNA50Aac 50B (seeFigure3.32).
sequence is largely hydrophilic with a small area of hydrophobic residues. Two
constructs were generated containing truncated versions of the ORF50 sequence, an
N-terminal and C-terminal region. These regions were generated by PCR
amplification using the A1HV-1 genome as the template.
The N-terminal region of the ORF50 sequence was amplified using primers 1) 5' -
AAG AAT TCA TGA GTG CCA ACA ACC CC (Nt 72825-72842) and 2) 5'- AAG
GATCCC ACA TAC CTC TGC CTG G (Nt 73868-73852) containing EcoBA and
BamHl restriction enzyme sites, respectively (underlined). The C-terminal region of
the ORF50 sequence was amplified using primers 3) 5' - AAG AAT TCA TGA
GGT ATG TGT TAC CAG (Nt 73859-73875) and 4) 5' - AAG GAT CCT ATG
GTC TGG TCA CGG G (Nt 74902-74886) containing EcoBA and BamHl restriction
enzyme sites, respectively (underlined). Primer 3) also had a start codon (in bold)
engineered into the primer. The PCR products were inserted into the pGEM-T Easy
vector and then subcloned using the EcoBA and BamHl sites into the
pcDNA3. Imyc/His, vector to derive pcDNA50A and pcDNA50B. The full-length
ORF50 was amplified by PCR using primers 1) and 4) above and inserted initially
into pGEM-T Easy vector and then subcloned into pcDNA3.1 wye/His to derive
pcDNA50 (Figure 3.32). Primer 4) did not contain the ORF50 stop codon because
there is a stop codon situated in-frame and downstream of the rayc/His tag of the
vector, which is at the 3' end of the cloned insert. The pcDNA3.1 rayc/His vector has
the advantage that proteins can be detected via the C-terminal myc tag and/or purified
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Figure 3.32: Construction of truncated versions of QRF50
(a) Diagram of full-length ORF50 and truncated sequences 50A and
50B, showing the location of PCR primers 1-4 used to amplify them, along
with the restriction enzymes attached.
(b) Diagram of the pcDNA3.1 myc/His vector, which has a C-terminal
myc epitope and His tag. The multiple cloning site is illustrated.
(c) EcoRI and SamHI digests of pcDNA50, pcDNA50A and pcDNA50B.
The observed insert sizes are ~1 kb for 50A and 50B and ~2 kb for ORF50.
The three plasmids were used in an initial experiment to assess if the full-length
ORF50 construct could transactivate 57prom similarly to pCMVORF50 (Figure 3.14
and 3.15) and also if pcDNA50A or pcDNA50B could activate the ORF57 promoter
(see Figure 3.33(a) and Appendix 11). The pGL3-Basic and 57prom constructs were
each transfected with or without pcDNA50, pcDNA50A or pcDNA50B.
The results shown in Figure 3.33(a) suggest that pcDNA50 activated the 57prom
luciferase reporter similarly to pCMVORF50, as expected. However, neither of the
domains of A1HV-1/Rta encoded by pcDNA50A and pcDNA50B had any effect on
57prom.
These constructs were then used in a further experiment to address if co-transfection
of any of these constructs could interfere with the activity of the A1HV-1/Rta,
encoded by pcDNA50, on 57prom. pcDNA50 was transfected with 57prom alone or
together with pcDNA50A, pcDNA50B or pEGFP-Nl. pEGFP-Nl expresses EGFP
under the control of the CMV promoter and this was included to demonstrate that
any effect of pcDNA50A or pcDNA50B on pcDNA50-mediated transactivation was
due to the truncated protein interfering with the activity of the full-length A1HV-
1/Rta and not due to dilution of transcription factors by the CMV promoter (Figure
3.33(b) and Appendix 12).
As seen in Figure 3.33(b), addition of pcDNA50B or pEGFP-Nl had no effect on the
transactivation of 57prom by the A1HV-1/Rta gene product, since the fold induction
in this sample was similar to that observed with 57prom and pcDNA50 alone. In
ill
pcDNA50 pcDNA50A pcDNA50B
pGL3-Basic: + - + - + -
57prom: - + - + - +
Figure 3.33 (a): Activity of 57prom when co-transfected with full-length or
truncated QRF50 expression constructs
BHK cells were co-transfected with either 2 jag of pGL3-Basic or 57prom with or
without 2 jig of pcDNA50, pcDNA50A or pcDNA50B. pRLSV40 (0.2 j.ig) was
used as an internal control in each transfection. The fold induction of activity in









Figure 3.33 (b): Effect of QRF50 truncations on the ability of
AIHV-1/Rta to transactivate the ORF57 promoter
BHK cells were transfected with the combinations of plasmids shown on the
graph. BHK cells were transfected with pGL3-Basic or 57prom in the
presence or absence of pCMVORF50 as a negative and positive control,
respectively. In all other samples BHK cells were transfected with 57prom in
the presence or absence of pCMVORF50 to permit fold induction to be
calculated. These samples containing pCMVORF50 also contained one of
pcDNA50A, pcDNA50B or pEGFP-N1 in three different concentrations
(2 pg, 10 pg and 20 pg).
The results show the fold induction of activity in the presence and absence
of ORF50 expression constructs. All samples were transfected with 0.2 pg
of pRLSV40 as an internal transfection efficiency control. The experiment
was performed in triplicate and error bars show the standard deviation.
contrast, addition of pcDNA50A did have an effect on AlHV-l/Rta-mediated
transactivation of 57prom. Addition of increasing amounts of pcDNA50A
diminished the activity of 57prom in a dose-dependent manner. Addition of 2 pg of
pcDNA50A decreased the fold-induction observed with pcDNA50 alone by around
30% and of 10 pg by around 70%. Addition of 20 pg pcDNA50A did not lead to a
further decrease in activity.
These results are consistent with the N-terminal region of A1HV-1/Rta (encoded by
pcDNA50A) containing a DNA-binding domain. Thus, expression of the DNA-
binding domain of A1HV-1/Rta alone could compete with A1HV-1/Rta for binding to
DNA thereby decreasing transactivation of the ORF57 promoter. In the time
available detection of expression from these constructs was not achieved and
therefore it is not known if protein was expressed from pcDNA50B.
3.7 Analysis of AIHV-1 ORFA6
3.7.1 Construction of an ORFA6 expression construct - pCMVORFA6
Preliminary studies were initiated to investigate the possibility that ORFA6 encodes
a transactivator. It was also of interest to determine if the ORFA6 gene product could
act in synergy with A1HV-1/Rta. This hypothesis is based on the situation in EBV,
where Rta (the ORF50 homologue) and Zta (a possible ORFA6 homologue) can act
in synergy (Holley-Guthrie et al., 1990).
The coding sequence for ORFA6 was amplified by PCR with primers 5' - AAG
GAT CCT CAT GCA TAA GCA CTC TGC T (Nt 75224-75243) and 5' - AAG
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CTAGCG TGT TAG CTT CAT GCA ACC T (Nt 75896-75877) containing BamHl
and Nhel restriction enzyme sites, respectively (underlined). The PCR product was
inserted into the pGEM-T Easy cloning vector. The ORFA6 sequence was then
subcloned into the pEGFP-N 1 plasmid by ligation of the BamHl (blunt-ended), Notl
restriction fragment with vector digested with Notl and Nhel (blunt-ended) to derive
pCMVORFA6. Again, as with pCMVORF50, the EGFP sequence was removed in
this process and replaced with the ORFA6 sequence (Figure 3.34(a)).
3.7.2 Expression of pCMVORFA6 using RT-PCR
Transcription of ORFA6 from pCMVORFA6 was assessed by RT-PCR analysis.
BHK cells were transfected with pCMVORFA6 (2 pg) or untransfected. Total
cellular RNA was extracted (section 2.5.1), DNAse treated, reverse transcribed and
amplified by PCR (section 2.2.2). The primers used to amplify the ORFA6 sequence
for subcloning (section 3.7.1) were used for the RT-PCR analysis. Figure 3.34(b)
clearly shows a band of the correct size, which is only present in the pCMVA6-
transfected cells but not in the negative controls. Thus, ORFA6 is transcribed from
this plasmid.
3.7.3 Analysis of the effect of pCMVORFA6 alone or in combination with
pCMVQRF50 on putative AIHV-1 promoters
pCMVORFA6 was used in transfection experiments in BHK cells alone or in
combination with pCMVORF50 to assess its ability to transactivate 57prom, 6prom
or TKprom. pGL3-Basic was again used as a background control. pCMVORFA6 had
no effect on any of the promoters in this experiment (Figure 3.34(c) and Appendix
13). This is the result of a single experiment and therefore it is not possible to make
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(") BamHI Nhe I
(b) RNA RT+ RT- water Template
Figure 3.34:
(a) Construction of pCMVA6
(i) The 0RFA6 sequence was amplified by PCR to yield a product of 672 bp.
The negative control using water instead of AIHV-1 DNA is also shown.
(ii) Schematic representation of pCMVORFA6. The ORFA6 sequence was
inserted into the BamHI and Nhe\ sites, replacing the EGFP sequence of
pEGFP-N1.
(b) RT-PCR of PCMVA6
RT-PCR analysis was carried out on total RNA extracted from BHK cells,
which had been transfected with 2 pg of pCMVORFA6 (RT+).Total RNA
extracted from BHK cells transfected with pCMVORFA6 that had not been
reverse transcribed (RT-), RNA from mock-transfected BHK cells (RNA)


















pCMVA6 pCMVA6 plus pCMVORF50
Figure 3.34 (c): Activity of pCMVA6 on AIHV-1 promoter constructs
BHK cells were transfected with 2 pg of pGL3-Basic, 57prom, TKprom or 6 prom
with either 2 pg of pCMVA6 or 2 pg of pCMVA6 plus pCMVORF50 as indicated.
The fold induction of activity in the presence and absence of expression
constructs is shown. The results represent a single experiment.
conclusions regarding the ability of the ORFA6 gene product to behave as a
transactivator.
3.8 Summary of Results
3.8.1 Expression of QRF50 and ORFA6
Examination of the slot blot experiment (Figure 3.4) suggests that ORF50 and
ORFA6 are expressed as IE genes. RT-PCR experiments carried out on RNA
extracted from virus-infected BT cells suggests that ORF50 is expressed at all times
in the virulent virus but not the attenuated virus and that ORFA6 is expressed at all
times in both the virulent and attenuated virus. However, results from the necessary
controls were not satisfactory and therefore the expression pattern of ORF50 and
ORFA6 within the virus has not been demonstrated unequivocally. Further work
addressing the temporal control of ORF50 and ORFA6 in the virus life cycle would
include a successful Northern blot. To address if ORF50 and ORFA6 are co-
transcribed, and if the predicted SD and SA sites of ORF50 are used 5'-RACE could
be performed.
3.8.2 The function of the AIHV-1/Rta
A1HV-1/Rta was shown to encode a transactivator protein. In transient transfection
assays it can strongly activate the A1HV-1 ORF57 promoter and moderately activate
the ORF6 promoter but not the TK promoter. TKprom and 6prom were shown to be
functional using virus superinfection. 57prom was not shown to be functional by
virus superinfection but was clearly shown to be functional in the subsequent
transient transfection assays.
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3.8.3 Analysis oftheAIHV-1 ORF57 promoter
Transcription of the 57prom luciferase reporter construct was examined and the
transcriptional start site was determined to lie within 409 bp upstream of the
predicted translational start site. 5'-RACE was then carried out on total RNA from
virus-infected cells to determine a more precise location for the transcriptional start
site. These experiments revealed that the transcriptional start site was 24 bp upstream
of the predicted start codon and 30 bp downstream from the predicted TATA box.
SD and SA sites were also identified.
The ORF57 promoter was analysed further in transient transfection assays to
determine the minimal length required for activation by A1HV-1/Rta and also to
determine the location of potential AlHV-l/Rta-responsive elements.
Through the use of deleted and truncated constructs of 57prom, a potentially
important sequence for the activation by A1HV-1/Rta was identified. The 57p(579)
construct was activated by A1HV-1/Rta, whereas the 57p(466) construct was not.
Thus, the sequence between 409-522 bp upstream from the translational start codon
was identified as being important for activation by A1HV-1/Rta. As it was possible
that a consensus sequence or motif responsible for conferring the A1HV-1/Rta-
responsiveness was contained in this sequence and could be straddling the border
between 57p(579) and 57p(466), a 155 bp fragment spanning this sequence was
investigated further.
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Prom57p(155) was used in transient transfection assays to test if this sequence alone
could act as an AlHV-l/Rta-responsive enhancer. The results suggested that this
sequence alone was not sufficient to confer AlHV-l/Rta-responsiveness.
57p(399) was generated to investigate if there was another element important for
activation by A1HV-1/Rta. This construct showed around 50% activation compared
to 57p(579) from which it was derived, indicating that the section 'excised' from the
centre of 57p(579) to create 57p(399), although not essential, was important for
activation by A1HV-1/Rta. It was concluded that this could either be because it
contained an important sequence or because it is important in separating the other
two fragments by a fixed distance.
3.8.4 EMSAs
To investigate whether A1HV-1/Rta interacted directly with ORF57 promoter
sequences, EMSAs were carried out. Whole cell extracts were prepared from cells
transfected with or without pCMVORF50. Double-stranded oligonucleotides E1-E7
were designed, which spanned the area of interest and which potentially contain an
AlHV-l/Rta-responsive region. Several incidences of potentially specific binding
were observed with double-stranded oligonucleotides El, E2, E6 and E7. However, it
was not clear if these involved A1HV-1/Rta, cellular proteins or a combination of the
two. E7 was investigated further to test if the proteins bound to E7 also interacted
with Oct-1 or E-box consensus sequences. Double-stranded oligonucleotides
corresponding to these consensus sequences did not compete for binding to E7. A
similar binding pattern was observed using extracts containing pCMVORF50 or the
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control plasmid, suggesting that cellular protein(s) rather than A1HV-1/Rta was
involved in the binding to oligonucleotide E7.
3.8.5 QRF50 truncations
To examine the domains of A1HV-1/Rta, two truncated versions of A1HV-1/Rta were
constructed, consisting of the N-terminal and C-terminal regions of A1HV-1/Rta.
These constructs were used to determine whether they were capable of competing
with full-length A1HV-1/Rta activation of 57prom, in transient transfection assays.
The N-terminal domain was capable of competing with AlHV-l/Rta-mediated
transactivation. This is in agreement with the hypothesis that the N-terminal domain
may be the DNA-binding domain.
3.8.6 Analysis of ORFA6
An expression plasmid of A1HV-1 ORFA6 was constructed to test if it could act as a
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A variety of methods have been employed to mutate genes in herpesviruses to
determine their function. Initially this was carried out using mutagenic chemicals
with a view to identifying the genotype change responsible for an altered phenotype.
This approach was used decades ago to produce HSV-1 temperature-sensitive (ts)
mutants (Schaffer et al., 1970). This was a random process and could result in the
occurrence of several mutations within a single genome, making assignment of a
phenotypic change to one particular mutation difficult. The sequencing of
herpesvirus genomes led to the development of a more targeted approach to create
specific mutations. This involved recombination within eukaryotic cells between the
virus DNA and a plasmid containing a marker gene and homologous sequences
flanking the region of the virus genome to be replaced (Mocarski et al., 1980; Post
and Roizman, 1981; Spaete and Mocarski, 1987).
The experiments in Chapter 3 examined A1HV-1 ORF50 in isolation. An alternative
approach was chosen to study the virus phenotype in the absence of ORF50. Initially
this was attempted using homologous recombination to partially or completely
remove the ORF50 sequences from the virus DNA, as described in section 4.2. If this
had been achieved the intention would have been to purify the recombinant virus and
test its ability to grow in tissue culture, and in the animal model, the rabbit, to allow
changes in pathology to be observed. Changes in the phenotype of a virus lacking
ORF50, compared to wild-type virus, would give an indication of possible roles for
ORF50. Finally a revertant would have been made to confirm that the changes were
due to the engineered mutation. Section 4.3 discusses an alternative approach that
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was attempted where the intention was to generate a bacterial artificial chromosome
(BAC) containing the A1HV-1 genome.
4.2 Attempts to make AIHV-1 lacking QRF50 using homologous
recombination
The main aim of this part of the study was to make AIHV-1 lacking ORF50. Two
approaches were attempted, which if successful would result in partial or complete
removal of ORF50. Thus, no viable protein product would be expressed. Both
strategies involved homologous recombination between the virus genome and a
plasmid containing two sequences homologous to the virus DNA bisected with a
marker gene.
4.2.1 Transfection of AIHV-1 DNA leads to virus production
It was not known whether or not transfection of AIHV-1 DNA resulted in productive
virus replication and so this was tested. Figure 4.1 shows BT cells transfected with
0.1 pg, 1 pg, 5 pg and 10 pg of AIHV-1 DNA exhibiting characteristic CPE 24 days
after transfection. Transfected cells were transferred onto fresh cells and CPE was
again observed.
Thus transfection of AIHV-1 DNA can lead to virus production in BT cells. This
meant that the virus DNA could be provided either by transfecting virus DNA or by
virus infection of cells.
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Figure4.1:Imagesofbovinturbinatcells.
1-mock-transfectedBTcells. 2-mock-transfectedBTcells. 3-BTcellstransf ctedwith0.1gofC500AIHV-1DNA. 4-BTcellstransf ctedwith1pgofC500AIHV-1DNA. 5-BTcellstransf ctedwith5(igofC 00AIHV-1DNA. 6-BTcellstransf ctedwith10j. gofC500AIHV-1DNA Allphotographsexcept1weretak n24d ysfttransfec ion. Photograph1wastakenfed ysaft rtransfec ion.
 
4.2.2 Strategy A - recombinant virus containing no QRF50 coding
sequence.
Strategy A - construction of a plasmid containing only sequences flanking ORF50
but lacking any ORF50 coding sequences.
A plasmid was designed to have a marker gene encoding the green fluorescent
protein flanked by virus sequences that lie upstream and downstream of ORF50 in
the A1HV-1 genome. No ORF50 coding sequence was present in this construct. The
sequences flanking ORF50 were amplified by PCR (see Table 4.1).
Table 4.1: Primers
The table shows the primers used to amplify the sequences
flanking ORF50 sequence by PCR to construct a plasmid for
use in strategy A. Regions underlined show the restriction























In principle, this strategy would have resulted in flanking sequences of 504 bp and
540 bp. The restriction enzyme sequences on the end of primers 50F2 and 50F3 were
designed to be used in overlap extension PCR creating a Pad site between the two
homologous ORF50 flanking regions. This would have allowed insertion of the
CMV-EGFP cassette between the flanking sequences, since it was amplified using
primers with Pad restriction sites (see Figure 4.2). The overlap extension PCR was
not successful and construction of this plasmid was not completed.
4.2.3 Strategy B - recombinant virus containing partial QRF50 coding
sequences
Strategy B - construction of a plasmid containing only ORF50 coding sequences
and no flanking sequences.
This strategy used the previously subcloned ORF50 sequence in the pGEM-T Easy
vector (see Figure 3.1(a)). A 923 bp central portion of the ORF50 sequence was
excised using Hindlll and Msd restriction enzymes and the CMV-EGFP expression
cassette was excised from pEGFP-Cl using AseI and Mlul. Blunt-end ligations were
carried out (section 2.2.6-2.2.8) to insert the CMV-EGFP cassette into the pGEM-T
Easy-ORF50 plasmid. This resulted in homologous sequences of 739 bp and 416 bp
of the ORF50 sequence flanking the CMV-EGFP cassette, deriving p50/EGFP








































Figure 4.2: Construction of plasmid for strategy A
Schematic diagram showing the location of primers and construction of the
plasmid designed in strategy A.
Blue arrows indicate the orientation of the cloned fragments.
Cut with Hind\\\ and Msc\
Hind\\\ Msc\
1









Figure 4.3 (a): Construction of p50/EGFP
(i) Construction of p50/EGFP, which contains a CMV-EGFP expression
cassette flanked by ORF50 sequences.


































Figure 4.3 (b): Construction of p50/EGFP
(i) Hind\\\/Msc\ digests of pGEM-T Easy-ORF50 (Lanes 1 and 2) and Ase\IMIu\ digests of
pEGFP-C1 (Lanes 3 and 4).
(ii) Fragments highlighted in (i) were extracted from the gel and these gel-purified products are
shown in this gel.
(iii) Successful insertion of the CMV-EGFP cassette into pGEM-T Easy-ORF50 to derive
p50/EGFP. Digest with EcoRI and BamHI. The CMV-EGFP cassette contains
EcoRI and BamHI restriction sites as shown on the right of the figure.
4.2.4 Transfections of plasmid and virus DNA to "knock out" QRF50
BT cells were transfected with 2 pg of p50/EGFP and after 48 h examined for
fluorescence. Approximately 10% of the cells fluoresced green indicating that they
expressed the CMV-EGFP cassette, and that this would therefore serve as a useful
marker. (Figure 4.3(a)(ii)).
In an attempt to generate recombinant viruses, BT cells were co-transfected with
between 0.1-10 pg of virus DNA along with 2 pg of p50/EGFP. BT cells were also
transfected with 2 pg of p50/EGFP and infected with A1HV-1 24 h later (see Table
4.2).
Table 4.2: Experimental design.
Experiment 1: co-transfection of BT cells with p50/EGFP and different
amounts of virus DNA.
Experiment 2: transfection of BT cells with p50/EGFP alone followed by
infection 24 h later with different amounts of virus.
Mock-transfected cells acted as a negative control for both experiments.
100pl of AIHV-1 represents 2 x 105 infected cells exhibiting 70-80 % CPE.
Experiment 1 Cell treatment:
A p50/EGFP (2 pg) and 10.0 pg of AIHV-1 DNA
B p50/EGFP (2 pg) and 5.0 pg of AIHV-1 DNA
C p50/EGFP (2 pg) and 1.0 pg of A1HV-1 DNA
D p50/EGFP (2 pg) and 0.1 pg of AIHV-1 DNA
Experiment 2 Cell treatment:
A p50/EGFP (2 pg) and infection with 20 pi AIHV-1
B p50/EGFP (2 pg) and infection with 30 pi AIHV-1
C p50/EGFP (2 pg) and infection with 40 pi AIHV-1
D p50/EGFP (2 pg) and infection with 60 pi AIHV-1
Negative control Mock transfection with sterile distilled water
123
After 24 h, all cells were assayed for successful transfection as determined by the
appearance of green fluorescing cells. The presence of green fluorescing cells within
areas of virus-induced CPE would suggest the presence of virus recombinants.
Experiment 1:
BT cells that had been transfected with virus DNA initially did not show evidence of
CPE, although 10% of cells were fluorescing green. Five days after transfection,
green fluorescence was still detected in the transfected cells although clear CPE was
still not observed. Fourteen days after transfection, the cells were harvested, freeze-
thawed and transferred to fresh BT cells in 75 cm3 (T75) flasks. After further
passaging, CPE was finally observed. However, green fluorescence was no longer
observed.
Experiment 2:
After 48 h some CPE was observed in the plates with virus-infected cells and there
were several green fluorescing cells within the areas of CPE (Figure 4.4). Five days
after infection, the virus-infected cells were harvested and an aliquot was transferred
onto fresh BT cells in 96-well plates and observed for green fluorescence. Three days
later, from wells containing green fluorescence, cells were harvested and plated onto
fresh cells in 60 mm plates. They were again observed for green fluorescence and
passaged one further time onto fresh BT cells after they reached confluency.
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Figure 4.4: Bovine turbinate cells transfected with p50/EGFP and infected
with C500 AIHV-1.
(a) Light microscopy indicating rounding up of cells, which is characteristic
of the CPE observed following AIHV-1 infection.
(b) Fluorescent microscopy of the same field as (a) indicating fluorescent
green cells within the area of CPE.
In both experiments, although CPE continued to be observed in some samples, green
fluorescence was not. The procedure was repeated using virus DNA once the
optimum electroporation conditions for BT cells had been determined (Figure 3.9),
but this was also without success.
At this point, this method of obtaining an ORF50 knockout virus was abandoned, as
it was felt that in order to obtain sufficient amounts of virus DNA, the virus would
have to be repeatedly passaged, thereby increasing the risk of additional, unwanted
mutations. Another challenge with this method included the purification of
recombinant virus. As A1HV-1 does not cause defined plaques in the cell monolayer,
purification involved selecting areas of CPE that were fluorescent. The intention was
to use limiting dilution to select recombinant virus. During the procedure, after
several rounds of selection, the green fluorescence was eventually lost, and
recombinant virus was not purified. It was hoped that as green fluorescent areas of
CPE were selected the amount of green fluorescence would be amplified due to the
amplification of the recombinant virus. It was not possible to establish if recombinant
virus was present in these areas, if the marker gene had been rejected or down
regulated, or if the recombination had been unsuccessful. For these reasons, a
different approach with more potential applications was pursued.
4.3 Strategy to make a bacterial artificial chromosome containing the
A1HV-1 genome
Several new approaches have been developed to allow the manipulation of
herpesvirus genomes. One of the first developments was to clone virus genomes into
several cosmids. Cosmids, which can hold 35-45 kb of DNA, allow packaging of
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DNA into phage particles. This development enabled researchers to exploit bacterial
systems to mutate a particular area of one of the cosmids. Following transfection into
mammalian cells the cosmids undergo homologous recombination resulting in a
productive virus replication. This method has been used successfully for HSV-1
(Cunningham and Davison, 1993; Kong et al., 1999), MCMV (Ehsani et al., 2000)
and pseudorabies virus (PRV) (van Zijl et al., 1988). The main advantage of this
method is that selection for the mutated cosmid occurs in the bacterial system,
therefore no selection against wild type virus is necessary. Two disadvantages are
that there is a risk of unwanted mutations when the cosmids are undergoing
recombination in mammalian cells, and cosmids can be unstable (Brune et al., 2000).
Recently there has been much interest and activity in the area of artificial
chromosomes. These were developed to provide a solution to the limitations of the
size of DNA insert that can be contained in plasmids and cosmids.
Yeast artificial chromosomes (YACs) are linear vectors containing the insert of
interest flanked by telomeres and containing an origin of replication and centrosome.
They hold between 100-2000 kb of DNA. YACs have been crucial in the mapping of
large genomes of higher organisms (Burke et al., 1987; Anand et al., 1989;
Schlessinger, 1990; Monaco and Larin, 1994) as they can hold large genes along
with all of their control elements. They have been used to make transgenic mice. A
human adenovirus genome has been produced as a YAC clone allowing it to be
manipulated and it has proved to be infectious (Ketner et al., 1994).
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YACs have several disadvantages. They are prone to chimaerism, they can be
unstable which results in some regions being deleted and the YAC cannot be
separated from the yeast chromosomes very easily (Monaco and Larin, 1994). The
possibility of cloning the A1HV-1 genome into a YAC was considered, but it was
thought that the repeat regions at the ends of the genome would be unstable in the
YAC system.
Other methods based on bacterial systems have also been developed. At the start of
this work, less information was available on these methods. However, there has since
been an increase in their utilisation. They have advantages over YACs with respect
to their lack of chimaerism and ease of purification, but they accommodate less DNA
than YACs. The PI cloning system uses the loxP recombination sites and packaging
site from bacteriophage PI and can hold 70-100 kb of DNA. PI-derived artificial
chromosomes (PACs) can hold 100-300 kb of DNA and, as well as containing
elements from the PI system, are based on the F-factor plasmid which is the bacterial
sex or fertility plasmid. BACs can hold up to 300 kb and are also based on the F-
factor plasmid for which the replication is strictly controlled. BACs do not require
separate packaging systems like the PI system, and are more stable than YACs
(Monaco and Larin, 1994; Brune et al., 2000). PACs and BACs can be purified using
standard bacterial selection procedures and methods of plasmid preparation with only
a few modifications, and they can also be directly sequenced (Yang et al., 1997).
BACs had previously only been used for the purposes of mapping and sequencing;
methods of modifying them were not available. There have since been significant
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developments in this area. In 1997, the first modification of a BAC and generation of
transgenic mice using pronuclear injection of a BAC were reported (Yang et al.,
1997).
The stability of BACs and their ability to hold up to 300 kb of DNA are attractive
features for the study of herpesvirus genomes. The first herpesvirus cloned into a
BAC was MCMV (Messerle et al., 1997). Transfection of a BAC containing the
virus genome resulted in a productive virus infection. A targeted mutation in one of
the IE genes was carried out and a mutant virus was produced. Subsequently, BACs
have been constructed that contain the genomes of HSV-1 (Horsburgh et al., 1999),
EBV (Delecluse et al., 1998), PRV (Smith and Enquist, 1999), HCMV (Borst et al.,
1999) and MHV-68 (Adler et al., 2000).
It was decided to attempt to insert the entire A1HV-1 genome into a BAC. As has
been outlined in Chapter 1, when the C500 virulent strain of A1HV-1 is passaged
through tissue culture it eventually becomes attenuated through genome alterations.
For this reason it is difficult to obtain large amounts of virulent A1HV-1 C500 DNA.
If an A1HV-1-BAC was available it could be grown in bacteria and large amounts of
virus DNA would be able to be produced with less risk of mutation. The use of the
BAC system also has the advantage that it avoids the selection procedure involving
limiting dilution, which had previously proved to be a challenge with A1HV-1, partly
owing to the lack of defined plaques. Once a recombinant was made using the A1HV-
1-BAC, pure stocks of a virus mutant could be obtained through the bacterial
selection system.
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At the time of initiating this strategy, only two instances of herpesviruses being
cloned into BACs were known, MCMV (Messerle et al., 1997) and HSV-1 (B.
Horsburgh, pers. comm.). The BAC vector was inserted into an area at the right hand
end of the MCMV genome that had been shown to be nonessential for in vitro
replication. Successful insertion was determined by inclusion of a marker gene in the
BAC. In HSV-1, the BAC was inserted into the TK locus, disrupting it, thereby
allowing selection against wild-type virus TK activity.
The method used for HSV-1 was adopted as a means for making an A1HV-1-BAC
since no nonessential regions of A1HV-1 have been identified. As part of the
strategy, a selection method to select for TK- recombinant viruses was required. The
principle of the method is to add a drug which inhibits replication of wild type virus
but which has no effect on recombinant TK- virus. Two possibilities were to use 4'-
S-Etdu (2' deoxy-5-ethyl-beta 4'-thiou'ridine), also called "C9" (Glaxo SmithKline)
(Barnes et al., 1999), or 9-[(2-hydroxyethoxy) methyl] guanine, called acyclovir. C9
and acyclovir have been shown to inhibit virus replication of other herpesviruses.
Before construction of an AIHV-1-BAC was initiated, both of these drugs were
tested to determine if they inhibited the growth of wild-type A1HV-1.
4.3.1 Testing C9 as an agent to select against wild type AIHV-1 replication
C9 has previously been shown to inhibit replication of MHV-68 and to delay the
onset of viral latency (Barnes et al., 1999). To test the sensitivity of AIHV-1 to C9, a
range of concentrations encompassing the dose known to be effective against MHV-
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68 replication, 2 pg/ml, was used. Subconfluent BHK cells and BT cells were plated
on to 60 mm plates, then infected with A1HV-1 in the presence or absence of
different concentrations of C9 (outlined in Table 4.3). Uninfected cells treated with
C9, infected cells without C9, and uninfected, untreated cells were included as
controls. The amount of virus added was equivalent to 2 x 105 cells with 70-80%
CPE. After observation for 7 days, the cells with virus alone and those with virus
plus C9 showed equivalent amounts of CPE. It was concluded that A1HV-1
replication was not inhibited by C9 at the concentrations used.
Table 4.3 Testing C9 as a selection agent.
Additions to each sample are indicated (+, added; not added).
Also indicated is whether or not CPE was observed (Y - yes, N
- no).
Samples 1 2 3 4 5 6 7 8
Virus - + - - - + + +
C9 (pg/ml 0 0 1 2 10 1 2 10
CPE N Y N N N Y Y Y
4.3.2 Testing acyclovir as an agent to select against AIHV-1
Acyclovir is a guanosine analogue and is an effective inhibitor of HSV-1, HSV-2 and
VZV replication, but not of EBV and CMV. It is phosphorylated by the virus-
encoded TK and is then further phosphorylated by cellular kinases to produce
acyclovir triphosphate. This is incorporated into DNA by the viral DNA polymerase,
causing chain termination (Fields et al., 1996).
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For MHV-68, 0.2 pg/ml of acyclovir reduces the ability of the virus to grow by 50%
and 2 pg/ml completely inhibits virus replication. A 96-well plate was set up with
serial dilutions of A1HV-1 virus, in the presence of either of these concentrations of
acyclovir. Controls included cells with virus in the absence of acyclovir, uninfected
cells treated with acyclovir, and untreated, uninfected cells.
Acyclovir did not inhibit the replication of A1HV-1. This has also been observed by
H. Reid (pers. comm.).
4.3.3 Bromodeoxvuridine (BUdR) as a selection agent.
Since C9 and acyclovir were shown to be ineffective against A1HV-1,
bromodeoxyuridine (5-bromo-2'-deoxyuridine, BUdR) was considered. BUdR is a
chain terminating thymidine analogue that is selectively incorporated into DNA
during S-phase and inhibits growth (Boccadoro et al., 1986). As BUdR is
phosphorylated by cellular and viral TK, TK- cells were required. A1HV-1 can cause
disease in hamsters (Jacoby et al., 1988a and b) and infects BHK cells (Figure 3.11).
Also, BHK cells gave much higher transfection efficiency than BT cells (section
3.3.8). Therefore, the cell line chosen was tk" tsl3 (ATCC CRL-1632), a temperature
sensitive, TK- derivative of the BHK-21 cell line from a Syrian golden hamster (a
kind gift from Dr. H. Marsden, University of Glasgow) (Talavera and Basilico,
1977).
4.3.4 Construction ofpBeloBACH containing AIHV-1 TK sequences.
A vector containing sequences homologous to the AIHV-1 TK region was
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constructed. Primers were designed to amplify regions spanning and incorporating
parts of the TK locus in A1HV-1 (Table 4.4). Initially, PCR amplification did not
work using virus DNA as the template, and so cosmids (c339P and c454B) were
obtained from Dr. Armin Ensser. These cosmids had been used in the sequencing of
the virus genome and contained the TK locus (Ensser et al., 1997) making them
useful templates for PCR. The primers TK1, TK2, TK3 and TK4 used in the PCR
reactions are shown in Table 4.4 and Figure 4.5. Primers TK1 and TK4 contained the
Pad restriction endonuclease sequence. Primers TK1 and TK2 were used to amplify
the left-hand section of the TK locus, TKA. Primers TK3 and TK4 were used to
amplify the right-hand region of the TK locus, TKB. The PCR products were cloned
into the pGEM-T Easy vector.
Table 4.4: Primers used to amplify AIHV-1 TK regions.
Pacl restriction enzyme sites are underlined.






Both clones were digested with Pad to ensure a functional Pad site had been
formed and they were also sequenced to determine the orientation. Fragment TKB1
was excised via the Pad and Sadl sites and inserted adjacent to fragment TKA1 in





















Figure 4.5: Position of primers in TK region
Diagram showing the location of the TK ORF in the AIHV-1
genome, the positions of primers used to amplify the TK regions
for insertion into pBeloBAC11 (see Table 4.4) and the PCR
















Figure 4.6: Subcloninq of the A1HV-1 TK fragments
a) Lanes 1 and 2 contain clones with TKA inserts. Lanes 5-8 contain clones
with TKB inserts. All clones were digested with Not\.
b) Lanes 1 and 2 contain TKA clones and lanes 3-6 contain TKB clones. Only
clones in lanes 1, 3 and 5 show the expected pattern following digestion with
Pacl.


















5,148bp—I 2,027bp—W 1,584bp—M 1,375bp-> 5,148bp 2,027bp 1,584bp 1,375bp
pGEM-TEasyandTKA1(4378bp) pGEM-TEasy(3018bp) TKB1insert(1580bp) pGEM-TEasy(3018bp) -TKB1(1580bp)
*TKA1(1360bp)
The pGEM-T Easy vector is 3018 bp and the TKAB fragment is 2940 bp, and so the
two fragments cannot be distinguished on a gel. Therefore, for subcloning of the
TKAB fragment, Seal was used in a double digest with Noil since Noil excises the
TKAB fragment and Seal does not cut the TKAB fragment but cuts the pGEM-T
Easy plasmid backbone into two pieces. The whole TKAB region was excised from
the pGEM-T Easy plasmid with Noil and inserted into the pBeloBACll vector
(accession number - U51113; obtained from Dr Linda Mullins) (see Figures 4.8,
4.9(a) and 4.9(b)).
4.3.5 Transfection of TK- BHK cells with BAC-TK and virus DNA
TK- BHK cells were co-transfected with BAC-TK and virus DNA with or without
the pCMVORF50 expression construct. The rationale for including the latter
construct was that Rta homologues in EBV, HVS, MHV-68 and KSHV can
reactivate virus from latency (Zalani et al., 1996; Ragoczy et al., 1998; Gradoville et
al., 2000; Wu et al., 2000; Goodwin et al., 2001). If A1HV-1/Rta behaves similarly it
could potentially facilitate the initiation of virus transcription from the virus DNA
and thus make replication more efficient. Problems with genomic contamination of
the BAC-TK preparation were rectified prior to the experiment by using the
QIAGEN maxiprep kit with modifications for large plasmids (section 2.3.4 and
2.3.5). The experimental design is shown in Table 4.5.
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Figure 4.8: Diagram of pBeloBAC11
The Not\ sites which were used for the insertion of TK sequences
are boxed in blue. The deletion of the sequence between these sites
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TKAB (pGEM-T Easy)





Figure 4.9 (a) Construction of BAC-TK
Diagram showing how the TKAB fragments, amplified from
the AIHV-1 cosmids, were subcloned into pBeloBAC11. The
TKAB fragment was excised from the pGEM-T Easy vector using
the Not\ sites in the multiple cloning site and inserted into the
Not\ sites in pBeloBAC11. The yellow arrows show the orientation
of the TKA and TKB sequences. The orientation can be compared


















Figure 4.9 (b): Construction of BAC-TK
(i) Not\ digests of pBeloBAC11 (lanes 3 + 4) and Sea \/Not\
digests of pGEM-T Easy-TKAB (lanes 1 + 2).
(ii) Digests of BAC-TK showing successful subcloning of TKAB into
pBeloBACH. Clones containing TKAB are in lanes 2,3,9,12.
Boxed bands are TKAB fragments excised from the
pBeloBACH backbone.
The top band is E. coli genomic DNA contamination.
(iii) Large preparation of BAC-TK. Lane 1 shows uncut BAC-TK. Lane 2
shows TKAB excised from pBeloBAC11 by Not\. Note the lack
of genomic DNA contamination in this preparation.
Table 4.5: Experimental design and results
TK- cells were transfected with different constructs in the
presence and absence of BUdR, as indicated in the table, to
allow insertion of BAC-TK into the AIHV-1 genome. Also
indicated is whether or not CPE was observed (Y - yes, N -
no).
Additions Samples
1 2 3 4 5 6 7 8
BUdR (25 pg/ml) + - + - + - +
Virus DNA (1 pg) + + + + + + -
BAC-TK (0.2 pg) - - + + + + -
pCMVORF50 (2 pg) - - - - + + -
CPE N Y Y Y Y Y N N
Only samples 3 and 5 contained potential recombinants because they contained virus
DNA and BAC-TK and were under BUdR selection. The other samples were
included as controls for the following reasons:
1 - cells with BUdR and virus DNA to ensure the BUdR selection was effective.
2 - cells with virus DNA only to ensure virus was being produced.
4 - cells with virus DNA and BAC-TK to ensure that CPE occurred using these
components without BUdR selection.
6 - cells with virus DNA, BAC-TK and pCMVORF50 to ensure that CPE occurred
using these components without BUdR selection.
7 - cells with BUdR only to ensure BUdR did not affect the cells.
8 - cells alone to allow for comparison with other samples.
The areas of CPE observed in the samples suggested that the BUdR drug selection
was acting as predicted and that virus was being produced (Table 4.5). The addition
of pCMVORF50 did not result in increased areas of CPE. When CPE was observed
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(Figure 4.10), cells from samples 3 and 5 were harvested and plated onto fresh
subconfluent TK- BHK cells in media containing 25 pg/ml BUdR. Areas of CPE that
developed were again harvested and plated onto fresh cells. Cells were harvested and
aliquots were tested by slot blot analysis using pBeloBACll DNA as a probe
(section 2.5.7). Separate aliquots were tested by PCR amplification using primers
that straddled the pBeloBACll and A1HV-1 sequences to determine whether the
BAC had inserted in the correct place. For both the slot blots and PCR, crude
preparations of cell extract were used as described in section 2.4.10. The results
obtained were all negative. The next step for this strategy would be to clean up these
preparations to try to obtain signals or products. In addition, the CPE was not well
defined and so it would be beneficial to be able to identify areas of CPE with more
certainty.
4.3.6 Progression of Strategy
Owing to the lack of defined areas of CPE, it was reasoned that an additional
selection was required. To achieve this a CMV-EGFP expression cassette, amplified
from the p-EGFP-Cl vector (Genbank accession number U55763) was inserted into
a Sacll site, in BAC-TK, deriving BAC-TK-EGFP. Cells could then be screened for
areas of green fluorescing CPE in the presence of BUdR (see Table 4.6).
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x 125
Figure 4.10: TK- BHK cells transfected with C500 AIHV-1 virus
DNA and BAC-TK
An area of CPE, which resembles the syncytia caused by C500
AIHV-1 infection, is indicated by an arrow.
Table 4.6: Primers used to amplify the CMV-EGFP expression cassette.





The GFP cassette was successfully cloned into BAC-TK (Figure 4.11(a) and (b)).
4.3.7 Transfection of virus DNA and BAC-TK-EGFP
A similar experimental procedure was carried out to that described in Table 4.5,
using 5 pg of BAC-TK-EGFP, 2 pg of virus DNA and 25 pg/ml BUdR.
Fluorescence was observed in an initial experiment, but the transfection efficiency
was low. The SuperFect method of transfection (section 2.4.7) was optimised for
BHK cells and gave much improved transfection efficiency compared with
electroporation. The optimal conditions involved adding 5pg of BAC-TK-EGFP to 2
x 105 cells on a 60 mm plate in transfection reagent for 2 h. Two days after
transfection the cells were passaged onto 90 mm plates. The samples with potential
recombinants, determined by the presence of green cells, were passaged onto further
plates. This experiment was repeated in triplicate (see Table 4.5 for experimental
design) varying the amount of virus DNA and the amount of BAC-TK-EGFP DNA
(see Table 4.7). From 42 90 mm plates, 28 areas of CPE were harvested and plated
onto 60 mm plates. Although fluorescence was detected up to 12 days after



























Figure 4.11 (a): Construction of BAC-TK-EGFP
Schematic diagrams showing construction of BAC-TK-EGFP.
BAC-TK-EGFP was generated by inserting the CMVEGFP
cassette into the Sacll site in BAC-TK (Figure 4.9 (a)). The
Sfi\ and Pacl sites were used to determine the orientation
of the TKAB fragment and the CMVEGFP cassette relative to


























Figure 4.11 (b): Construction of BAC-TK-EGFP
a) Sacll digest showing successful cloning of the CMVEGFP expression
cassette into BAC-TK. Clones containing CMVEGFP are in lanes 4,5,7,8,
9,11,12 and 13.
b) To establish the orientation of the TKAB fragment and also the CMVEGFP
cassette relative to it, Pac I and Sfi\ digests were carried out on BAC-TK
(lane 1) and BAC-TK-EGFP (lane 2). This digest excised TKB from BAC-TK.
The two possible orientations are shown for BAC-TK-EGFP (A and B).
Diagram A shows the actual orientation.
Figure 4.12 : TK- BHK cells transfected with virus DNA and BAC-TK-GFP.
Examples of green fluorescing cells are shown. The images are arranged
in 4 numbered rows, each row showing examples of cells from a different
timepoint. Row 1-1 day after transfection, Row 2-2 days after transfection,
Row 3-3 days after transfection, Row 4-9 days after transfection.
clear CPE was observed. It was at this point that the attempts to make an A1HV-1-
BAC and ORF50 mutant were halted due to time constraints.
Table 4.7: Experimental Design
Varying amounts of BAC-TK-EGFP DNA and virus DNA used in
transfections to insert the BAC into AIHV-1.
Experiment A B C
Virus DNA (pg) 2 5 5
BAC-TK-EGFP (pg) 5 5 7.5
4.4 Future Work
During the period when these attempts were being made, substantially more
literature was published on the process of making a BAC containing an entire
herpesvirus genome. New considerations have been unearthed and ingenious
strategies have been developed to cope with these.
The key difference between traditional methods and this method of creating mutant
viruses is that the recombinant virus can be made using recombination in a
prokaryotic system rather than a eukaryotic system. This means the process is more
precise and faster: in theory, it can take 7 days to make a mutant virus (Horsburgh et
al., 1999). However, this can only occur once the virus DNA has already been cloned
into the BAC vector. Construction of a BAC containing a virus genome can be a
laborious procedure and is the most difficult part of the method largely owing to
dependence upon recombination in a eukaryotic system. Direct cloning of virus DNA
into the BAC vector is possible, but is not very efficient, although it can be done if
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very large numbers of colonies are screened. However, the more common method
involves homologous recombination of the virus genome into the BAC vector in
eukaryotic cells. This approach can be problematic as success depends on how
tolerant the virus is to having extra DNA inserted into its genome. The first MCMV
BAC construct replicated similarly to wild-type virus in vitro but was attenuated in
vivo (Messerle et al., 1997). These workers overcame this issue by developing a
method whereby the BAC sequences, after the MCMV BAC had been manipulated,
were excised from the recombinant viral DNA and the deleted region of MCMV
sequence was replaced, thereby eliminating the possibility that the insertion of BAC
sequences disrupts the virus life cycle.
A method has recently been developed involving the use of the Cre-lox system. A
cassette consisting of a marker gene flanked by loxP sites is inserted by homologous
recombination into the herpesvirus genome. Recombinants that have excised the
marker gene by recombination, leaving a single loxP site, are then selected. A BAC
vector containing one loxP site can then be recombined into the genome in
eukaryotic cells. Manipulations can then be carried out in a prokaryotic system, and
mutants obtained by transfecting into mammalian cells. The Cre recombinase excises
the BAC from the virus genome leaving no BAC DNA in the virus. The system was
developed such that the Cre-lox system is not functional in the prokaryotic host
because a synthetic intron was engineered into the Cre recombinase gene, which is
present on the BAC, and therefore it is only transcribed and translated in mammalian
cells (Smith and Enquist, 2000).
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Cloning of herpesvirus genomes into BACs is a growth area. There are a variety of
new developments emerging that achieve the same aim, but all have merits and
pitfalls. This work has explored various strategies with the aim of constructing a
recombinant A1HV-1 virus and has illustrated some of the challenges when working
with A1HV-1. It is not known if A1HV-1 would accept insertion of the BAC vector as
outlined. However, with the new methods now available, there is potential for a









The aim of this project was to characterise A1HV-1 ORF50. Two approaches were
taken:
1) To analyse the function of A1HV-1/Rta, the ORF50 gene product, in isolation.
2) To attempt to create a virus lacking ORF50.
5.2 Characterisation ofAIHV-1 QRF50
5.2.1 Analysis of the function of AIHV-1/Rta
Examination of the functions of Rta homologues in other yHVs led to the hypothesis
that A1HV-1/Rta may encode a transactivator. Transient transfection assays showed
that A1HV-1/Rta transactivates the A1HV-1 ORF57 and ORF6 promoters but does
not transactivate the TK promoter (Figure 3.14 and 3.15). This is similar to findings
in other yHVs. The Rta homologues of HVS (Whitehouse et al., 1997b), KSHV
(Lukac et al., 1999), EBV (Ragoczy et al., 1999) and MHV-68 (Liu et al., 2000) all
activate the cognate ORF57 promoter. In addition, the Rta homologues of KSHV
(Lukac et al., 1998), HVS (Whitehouse et al., 1998a) and BHV-4 (van Santen 1993)
transactivate the cognate ORF6 promoter. However, in contrast to the results
obtained with A1HV-1/Rta, KSHV/Rta activates the KSHV TK promoter (Lukac et
al., 1998).
5.2.2 Transcription of ORF57
ORF57 was subjected to 5'-RACE analysis (Figure 3.18). The results indicate that
the ORF57 transcriptional start site is at nucleotide position 84438 of the genome,
which is 30 bp downstream of the TATA box and 24 bp upstream of the translational
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initiation codon predicted by Ensser et al., (1997). SD and SA sites are located at
positions 84513 and 84605, respectively. Cavener and Ray (1991) published a
comprehensive analysis of sequences surrounding start codons for a variety of
organisms, including vertebrate viruses. A1HV-1 ORF57 has the most common
arrangement of nucleotides in key positions (-1), (-2) and (-3) from the predicted
initiation codon, i.e. AACATG.
Comparison of A1HV-1 ORF57 with ORF57 from other yHVs showed notable
similarities in the length of their exons and introns as well as the positions of their
splice sites. ORF57 in A1HV-1 and in KSHV both have an SD site 50 bp downstream
from the initiation codon while HVS ORF57 has an SD site 18 bp downstream from
the initiation codon. The introns of ORF57 in A1HV-1, KSHV and HVS are 92 bp,
105 bp and 87 bp, respectively. The predicted lengths of the A1HV-1 and HVS
ORF57 proteins are 435 aa and 410 aa, respectively, which is similar to the observed
length of 435 aa for the KSHV ORF57 protein (Russo et al., 1996; Whitehouse et al.,
1998b; Bello et al., 1999; Kirshner et al., 2000).
Ensser et al. (1997) also performed 5'-RACE on ORF57 of A1HV-1, and their results
are in agreement with the results presented here with regard to the positions of the
SD and SA sites. However, these workers identified the transcriptional start site of
ORF57 as being located only 7 bp upstream of the start codon rather than 24 bp
upstream. Both studies relied on data from one clone and there were experimental
differences between them. The RNA used in this project was harvested from virus-
infected BT cells treated with cycloheximide, and so only IE transcripts would have
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been present. Ensser et al. (1997) used virus-infected bovine epithelial kidney cells
in the absence of cycloheximide, and thus the RNA harvested would be expected to
contain IE, E and L transcripts. It is possible that alternate initiation sites are used at
different times throughout the virus life cycle, but this remains to be tested.
5.2.3 Control of aene expression by AIHV-1/Rta
From studies with EBV and HVS it could be inferred that A1HV-1/Rta might bind
directly to DNA (Quinlivan et al., 1990; Gruffat and Sergeant, 1994; Hall et al.,
1999). Specific response elements (REs) have been identified for EBV (Figure
5.1(a)) (Kenney et al., 1989b; Chevalier-Greco et al., 1989; Manet et al., 1991;
Gruffat et al., 1992; Gruffat and Sergeant, 1994) and HVS Rta homologues
(Whitehouse et al., 1997b). The consensus RE for HVS Rta is CCN9GG. Various
workers reported four binding sites for EBV Rta (see Figure 5.1(a)). Gruffat and
Sergeant (1994) analysed a pool of random DNA sequences to determine conserved
sites within these REs. Initially the consensus sequence was defined as
GNCCN9GGNG but subsequently a simplified form of the prototype Rta-binding site
was proposed as CCN9GG, which is identical to the consensus sequence determined
independently for HVS Rta.
Two distinct REs have been found in two different sets of lytic genes activated by
KSHV/Rta (Figure 5.1(a)). RE1 is found in the ORF57 and K-bZIP promoters, which
encode virus regulatory proteins, and are highly responsive to KSHV/Rta. RE2 is
found in DE promoters for PAN-RNA and kaposin, which are less responsive to
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work by Song et al. (2001) in which a specific sequence in the PAN-RNA promoter,
corresponding to RJE2, was shown to bind KSHV/Rta directly. KSHV/Rta
recombinant protein has also been shown to bind to RE1 (Lukac et al., 2001).
To assess the regions important for transcriptional control by A1HV-1/Rta,
truncations of the ORF57 promoter were made. The results obtained with these
deletion constructs suggested that a 113 bp region, 409-522 bp upstream of the
ORF57 start codon, was critical for transactivation since a construct lacking this part
of the promoter was not activated by A1HV-1/Rta (Figure 3.19(b)). This suggests that
the transcription of A1HV-1 ORF57 by A1HV-1/Rta relies on a sequence situated at a
considerable distance upstream from the translational start codon. The RE in the
HVS ORF57 promoter also lies at a considerable distance from the transcriptional
start site, between 751 bp and 764 bp (Whitehouse et al., 1998a), whereas in the
HVS ORF6 promoter the RE is only 127-259 bp upstream of the transcriptional start
site (Whitehouse et al., 1997b). Thus, the distance of the REs from the transcriptional
start site does not appear to be conserved in HVS promoters that are transactivated
by Rta, or indeed between ORF57 promoters of different viruses. A 565 bp MHV-68
ORF57 putative promoter sequence was activated by MHV-68/Rta suggesting that
although the REs have not yet been identified, they are contained within this 565 bp
region (Liu et al., 2000).
Comparisons between the A1HV-1 ORF57 promoter sequence and the various REs
discussed above highlighted two sequences within the promoter that contain the HVS
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in the 113 bp sequence and this study showed that removal of this sequence
abolished activation by A1HV-1/Rta (Figure 3.19(b) and (c)). The other motif is
located close to the start codon and this study showed that 194 bp of promoter
sequence containing this motif was not activated by A1HV-1/Rta (Figure 3.19(b) and
(c)). The positions of these sequences are shown in Figure 5.1(b). The similarity of
sequences in the AIHV-1 ORF57 promoter to known REs in other yHVs is
noteworthy but the functional significance is yet to be fully tested.
To test if the 113 bp sequence was responsive to A1HV-1/Rta, a construct was
generated that encompassed this region and extended 42 bp 3' downstream, termed
Prom57p(155). However, it did not act as an AlHV-l/Rta-responsive sequence
(Figure 3.20). It may be that this region of the promoter is required in addition to
downstream sequences in order to respond to A1HV-1/Rta. The position of this
sequence relative to the transcriptional start may also be important. The two
possibilities were tested by constructing 57p(399), which contained both of the
putative REs as determined by similarity to the HVS and EBV REs. 57p(399)
included 205 bp at the 5' end of 57p(579) and 194 bp at the 3' end but lacked the
middle 180 bp. The activity of 57p(399) was around half that of 57p(579), indicating
that the central 180 bp, although not essential, was important for A1HV-1/Rta
activation (Figure 3.21(a) and (b)). This may be because of elements in its sequence
or because it spatially distances the other two sections containing the putative REs.
To test which of these two scenarios is correct, Gavin Borthwick (Honours student)
is in the process of making a construct containing a 180 bp fragment from the A1HV-
1 glycoprotein B gene, which will be flanked by the 205 bp and 194 bp sequences.
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This should help to determine whether it is the precise spacing or the sequence that is
important for AlHV-l/Rta-mediated transactivation of the ORF57 promoter.
To examine this further, nucleotides in the conserved CCN9GG motif could be
mutated by site-directed mutagenesis. Alternatively, the sequences forming the
putative REs could be multimerised and placed upstream of a reporter gene. In both
cases, the ability of A1HV-1/Rta to activate or bind to these sequences could be
tested.
5.2.4 EMSAs
EMSAs were used to investigate whether A1HV-1/Rta bound to part of the 113 bp
sequence. In some cases no evidence for specific binding of A1HV-1/Rta to this
sequence was found, as the extracts containing or lacking A1HV-1/Rta gave similar
results. It was concluded that cellular factors were responsible for binding. In other
cases the pattern of bands using the extracts containing or lacking A1HV-1/Rta
differed, and therefore it could be inferred that A1HV-1/Rta might be involved in
some binding (Figures 3.23-3.29).
To clarify whether or not A1HV-1/Rta directly binds DNA, a next step would be to
use purified A1HV-1/Rta. Towards the end of this project, a plasmid was constructed
which encodes A1HV-1/Rta with the myc epitope and His tag at the C-terminus. The
protein could be purified via the His tag, and utilised in EMSAs.
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5.2.5 AIHV-1/Rta truncations
The amino acid sequence of A1HV-1/Rta was compared with the Rta homologues of
other yHVs (Table 5.1 and Figure 5.2). Although there is well documented functional
homology of the Rta homologues of yHVs, the amino acid sequence is weakly
conserved between them. The sequence alignment in Figure 5.2 shows that there is
slightly more similarity in the N-terminal region than the C-terminal region. The N-
terminal regions of EBV and KSHV Rtas contain DNA binding domains that bind to
specific response elements (Manet et al., 1991; Lukac et al., 2001). The higher
sequence identity of these regions between viruses is in accord with the conservation
of the response elements (Figure 5.1).
Table 5.1: Percent identity of yHV Rta homoloaues
The percent identity of amino acid sequences of Rta homologues from the yHVs
indicated. Percentages were obtained from Albrecht et al. (1992), Russo et al.
(1996), Ensser et al. (1997) and Virgin et al. (1997).
Virus AIHV-1 HVS MHV-68 KSHV EBV
AIHV-1 100 17.2 - 19.2 20.2
HVS 17.2 100 26.6 24.9 22.7
MHV-68 - 26.6 100 16.4 13.1
KSHV 19.2 24.9 16.4 100 19.0
EBV 20.2 22.7 13.1 19.0 100
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To investigate the functional domains of A1HV-1/Rta, two truncated versions were
constructed. In co-transfection experiments it was found that only the N-terminal
portion of A1HV-1/Rta inhibited full-length AlHV-l/Rta-mediated transactivation of
the ORF57 promoter (Figure 3.33(b)). It may be inferred from this that the N-
terminal region contains a DNA-binding domain and therefore may prevent binding
of full-length A1HV-1/Rta. Alternatively, it might contain the activation domain, in
which case it may sequester transcription factors required for activation. The C-
terminal regions of EBV Rta, HVS Rta and K.SHV Rta have potent activation
domains. The EBV Rta contains important hydrophobic residues that are conserved
in the HSV-1 VP 16 transactivator (Hardwick et al., 1992). It is likely that the overall
low sequence identity is due to the adaptation of this regulatory gene to different host
and cell environments. Regarding the activation domain, it is more likely that there
are a few crucial residues involved, as is the case with EBV Rta (Hardwick et al.,
1992), which would require experimental verification.
To confirm whether or not the N-terminal region of A1HV-1/Rta contains a DNA-
binding domain, the N-terminal product expressed from pcDNA50A could be
purified by using the His tag and tested in EMSAs. The putative activation domain
could be investigated by joining it to a known DNA-binding domain and assessing its
activity in transient transfection assays.
5.2.6 Expression pattern of AIHV-1 QRF50 within the AIHV-1 virus life cycle
Northern blots and RT-PCR were used to determine when ORF50 was expressed in
the virus life cycle. Clear results were not obtained even though the RNA was of
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good quality and the RT control reactions worked. This may have been because the
mRNA of ORF50 is unstable or present in very small amounts.
5.2.7 Transcription patterns of QRF50 homologues
HVS ORF50 is transcribed from two distinct promoters in two temporal phases of
gene expression; ORF50a is an E spliced transcript and ORF50b is a DE unspliced
transcript which is produced from a promoter within the second exon of the ORF50a
DNA sequence (Whitehouse et al., 1997a). The transcription of MHV-68 ORF50, an
IE gene, is initiated from several sites within a 34 bp region, and is transcribed in
spliced and unspliced forms (Liu et al., 2000). There are two main transcripts
encoding ORF50 in KSHV, one of which also encodes K8 (Seaman et al., 1999).
KSHV ORF50 and K8 are IE and E genes, respectively. BRLF1 of EBV is translated
from a bicistronic mRNA, which also encodes BZLF1; both are IE genes (Hardwick
et al., 1988). In light of these findings, it is possible that A1HV-1 ORF50 may also
encode multiple transcripts.
5.2.8 Possible functions of AIHV-1/Rta
Studies carried out by other members of the laboratory indicate that A1HV-1/Rta
activates the ORFA9 promoter (K. Knudson, pers. comm.). ORFA9 encodes a
potential Bcl-2 homologue (Ensser et al., 1997; Coulter et al., 2001), which in
mammalian cells is an anti-apoptotic protein. It has also been shown that the A1HV-1
ORF57 protein, whose promoter is activated by A1HV-1/Rta, can activate the ORF50
promoter (L. Devi, pers. comm.) suggesting a potential feedback regulation system.
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Several of the Rta homologues have been shown to play a critical role in the latent to
lytic transition, acting as a 'molecular switch' (Goodwin et ah, 2001; Sun et ah, 1998;
Wu et al., 2000; Lukac et al., 1999; Gradoville et al., 2000). Future studies should
therefore assess the role of A1HV-1/Rta in reactivation of the virus from latency.
This could be examined by introducing an A1HV-1/Rta expression plasmid into cell
lines that contained latent virus genomes e.g. LGLs harbouring latent AfHV-1.
Reactivation could then be assessed by detecting early and late gene transcripts,
which are not transcribed during latency as well as virus replication and release of
virus, as described in previous studies (Wu et al., 2000; Sato et al., 1990).
5.3 Recombinant Virus
The attempts to make a recombinant A1HV-1 lacking ORF50 are described in
Chapter 4. The premise behind creating a virus lacking ORF50 stemmed from the
discovery of an attenuated version of the virus, which resulted from repeated passage
in tissue culture (Handley et al., 1995). The precise alterations that occurred in the
attenuated virus are not known and so the creation of a virus lacking only ORF50
would allow the role of this gene to be assessed. It would be envisaged that a
revertant would be made, thus enabling accurate assignment of the function of
ORF50.
5.3.1 Attempts to make AIHV-1 lacking QRF50 bv homologous
recombination
The first attempt in this project involved replacing part of ORF50 with a marker
gene. This method was chosen because it was less likely to disrupt adjacent
regulatory sequences. The lack of success of this procedure may have been due to
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recombinants not being generated, rejection of the inserted GFP cassette by the virus
or the possibility that the recombinant virus was less productive than wild-type virus.
In other studies, complete purification or recombinant virus has been reported to be
unsuccessful owing to the disadvantageous nature of the mutation. To overcome this
problem, a complementary cell line has been used (DeLuca et al., 1985).
During homologous recombination, insertion of the whole plasmid can sometimes
occur due to a single recombination event (Lee et al., 1992). The use of greater
lengths of homologous sequences increases the chances of two recombination events
occurring either side of the marker gene. In the case of A1HV-1, greater lengths of
homologous sequences could be used to enhance homologous recombination.
5.3.2 Attempts to make an AIHV-1 BAC
The insertion of the whole AIHV-1 genome into a BAC was attempted since its
construction could have been a useful tool to generate viruses lacking one or more
genes. Mutant virus genomes could be constructed irrespective of their viability in a
eukaryotic host since the recombinant is purified after manipulation and selection in
bacteria. This approach has an advantage over homologous recombination in
eukaryotic cells, since the lack of recombinants from eukaryotes could be due to
either failure of the recombination event or lack of viability of the mutant virus.
However, the initial generation of the BAC still involves homologous recombination
in eukaryotic cells.
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If the method outlined had been successful, it would be important to restore the TK
gene before generating further mutations so that they could be compared with the
wild-type phenotype.
5.3.3 Future Strategies
To improve the chances of generating an A1HV-1-BAC the following approaches
could be used:
1) Introduce more selection methods to overcome the poorly defined areas of
CPE and improve the chances of recovering a recombinant virus.
2) Improve the introduction of virus DNA into cells by enhancing transfection
efficiency.
3) Increase the lengths of sequences flanking the marker gene for use in
homologous recombination.
4) Develop a screening method to enable large numbers of areas of CPE to be
analysed for recombinant virus.
5) Overcome potential problems due to extra DNA in the virus genome, which
may affect the packaging of the virus and its growth efficiency, by pursuing
strategies that utilise the BAC system but result in mutant viruses lacking
BAC sequences.
5.4 Concluding Remarks
This project partially characterised the function of A1HV-1/Rta and initiated
investigations into its mechanism of action. Some aspects of the results obtained are
similar to those observed with other yHV homologues. Several avenues for future
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investigations have been proposed, including how to develop the methodology that
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The following appendices contain the 'raw' luciferase values and fold induction
values for all the luciferase assay results shown in Chapter 3.
In experiments utilising pRLSV40, the Renilla luciferase value was divided by either
10 or 100. This did not alter the fold induction values.
Appendix 1
Raw luciferase values for Figure 3.8
Construct
Luciferase Values
No additions Plus Virus Plus pLXSN-ORF50
pGL3-Basic 0.037 0.224 0.039
57 prom 0.063 0.277 0.248
TKprom 0.080 0.990 0.061
6prom 0.073 1.366 0.057
Construct
Fold Induction














Raw luciferase values for Figure 3.12
Single Pulse Luciferase Value Double Pulse Lucerifase Value
220 1297 650 401.5
240 1733 700 365.7
260 1877 750 367.6
280 1777 800 415.1
300 2468 850 391.1
Appendix 4
Raw luciferase values for Figure 3.13
Construct
Luciferase Values
No Additions Plus pCMVORF50 Fold Induction
1 pGL3-Basic 70.550 293.600 4.20
57prom 9.198 1648.000 179.20
TKprom 90.200 517.400 5.70
6prom 27.440 601.900 21.90
2 pGL3-Basic 0.097 0.397 4.10
57prom 0.059 23.330 395.00
TKprom 0.152 1.251 8.23
6prom 0.115 1.786 15.53
3 pGL3-Basic 0.438 0.843 1.90
57prom 0.027 6.737 249.00
TKprom 0.106 0.259 2.40
6prom 0.067 0.862 12.86
iii
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pGL3-Basic 0.781 0.916 0.85
57prom 0.440 0.976 0.45
TKprom 2.526 0.880 2.86
6prom 1.455 0.931 1.56
Plus pCIV [VORF50
pGL3-Basic 4.055 0.942 4.30
57prom 24.760 0.835 29.60
TKprom 5.482 0.923 5.90







pGL3-Basic 0.168 0.5880 0.286
57prom 0.089 0.4614 0.193
TKprom 0.467 0.6157 0.758
6prom 0.241 0.5481 0.440
Plus pCIV1VORF50
pGL3-Basic 1.829 0.6097 2.999
57prom 4.171 0.4429 9.417
TKprom 1.986 0.6280 3.162







pGL3-Basic 2.485 1.603 1.55
57prom 0.925 1.533 0.60
TKprom 6.153 1.178 5.20
6prom 5.983 1.485 4.03
Plus pCIV1VORF50
pGL3-Basic 11.76 1.638 7.12
57prom 64.55 1.606 40.19
TKprom 16.91 1.680 10.00















Raw luciferase values for Figure 3.15
Firefly luciferase Renilla luciferase Fireflv value
value Value Renilla value
pGL3-Basic 0.832 0.263 3.17
0.932 0.277 3.36
0.624 0.161 3.87
pGL3-Basic Plus 3.228 0.508 6.35
pCMVORF50 3.259 0.520 6.26
2.687 0.402 6.69
57prom 0.226 0.282 0.80
0.475 0.269 1.76
0.443 0.288 1.54
57prom Plus 12.640 0.438 28.87
pCMVORF50 11.700 0.437 26.75
10.330 0.409 25.28
TKprom 3.138 0.307 10.22
3.478 0.309 11.27
3.592 0.361 9.96
TKprom Plus 7.056 0.447 15.77
pCMVORF50 8.529 0.451 18.90
9.450 0.454 20.83
6prom 3.360 0.272 12.17
3.321 0.312 10.66
4.515 0.234 19.27
6prom Plus 38.91 0.484 80.46
















Raw luciferase values for Figure 3.16
Constructs No additions Plus pCMVORF50 Fold induction
pGL3-Basic 1.55 5.04 3.25
pGL3-Basic 1.78 5.42 3.04
pGL3-Basic 1.32 4.27 3.23
pHSV-TKluc 974.6 816.9 0.84
pHSV-TKluc 631.5 824.6 1.30
pHSV-TKluc 597.1 1008.0 1.69
pRLSV40 415.1 780.1 1.88
pRLSV40 440.0 937.0 2.13
pRLSV40 380.5 775.7 2.03
pCMVluc 838.1 885.3 1.06
pCMVluc 825.0 798.1 0.97
pCMVluc 767.5 931.9 1.21
Appendix 8
Raw luciferase values for Figure 3.19 (b) and (c)
Figure 3.19(b) shows a summary of several experiments, the results of which are
shown in graphs in Figure 3.19 (c).
Raw luciferase values for Figure 3.19 (c) (i)
1 Firefly luciferase Renilla luciferase Fireflv value
value value Renilla value
pGL3Basic 0.781 0.916 0.85
57prom 0.440 0.976 0.45
57p(768) 0.501 0.970 0.52
57p(579) 0.571 1.026 0.56
57p(466) 0.654 0.955 0.68
plus pCMVORF50
pGL3Basic 4.055 0.942 4.3
57prom 24.76 0.835 29.6
57p(768) 41.08 0.723 56.8
57p(579) 26.10 0.986 26.5
57p(466) 3.780 0.923 4.19
2 Firefly luciferase Renilla luciferase Fireflv value
value value Renilla value
pGL3Basic 0.168 0.5880 0.286
57prom 0.089 0.4614 0.193
57p(768) 0.106 0.5786 0.183
57p(579) 0.123 0.5529 0.222
57p(466) 0.189 0.5543 0.341
plus pCMVORF50
pGL3Basic 1.829 0.6097 2.999
57prom 4.171 0.4429 9.417
57p(768) 10.47 0.5328 19.651
57p(579) 6.557 0.5407 12.127
57p(466) 0.936 0.6029 1.552
viii
3 Firefly luciferase Renilla luciferase Fireflv value
Value value Renilla value
pGL3Basic 2.485 1.603 1.55
57prom 0.925 1.533 0.6
57p(768) 1.166 1.818 0.6
57p(579) 1.157 1.516 0.763
57p(466) 1.095 1.075 1.01
plus pCMVORF50
pGL3Basic 11.76 1.638 7.12
57prom 64.55 1.606 40.19
57p(768) 72.85 1.585 45.96
57p(579) 38.16 1.550 24.6


















Raw luciferase values for Figure 3.19 (c) (ii).
Firefly luciferase Renilla luciferase Fireflv value
Constructs value value Renilla value
pGL3Basic 0.970 0.1809 5.36
1.029 1.7150 6.00
1.053 1.7560 5.99
pGL3Basic 3.234 0.2377 13.60
plus pCMVORF50 1.855 0.1656 11.20
2.268 0.1930 11.75
57prom 0.286 0.1964 1.46
0.307 0.1611 1.90
0.217 0.1938 1.12
57prom 7.947 0.2117 37.54
plus pCMVORF50 5.633 0.1482 38.01
5.955 0.1488 40.02
57p(466) 0.433 0.1756 2.46
0.396 0.1590 2.49
0.496 0.1879 2.64
57p(466) 1.442 0.2022 7.13
plus pCMVORF50 1.828 0.2163 8.45
1.689 0.2029 8.32
57p(686) 0.310 0.1630 1.90
0.368 0.1746 2.11
0.410 0.2095 1.96
57p(686) 10.00 0.1652 60.53
plus pCMVORF50 9.272 0.1831 50.64
7.193 0.1293 55.63
57p( 180) 2.298 0.1429 16.08
2.350 0.1701 13.82
1.763 0.1299 13.57
57p(180) 6.281 0.1992 31.53


















Raw luciferase values for Figure 3.19 (c) (iii)
Firefly luciferase Renilla luciferase Fireflv value
Constructs value value Renilla value
pGL3Basic 7.135 5.587 1.30
5.656 2.961 10.90
6.405 3.638 1.80
pGL3Basic 19.990 4.203 4.76
plus pCMVORF50 27.870 1.808 15.40
41.130 5.026 8.2
57prom 2.204 6.109 0.36
1.449 2.062 0.70
1.902 4.084 0.50
57prom 149.900 7.101 21.10
plus pCMVORF50 47.790 1.109 43.10
134.000 6.808 19.70
57p(466) 4.234 6.743 0.63
2.299 2.198 1.04
3.490 4.124 0.85
57p(466) 15.560 4.157 3.70
plus pCMVORF50 30.710 3.752 8.20
13.450 3.670 3.66
57p(194) 0.723 6.096 0.12
0.487 4.138 0.12
0.428 2.243 0.19
57p(194) 2.081 4.933 0.42















Raw luciferase values for 3.19 (c) (iv).
Firefly luciferase Renilla luciferase Fireflv value
Constructs value value Renilla value
pGL3Basic 0.217 0.3001 0.72
0.489 0.3383 1.40
0.425 0.3151 1.35
pGL3Basic plus 1.227 0.5803 2.10
pCMVORF50 1.436 0.6473 2.20
1.476 0.6848 2.10
57prom 0.196 0.3052 0.64
0.198 0.3323 0.59
0.135 0.3562 0.38
57prom plus 4.997 0.7560 6.60
pCMVORF50 5.866 0.6646 8.83
4.965 0.5308 9.30
57p(466)B 0.180 0.3359 0.53
0.116 0.3564 0.32
0.201 0.4074 0.49
57p(466)B plus 1.079 0.6905 1.56
pCMVORF50 0.727 0.5708 1.27
0.639 0.5566 1.10
57p(133) 0.131 0.3236 0.40
0.303 0.3301 0.92
0.269 0.4006 0.67
57p(133) plus 0.718 0.6676 1.07

















Raw luciferase values for Figure 3.20
Firefly luciferase Renilla luciferase Fireflv value
Constructs value value Renilla Value
pGL3promoter 42.40 0.224 189.03
51.46 0.271 190.09
55.93 0.302 185.38
pGL3-promoter plus 78.28 0.378 206.70
pCMVORF50 16.88 0.114 148.20
64.95 0.390 166.62
Prom57p(155) 102.80 0.457 224.89
125.20 0.496 252.16
113.40 0.416 272.33
Prom57p(155) plus 304.00 0.829 366.50










Raw values for Figure 3.21 (b).
Firefly luciferase Renilla luciferase Fireflv value
Constructs value value Renilla value
pGL3Basic 6.064 2.135 2.84
6.969 1.220 5.7
6.201 1.464 4.24
pGL3Basic plus 29.81 1.673 17.82
pCMVORF50 33.34 1.775 18.8
29.12 1.725 16.9
57prom 2.274 1.256 1.81
2.173 1.449 1.5
2.478 1.426 1.74
57prom plus 73.75 1.773 41.6
pCMVORF50 75.04 1.624 46.21
62.74 1.623 38.66
57p(579) 2.341 1.822 1.285
2.975 1.495 1.99
2.925 1.658 1.76
57p(579) plus 69.76 1.982 35.2
pCMVORF50 52.52 1.593 32.97
59.31 1.734 34.2
57p(399) 2.682 1.181 2.27
2.427 1.222 1.99
2.491 1.072 2.32
57p(399) plus 38.04 1.570 24.23

















Raw luciferase values for the Figure 3.33 (a)
Promoter Expression Firefly Renilla Fireflv value
Construct Construct luciferase value luciferase value Renilla value
PGL3-Basic None 0.770 0.1661 4.6
57prom None 0.541 0.1910 2.8
PGL3-Basic pcDNA50 1.909 0.2556 7.5
57prom pcDNA50 6.350 0.3378 18.8
PGL3-Basic pcDNA50A 1.009 0.3687 4.5
57prom pcDNA50A 0.705 0.4395 2.8
PGL3-Basic PcDNA50B 1.234 0.2248 5.8
57prom PcDNA50B 0.647 0.2501 2.8
Constructs Fold Induction
pGL3-Basic plus pcDNA50 1.60
57prom plus pcDNA50 6.70
pGL3-Basic plus pcDNA50A 0.97
57prom plus pcDNA50A 1.00
pGL3-Basic plus pcDNA50B 1.26
57prom plus pcDNA 50B 1.00
Appendix 12
Raw lucifcrase values for Figure 3.33 (b)
Firefly luciferase Renilla luciferase Fireflv value
value Value Renilla value
pGL3-Basic 1.892 1.209 1.56
2.356 1.332 1.78
1.428 1.085 1.32
pGL3-Basic 8.239 1.634 5.04
plus pcDNA3.1-50 9.267 1.709 5.42
5.745 1.346 4.27
57prom 1.117 1.169 0.95
1.015 1.259 0.81
1.040 1.297 0.80
57prom 59.61 1.725 34.5
plus pcDNA3.1-50 58.12 1.814 32.04
44.54 1.552 28.7
57prom 38.30 1.693 22.6
plus pcDNA3.1-50 29.63 1.555 19.05
plus pcDNA3.l-50A (2 pg) 32.87 1.361 24.15
57prom 16.31 1.780 9.16
plus pcDNA3.1-50 16.90 1.859 9.09
plus pcDNA3.1-50A (10 pg) 13.26 1.718 7.72
57prom 18.03 2.125 8.5
plus pcDNA3.1-50 14.46 1.771 8.16
plus pcDNA3.1-50A (20 pg) 13.85 1.594 8.69
57prom 55.88 1.712 32.6
plus pcDNA3.1-50 68.42 1.985 34.5
Plus pcDNA3.1-50B (2 pg) 63.42 1.821 34.83
57prom 57.55 2.224 25.9
plus pcDNA3.1-50 43.72 1.801 24.27
plus pcDNA3.1-50B (10 pg) 50.57 1.764 28.67
57prom 84.61 2.607 32.4
plus pcDNA3.1-50 66.97 2.163 30.96
plus pcDNA3.1-50B (20 pg) 71.62 2.300 31.14
57prom 55.26 1.653 33.4
plus pcDNA3.1-50 60.08 1.777 33.81
plus pEGFP-Nl (2 pg) 55.16 1.415 38.98
57prom 48.48 1.827 26.5
plus pcDNA3.1-50 58.15 2.143 27.13
plus pEGFP-Nl (10 pg) 57.78 1.741 33.19
57prom 64.38 2.485 25.91
plus pcDNA3.1-50 70.65 2.280 30.99
plus pEGFP-Nl (20 pg) 65.22 2.146 30.39
xvi
Constructs Fold Induction i
pGL3-Basic plus pcDNA50 3.23
3.04
3.23
57prom plus pcDNA50 36.31
39.55
35.87
57prom plus pcDNA50 23.79
plus pcDNA50A 23.52
(2 pg) 30.19
57prom plus pcDNA50 9.64
plus pcDNA50A 11.22
(10 pg) 9.65
57prom plus pcDNA50 8.95
plus pcDNA50A 10.07
(20 pg) 10.86
57prom plus pcDNA50 34.31
plus pcDNA50B 42.59
(2 pg) 43.54
57prom plus pcDNA50 27.26
plus pcDNA50B 29.96
(10 pg) 35.84
57prom plus pcDNA50 34.10
plus pcDNA50B 38.22
(20 pg) 38.92
57prom plus pcDNA50 35.16
plus pEGFP-N 1 41.74
(2 pg) 48.50
57prom plus pcDNA50 27.89
plus pEGFP-N 1 33.49
(10 pg) 41.49
57prom plus pcDNA50 27.27




Raw luciferase values for Figure 3.34(c)
Promoter Expression Firefly luciferase Renilla luciferase Firefly value
Construct Construct value value Renilla value
pGL3-Basic 0.235 0.075 3.13
57prom None 0.078 0.092 0.85
TKprom 0.521 0.086 6.06
6prom 0.466 0.087 5.36
pGL3-Basic 0.303 0.088 3.54
57prom pCMVORFA6 0.097 0.083 1.20
TKprom 0.7888 0.089 8.80
6prom 0.606 0.089 6.80
pGL3-Basic 0.884 0.076 11.60
57prom pCMVORFA6 plus 2.768 0.078 35.50
TKprom pCMVORF50 1.417 0.055 25.76
6prom 9.203 0.170 54.13
Constructs Fold Induction
pGL3-Basic plus pCMVORFA6 1.1
57prom plus pCMVORFA6 1.4
TKprom plus pCMVORFA6 1.4
6prom plus pCMVORFA6 1.3
pGL3-Basic plus pCMVA6 plus pCMVORF50 3.7
57prom plus pCMVA6 plus pCMVORF50 41.7
TKprom plus pCMVA6 plus pCMVORF50 4.2


























Average = 3.69 +/- 2.28
xix
